ANNUAL REPORT
2009-10
CONTENTS ABOUT QIMR
1
RESEARCH DIVISIONS
14
QIMR at a glance
2
Cancer and Cell Biology
16
Research highlights
4
Genetics and Population Health
27
Awards and achievements
6
Immunology
43
Chairman’s report
8
Infectious Diseases
56
Members of Council
9
Mental Health
72
11
Joint Research
74
Director’s report
Cover: Tissue culture plate courtesy of phototonyphillips.com | Inside Cover: Aedan Roberts, PhD student, Familial Cancer Laboratory
ABOUT US QIMR is one of Australia’s largest and most successful medical research institutes. Our researchers are investigating the genetic and environmental causes of more than 40 diseases as well as developing new diagnostics, better treatments and prevention strategies. The Institute’s diverse research program extends from tropical diseases to cancers to Indigenous health, mental health, obesity, HIV and asthma.
OUR PHILOSOPHY QIMR supports scientists who perform world-class medical research aimed at improving the health and well-being of all people.
OUR VISION
OUR LOGO
To be a world renowned medical research institution.
The QIMR logo is comprised of superimposed benzene rings which symbolise one of the fundamental molecular arrangements of the chemicals which make up living things.
OUR MISSION Better health through medical research.
Director – Professor Michael Good AO Deputy Director – Professor Adèle Green AC Patron – Her Excellency Ms Penelope Wensley AO www.qimr.edu.au | enquiries@qimr.edu.au
CORPORATE DIVISION
78
Patents
93
Trust report
83
Official Committees
94
Members of Trust
84
Publications
96
POSTGRADUATE TRAINING
85
Lectures
108
Completed students
87
Staff
117
Student awards
88
Students
124
AWARDS
89
Visiting Scientists
125
Grants and funding
91
Organisational Structure
128
QIMR Annual Report 2009/10
1
QIMR AT A GLANCE Supporting scientists who perform world-class medical research aimed at improving the health and well-being of all people. PATENT PORTFOLIO BY CATEGORY
RESEARCH AGREEMENTS
New treatment patents
Research service agreements
Vaccine patents
Clinical trial agreements
Delivery platform patents
Commercialisation agreements
Diagnostic patents
Intellectual property agreements
Drug target patents
License agreements Others
2
QIMR Annual Report 2009/10
NHMRC GRANTS $ Millions 20 16 12 8
Grants
2010
2009
2008
2007
2006
2005
0
2004
4
Fellowships
FUNDRAISING REVENUE
SCIENTIFIC PUBLICATIONS
$ Millions 450 8.0 7.0
350
6.0 250
5.0 4.0
150
3.0 2.0
Articles
Bequests/Gifts in Kind Sponsorship Event Revenue Donations & Gifts
2010
2009
2008
2007
2006
2004
0
2009/10
2008/09
2007/08
2006/07
2005/06
2004/05
0
2005
50
1.0
High Impacts
QIMR TRUST RESEARCH FUNDING
STAFF NUMBERS
$ Millions 700 7.0
600
6.0
500
5.0
400
4.0
300
3.0
200
2.0
100
2009/10
2008/09
2007/08
2006/07
2010
2009
2005/06
Students
0
2004/05
Staff
2008
2007
2006
1.0 0
3
RESEARCH
HIGHLIGHTS •
Identified a new gene linked to schizophrenia and bipolar disorder.
•
Used an experimental immunotherapy treatment to help a bone marrow transplant patient overcome a life threatening infection.
Developed a more effective treatment against visceral leishmaniasis, using an antibody which stimulates the immune system.
•
Discovered strong period pain and excess weight in childhood doubles risk of endometriosis.
•
Effectively prevented mosquitoes from spreading dengue fever by infecting them with a naturally occurring bacterium, Wolbachia.
•
Developed a simple blood test to monitor risk of contracting cytomegalovirus which is one of the leading causes of death for transplant patients.
•
Assisted the World Health Organization identify the best malaria rapid diagnostic tests to control malaria.
•
•
Found two new genes that increase the risk of late onset Alzheimer’s disease.
Identified and successfully treated a previously undiagnosed condition, an immune defect that leads to fulminant infectious mononucleosis.
•
•
Proved the consumption of moderate amounts of alcohol during pregnancy affects the expression of genes in the developing fetus and that these changes last into adulthood.
Discovered the cumulative effect of lots of small genetic variations in many of our genes determine complex traits such as height.
•
Identified a potential new target for future anti-malarial drugs, an enzyme used by the malaria parasite to obtain nutrients.
Identified a new variant of a gene that helps regulate iron and haemoglobin levels.
•
Commenced human clinical trials using live malaria to develop a method to test future anti-malarial drugs.
•
4
•
QIMR Annual Report 2009/10
CANCER RELATED RESEARCH
Dr Kelly Landers, Conjoint Endocrine Laboratory
HIGHLIGHTS •
Identified two gene variants that double the risk of developing melanoma.
•
Discovered that missense mutations in DNA have a greater impact on breast cancer risk than previously thought.
•
Discovered the human liver fluke (Opisthorchis viverrini) contributes to the development of liver cancer by secreting granulin.
•
Identified a gene variant associated with increased survival in breast cancer patients.
•
Found that drinking more than four cups a day of black, green or herbal tea reduces ovarian cancer risk by almost 30%.
•
Found that women who eat processed meat several times a week increase their risk of developing ovarian cancer by 20%.
•
Discovered the bacteria that cause stomach ulcers dramatically reduce the risk of oesophageal cancer.
•
Developed a compound from the rainforest that has shown significant anti-cancer activity in animal cancers.
•
Demonstrated increased risk of cancer risk in haemochromatosis patients.
5
AWARDS AND
ACHIEVEMENTS •
•
6
QIMR received its largest-ever number of project grants from the National Health and Medical Research Council (NHMRC) with 26 successful applications representing a 41% success rate. This is significantly higher than the national average of 23%. Professor Michael Good, QIMR Director received an Australia Fellowship providing $4 million over five years to continue his lifesaving work into combating malaria and streptococcus A – two of the world’s biggest killers. Professor Good was also awarded the 2009 CSIRO Eureka Prize for Leadership in Science and selected as a 2010 Queensland Great.
QIMR Annual Report 2009/10
•
Professor Peter Visscher, head of QIMR’s Queensland Statistical Genetics Laboratory, was honoured by being elected to the Australian Academy of Science.
•
Associate Professor Maher Gandhi, head of Clinical Immunohaematology won the Australian Society for Medical Research's (ASMR) Research Week Clinical Researcher Award for his work investigating the immunobiology of lymphoma.
•
Kimberley Jones, from the same laboratory won the Postgraduate Student Award.
•
Dr Michelle Wykes was awarded a $300,000 Queensland Government Smart Futures Fellowship for research on the body’s immune response to malaria infection.
Jatin Patel, PhD student, Conjoint Endocrine Laboratory
•
Associate Professor Gail Garvey won the Our Women, Our State Award for Promoting Indigenous Women in recognition of QIMR’s Spotlighting Careers in Indigenous Heath and Science Program.
•
Dr Manuel Ferreira won the QIMR Post-doctoral award and was a finalist in the ASMR 2010 Post-doctoral awards. Dr Ferreira was also successful in securing NHMRC funding to embark on Australia’s largest genetic asthma study.
•
Dr Alberto Pinzón-Charry, won a 2009 Queensland Young Tall Poppy Science Award for excellence in research and public engagement.
•
Dr Daniel Worthley was awarded the NHMRC RG Menzies Fellowship which is awarded to the highest ranked postdoctoral fellowship application and a NHMRC CJ Martin Postdoctoral Training Fellowship to undertake further research in the USA.
•
Dr Stuart MacGregor won the prestigious Ruth Stephens Gani Medal of the Australian Academy of Science.
•
Dr Li Yuesheng was awarded a Future Fellowship by Australian Research Council (ARC) and is the only scientist from Queensland to receive the Howard Hughes Medical Institute Fellowship which has been extended until 2011.
7
CHAIRMAN'S REPORT
I was honoured when approached by the Premier of Queensland. The Honourable Anna Bligh, in 2009 to take up the position of Chair of the QIMR Council. As Vice Chancellor of The University of Queensland from 1996 to 2007, I have been involved in the development of many major new research institutes including the Institute for Molecular Bioscience and the Queensland Brain Institute and am aware of the challenges facing a growing QIMR. The last 12 months has seen QIMR move into a period of significant growth with construction commencing on the Smart State Medical Research Centre, a 13 floor research facility due for completion in 2012. The first sod was turned by Premier Bligh on 9 February 2010.
The state-of-the-art facility will accommodate 20 new research laboratories, increasing QIMR’s staff capacity by more than 60 percent to around 1,200. The project is not only an important asset to QIMR, but also to the wider community with the research completed within its walls benefiting the health and well-being of all. The Queensland Government has shown its long term commitment to our endeavours by substantially increasing our core financial support. This generous commitment will allow the recruitment of first class scientists and the establishment of additional innovative projects. It has also been a time of change as we search for a new Director to take over the leadership of the Institute following the resignation of Professor Michael Good. Michael leaves after ten years as Director to take up a prestigious Australia Fellowship at Griffith University and return to the Laboratory bench to follow his passion and life time work – developing vaccines for malaria and streptococcus A. I would like to take this opportunity of thanking Michael whose leadership helped position QIMR as a global research leader.
8
QIMR Annual Report 2009/10
Professor John Hay AC - QIMR Council Chair
Our research program, publications and competitive funding continues to grow and attract world-class researchers and students from around the globe. During his time as Director, Michael was instrumental in securing funding for the new building; established QIMR’s Indigenous Health Research Program, and a new Division of Mental Health Research. The Institute’s successful education program is testament to his commitment to inspiring the scientists of tomorrow. The past year also saw the departure of the General Manager, Dr Julie-Anne Tarr who after two years at QIMR took up a position with the Queensland University of Technology. During her time at QIMR, Dr Tarr was heavily involved in securing funding for the construction of the new $180 million Smart State Medical Research Centre and overseeing the re-organisation of the Corporate Division. The QIMR Council is grateful for the continued support of the QIMR Trust and the many volunteers and supporters in the community. I look forward to working with Council members and our dedicated staff in order to continue to build on QIMR’s achievements as one of the world’s leading medical research institutes. QIMR Council Chair Professor John Hay AC
COUNCIL MEMBERS Professor John Hay BA (Hons) (Western Australia and Cambridge), MA (Cambridge), PhD (Western Australia), Hon LittD (Deakin), Hon DLitt. (UWA); Hon DU (QUT); Hon LLD (Queensland); FAHA; FACE; FAIM; FQA (Chair from 24/09/09) Professor Hay was Vice-Chancellor of The University of Queensland from 1996-2007. In that time he led the development of many major new research institutes including the Institute for Molecular Bioscience, the Australian Institute of Bioengineering and Nanotechnology and the Queensland Brain Institute. He was also instrumental in securing funding for the Translational Research Institute to be built at the Princess Alexandra Hospital. He has led both Deakin University and The University of Queensland to be named Australian University of the Year by the Good Universities Guide. Professor Hay is Chair of nine boards, including QIMR to which he was appointed by the Queensland Government in September 2009.
Professor Emeritus Bryan Campbell AM MD BS FRACP FRACMA Professor Campbell was formerly Chief Health Officer Queensland and Head of The University of Queensland Medical School. He has been a Councillor of the Royal Australasian College of Physicians, the Royal Australian College of Medical Administrators and a member of the National Health and Medical Research Council. He was Deputy Chair of the Australian Health Ethics Committee and a member of the NHMRC Embryo Research Licensing Committee. Professor Campbell has been a member of the Queensland Institute of Medical Research Council for over 20 years. Professor Campbell is also a member of the QIMR Finance and Audit Committee.
Professor Judith Clements BAppSc MAppSc PhD
Mr Christopher Coyne LLB (Acting Chair to 23/09/09) Christopher Coyne is a solicitor of the Supreme Court of Queensland, an accredited specialist in the field of Commercial Litigation, specialising in insurance law, health law, corporate governance and risk management. Following his admission as a solicitor in 1979 he practised law in Brisbane and was a partner in the national law firm Clayton Utz from 1984 to 2004. Chris now practices on his own account. He was appointed an Adjunct Professor of The University of Queensland School of Law in 2002. Chris is Board Chairman of Lexon Insurance Ltd (Queensland Law Society, Singapore Captive Insurer), a Director of the Incorporated Council of Law Reporting for the State of Queensland, Past President Medico-Legal Society of Queensland and Australian Insurance Law Association and former legal member Australian Health Ethics Committee. Chris is a sessional member of the Queensland Civil and Administrative Tribunal. Chris is also a member of the QIMR Personnel Administration Committee.
Professor Clements has over 20 years experience as a basic researcher in biomedical research, primarily in the general field of molecular endocrinology. Her current research seeks understanding of the molecular basis of hormone dependent and urogenital cancers such as prostate, breast, ovarian and endometrial carcinoma. She is currently Scientific Director of the Australian Prostate Cancer Research Centre−Queensland and Program Leader of the Hormone-Dependent Cancer Program within the Institute of Health and Biomedical Innovation at the Queensland University of Technology. She is also an NHMRC Principal Research Fellow and NHMRC Academy member (2009-2010). In 2007 Professor Clements was awarded the prestigious international Frey-Werle Foundation Gold Medal for her significant contributions to the kallikrein protease field. Professor Clements is Chair of the QIMR Appointment and Promotions Committee.
9
COUNCIL MEMBERS (CONTINUED) Mr Paul Fennelly
Associate Professor Paula Marlton
BA LLB
MB BS (Hons I) FRACP FRCPA
Paul Fennelly has wide experience in financial management, business and public administration. He is an executive with Hastings Funds Management which is a member of the Westpac Group. His focus is on major equity investments, primarily in social and economic infrastructure. From 2002 - 2006 Mr Fennelly was DirectorGeneral of the then Department of State Development; concurrently he served as Queensland's Co-ordinator-General. Prior to joining the Queensland Government he was Victorian Director of the Australian Industry Group which is the nation's largest industry association. Mr Fennelly is the Chair of the QIMR Finance and Audit Committee and Chair of the QIMR Personnel Administration Committee.
Professor Lyn Griffiths BSc (Hons) PhD Professor Griffiths is Director of the Griffith Health Institute and the Genomics Research Centre at Griffith University. She has expertise in human molecular genetics, undertaking research to map and identify genes involved in common complex human disorders, including studies on migraine, cardio-vascular disease risk, multiple sclerosis and certain types of cancer. Her research has been well funded by national competitive grants and industry and she has authored 176 peer-reviewed publications to date in molecular genetics international journals as well as supervising 24 PhD students to completion. She is a current Queensland President Human Genetics Society Australasia, past Australian Society of Medical Research Director, current Member and past Chair of the Scientific Program Committee for the International Congress of Human Genetics and has been awarded the Centenary Medal for Distinguished Service to Education and Medical Research.
10
QIMR R Annual Report 2009/10
Paula Marlton is the Head of Leukaemia and Lymphoma Services at the Princess Alexandra Hospital where she is also Deputy Director of Haematology. Her previous appointments include three years at the MD Anderson Cancer Centre in Houston, Texas. She has extensive experience in clinical research including the role of principal investigator for national multi-centre trials and supervisor of molecular translational research associated with trials. She was the founding Chair of the Australasian Leukaemia and Lymphoma Group Laboratory Science Committee and has established and continues to direct the PwC Leukaemia and Lymphoma Tissue Bank. Her other professional roles include Medical Advisor and Board member of the Leukaemia Foundation, member of several Drug Advisory Boards and Government and College Advisory Committees as well as a wide range of academic and clinical service roles.
Dr Jeannette Young MB BS FRACMA MBA AFACHSE Dr Jeannette Young is the Chief Health Officer for Queensland, a role she has filled since August 2005. Prior to this, she held the position of Executive Director of Medical Services at the Princess Alexandra Hospital. Today she is responsible for such matters as disaster planning and response, retrieval services, licensing of Private Hospitals, organ and tissue donation services, offender health services, population health services and mental health policy and legislation. Dr Young is a member of numerous State and National committees and Boards, some of which include the Queensland Board of the Medical Board of Australia, the NHMRC and the Australian Health Protection Committee.
Sod turning ceremony of the Smart State Medical Research Centre with the Premier of Queensland, The Honourable Anna Bligh MP, Professor John Hay and Professor Michael Good.
DIRECTOR'S REPORT As this is my last report as Director, I thought it appropriate to reflect on some of the changes at the Institute and some of the great contributions made by QIMR staff and students. It has been an enormous honour and privilege to lead so many dedicated and brilliant scientists, support staff and students over the last ten years. I thank them all for the very generous support and friendship they have shown me, not just over the decade during which I served as Director, but over the 22 years that I have worked at the Institute. I have seen many changes in those years as we moved from the old building on Bramston Terrace in 1991 to the new Bancroft Centre and under the leadership of Lawrie Powell embarked on clinical research. With the generosity of Chuck Feeney and the support of Queensland and Federal governments we secured funding for the Berghofer Building which opened early in my tenure as Director. That building provided the impetus to further expand clinical research and the NHMRC funded our Good
Manufacturing Practice facility, Q-Gen, charged with making therapies for experimental human use. With the establishment of the clinical trials company, Q-Pharm, clinical research received a significant boost and made us far more competitive in translational research. The opening of the Clive Berghofer Cancer Research Centre (CBCRC) also coincided with the establishment of our Indigenous Health Research Program, a highlight of which has been the cross-cultural Spotlight on Science program that brings Aboriginal and Torres Strait Islander high school students for a week research immersion experience. This has been co-sponsored by industry and Education Queensland and has now resulted in 80 students and 14 teachers from all parts of Queensland learning about QIMR research first hand. The Indigenous Health Research Program brought an indigenous focus to research studies across all disciplines including cancer, vaccine research, mental health and genetics.
11
DIRECTOR'S REPORT (CONTINUED) While the CBCRC gave us more space, the hard work and ingenuity of our staff gave us the extra grant funding that enabled us to fill the new building while maintaining our focus on the common but important conditions that affect human health. We saw our grant income from NHMRC increase over the last ten years from approximately $5 million to $30 million today, this year receiving our largest-ever number of project grants with 26 successful applications. At the same time the number of our publications in high impact factor journals increased three-fold. This year, we published 390 peer reviewed research papers with 50 of these being in the most highly cited journals. The number of senior scientists who held externally-funded fellowships increased from four to 30 and at the same time, our younger scientific staff have been remarkably successful, perhaps best illustrated by the awards won by QIMR at the gala ASMR - Premier of Queensland annual awards showcase. This year, Associate Professor Maher Gandhi won the Clinical Research Award and the Postgraduate Student Award went to his PhD student Kimberly Jones.
12
We identified genes that increase the risk of developing melanoma and breast cancer, identified a protective action against oesophageal cancer by the organisms responsible for stomach ulcers, as well as helping investigate the mechanism of a natural anti-cancer compound that has since been used successfully to treat tumours in animals. Chuck Feeney, along with the State and Federal governments, has now provided funding for a new building, the $180 million Smart State Medical Research Centre. This will house our newest Division, the Mental Health Research Division and our new Education Centre, and at the same time provide much needed space for our other research programs when it opens in 2012. Securing the Mental Health Research Division and its inaugural Head, Associate Professor Michael Breakspear, has been a wonderful result for the campus and demonstrated how the Institute and the Royal Brisbane and Women’s Hospital are working so well together. In total, 14 of our scientists now also hold senior clinical positions, mostly at the RBWH.
The success of our staff continues to be recognised and rewarded. Included among high achievements Professor Peter Visscher was honoured by being elected to the Australian Academy of Science, Dr Michelle Wykes awarded a Smart Futures Fellowship for her research into malaria infection, and Associate Professor Gail Garvey won the Our Women, Our State award for promoting Indigenous Women.
The High School Education Program currently hosts over 1,400 high school students every year for a daylong seminar program and it is our hope that many of these bright students will return in later years to undertake research at the Institute or elsewhere. Our staff and students are to be congratulated for the fervor with which they welcome and enthuse the school students by explaining their own research and why they have chosen science as a career.
Our research achievements make QIMR one of the most successful research institutes in Australia.
Australia is a great country in which to do research and QIMR is one of our nation’s leading institutions. However, we must all work harder to convince governments of the need to invest further in medical research. The value of medical research is best summed up in the statement that a child born today will live on average three months longer than a child born on this day only one year ago. This trend is due to research leading to new public health knowledge, new drugs, diagnostics, vaccines and medical and health procedures.
This year, we embarked on clinical trials to develop a new technique for testing potential anti-malaria drugs, used natural occurring bacteria to control the spread of Dengue fever, and identified two new genes that increase the risk of developing Alzheimer’s disease.
The public have been extremely generous in their support of QIMR and I thank them most sincerely. I would especially like to thank Chuck Feeney, Marno Parsons, Sean Ryan, Royce Blackburne and Clive Berghofer, and many others for their ongoing support.
With 1 in 2 Australian suffering from cancer during their lifetime we continue to dedicate half of our research to understanding the genetic and environmental causes and developing new treatments for this horrible disease.
As a non-profit organisation, all our work is funded by grants and donations and I strongly believe it is our duty as researchers to keep the public informed about our achievements.
QIMR Annual Report 2009/10
One of the highlights of my job has been the opportunity to meet so many people outside the Institute who have supported us and explain to them the nature of our research and what we have discovered. That has been a true privilege.
After ten years, it is time to gi g give v another no ot r p person rso son tthe he o opportunity p ort rtu n is to focus my efforts on m to lead the Institute. My plan my lop vaccines for m own research program to develop malaria and om an Australia rheumatic heart disease with the support from ity will sstrengthen Fellowship. My relocation to GrifďŹ th University the already strong bonds that exist between QIMR and the University. The Institute has been very kind to me and very supportive and the friendships and research collaborations that I have here mean a great deal to me. My prayers will always be for the ongoing success of the Institute’s staff and students as they work to make this world a healthier place. Professor Michael Good AO Director
(Left to Right) The Honourable Anna Bligh MP, Helga and Chuck Feeney, Professor Michael Good and Clive Berghofer
13
RESEARCH CANCER AND CELL BIOLOGY GENETICS AND POPULATION HEALTH IMMUNOLOGY INFECTIOUS DISEASES MENTAL HEALTH JOINT PROGRAMS
14 QIMR Annual Report 2009/10
Peer recognition is one of the most satisfying rewards for scientists, and my election as Fellow of the Australian Academy of Science is probably the ultimate form of peer recognition in Australia. It is a reection on the fantastic bunch of people that I have had the pleasure and privilege of working with throughout my career. Professor Peter Visscher, Head of Queensland Statistical Genetics Laboratory
15
CANCER AND CELL BIOLOGY DIVISION DIVISION CHAIR: PROFESSOR GREG ANDERSON The Cancer and Cell Biology Division consists of ten laboratories located in the Bancroft Centre and the Clive Berghofer Cancer Research Centre. Research carried out in the Division covers a variety of topics from specific investigations of the molecular and genetic aberrations of tumour cells, to clinical and pathological studies of cancers and metabolic disorders. Scientists in the Division are particularly devoted to translating research findings into clinical outcomes. Tumours studied include melanoma, leukaemia, breast, prostate, liver and colorectal cancer. Research themes cover the normal mechanisms that control cell growth, cell division and inheritance; the DNA damage response and DNA repair; mechanisms of iron homeostasis; development of mouse models to study in vitro functions of cancer genes; developing screening tools for early detection of cancers; devising strategies for cancer treatment; and investigation of liver disease in both the adult and paediatric populations. The Division has strong collaborative links with other QIMR Divisions, the Royal Brisbane and Women’s Hospital and The University of Queensland. Research highlights for the past year include developing a compound from the rainforest that has shown significant anti-cancer activity in animal cancers; completing a study demonstrating the clinical utility of performing liver biopsies to detect fibrosis in children with cystic fibrosis; demonstrating increased cancer risk in haemochromatosis patients and producing mouse models to investigate colon cancer development, melanoma formation and ataxia with oculomotor apraxia type 2 (AOA2).
16
QIMR Annual Report 2009/10
CANCER AND CELL BIOLOGY DIVISION
DRUG DISCOVERY GROUP Laboratory Head: Professor Peter Parsons
This Group combines expertise in cancer biology with genomics and drug discovery. Cell communication networks in serious cancers reveal responses that provide opportunities for prevention and treatment. HIGHLIGHTS •
Identified new markers of melanoma invasion.
•
Identified a target lost in perineural invasion of cutaneous squamous cell carcinoma of the head and neck.
•
Developed a compound from the rainforest that has shown significant anti-cancer activity in animal cancers.
The overall theme of the Drug Discovery Group is to identify and study the function of genes that are important in the development and treatment of certain cancers, with the longer term aim of discovering agents that can be aimed at specific targets. Several such genes have been identified in melanoma and squamous cell carcinoma of the head and neck and are being followed up at the functional level. Recent research has found that MIC-1 is controlled by a pathway that is activated in almost all melanomas. Further, it was found that H-cadherin may be controlled by the same pathway that alters the invasion of melanoma cells.
A new target, alphaB-crystallin was identified. It is lost in perineural invasion of cutaneous squamous cell carcinoma of the head and neck, compared to cutaneous squamous cell carcinoma that does not invade neurons. This target was previously found to be highly expressed in head and neck squamous cell carcinoma. Work has focused on a QBiotics compound called EBC46 that has very significant anti-cancer activity against transplanted tumours in animal models, as well as against a wide range of spontaneous tumours in companion animals. Studies of the mechanism of action have so far revealed the primary target of the compound and given important clues about the cell signalling pathways that might be relevant to its action. EBC-46 is a plant product originating from the Queensland rainforest and this group has developed a viable method for producing the compound in pure form from cultivated plants.
Oscar pre-treatment; 15 days and 6 weeks post treatment
17
Dr Richard Ruddell, Hepatic Fibrosis Laboratory
CANCER AND CELL BIOLOGY DIVISION
HEPATIC FIBROSIS Laboratory Head: Associate Professor Grant Ramm
The Hepatic Fibrosis Laboratory investigates the cellular and molecular mechanisms of scar tissue formation in the liver, such as the iron overload disease haemochromatosis, that leads to fibrosis and cirrhosis in adults, and cystic fibrosis and biliary atresia in children. HIGHLIGHTS •
Discovered the role of neutrophils in liver repair.
•
Completed a study which demonstrated the clinical utility of performing liver biopsies to detect liver scarring (fibrosis) in children with cystic fibrosis who are suspected of having serious liver disease.
•
Demonstrated that current methods to detect liver scarring and predict the development of liver disease complications are insensitive and non-specific.
In an animal model that mimics cystic fibrosis liver disease and biliary atresia, a type of blood cell called a neutrophil has been shown to assist with the repair of injured and scarred liver tissue. This is achieved through the production of enzymes called collagenases, which digest scar tissue and allow the liver to heal itself. The hepatic stellate cell is one of the principal regulators of liver scar (fibrosis) formation via the deposition of fibrillar collagens in chronic liver disease.
18
QIMR Annual Report 2009/10
This year, in a collaboration with paediatric surgeons at Brown University, Rhode Island, a study found a major role for neutrophils in the resorption of this scar tissue in an animal model that mimics liver disease in children including cystic fibrosis (CF) and biliary atresia. When the bile duct obstruction is removed in this model, these cells assist in liver repair by producing matrix-degrading metalloproteinase enzymes (MMP8). MMP-8 act as collagenases to digest fibrillar collagens deposited by hepatic stellate cells. In a recently completed clinical trial, collaborative research with the Royal Children's Hospital demonstrated that liver fibrosis identified via liver biopsy, predicts the future development of clinically significant liver disease (portal hypertension), in children with CF. Current clinical modalities used in evaluating liver disease in CF, such as clinical examination, blood tests for elevated liver enzymes or liver ultrasound scanning, do not predict liver fibrosis or the development of portal hypertension. Liver biopsy is now proposed as the gold standard to detect liver scarring and thus may be adopted clinically to better manage patient care and assist in developing more targeted medical interventions in children with CF.
CANCER AND CELL BIOLOGY DIVISION
IRON METABOLISM Laboratory Head: Professor Greg Anderson
The Iron Metabolism Laboratory focuses on understanding the homeostasis of iron in the body and the natural history of disorders of iron metabolism such as the iron loading disease haemochromatosis. HIGHLIGHTS •
Identified the iron reductase enzyme Dcytb as a modifier of hereditary haemochromatosis severity.
•
Demonstrated increased cancer risk in haemochromatosis patients.
•
Defined disease progression and penetrance in hereditary haemochromatosis.
•
Examined iron homeostasis in chronic haemolytic anaemia.
•
Identified key factors involved in the modulating expression of the iron regulatory hormone hepcidin.
Iron is essential for a large number of critical cellular processes but its concentration in the body must be kept within defined limits. Too little iron can result in anaemia while too much can cause damage to vital organs such as the liver and heart. A central goal of the Iron Metabolism Laboratory is to understand the mechanisms of cellular iron transport and the way in which these processes are regulated. A particular theme is to describe the pathways of intestinal iron absorption and
to understand how absorption is altered in disorders of iron metabolism such as haemochromatosis, thalassaemia and haemolytic anaemia. Much effort has been directed towards understanding physiological variations in iron absorption at the molecular level. Key recent studies have examined how iron absorption and its major regulator, hepcidin, are altered in neonates and during pregnancy, and in chronic haemolytic anaemia and thalassaemia. The Laboratory also maintains a strong interest in the pathogenesis, penetrance and genetics of the iron loading disorder haemochromatosis and has continued to study the natural history of the disease. During the year, a series of important new studies have commenced including an analysis of iron-related oxidative stress in haemochromatosis to provide an objective endpoint for phlebotomy therapy, defining the role iron plays in lung injury in cystic fibrosis, and developing novel oral iron supplements that deliver iron more efficiently and with less toxicity than current preparations.
Rat duodenal villi
19
CANCER AND CELL BIOLOGY DIVISION
LEUKAEMIA FOUNDATION Laboratory Head: Professor Andrew Boyd
HIGHLIGHTS •
Completed preclinical testing of an antibody against the EphA3 protein for treatment of leukaemia.
•
Identified a key role for Mcl-1 in cell survival and explored the loss of a key transcription factor in glioma expression.
•
Completed preclinical testing of novel Eph-based therapies for spinal cord injury.
Antibodies to other EphA proteins have been investigated in a variety of human tumours, complementing studies of expression in clinical samples. Eph proteins have oncogenic roles in some cancers, including leukaemia, melanoma and glioma. In others, they appear to have tumour suppressor roles, especially those of epithelial cancers. The function in
different cancers is being explored using biochemical studies and animal models. As part of the work on glioma, the Laboratory has discovered a key role for Mcl-1 in cell survival and has also explored the loss of a key transcription factor in glioma expression. Preclinical studies on antibodies to Eph proteins have continued. In particular, an antibody to EphA3, raised initially against a childhood leukaemia, has been tested in leukaemia and other cancer models. In collaboration with laboratories in Melbourne and a US biotech, one antibody has completed preclinical testing and is expected to go into a clinical trial within a year. Investigation of EphA4 function has revealed a critical role in spinal cord injury. In collaboration with Queensland Brain Institute, inhibitors of EphA4 in spinal cord injury models in mice and rats are being tested.
The Leukaemia Foundation of Queensland Laboratory is seeking to understand the role of critical cellular proteins in the causation and evolution of leukaemia and other cancers. Corticospinal nerves in mice regrow past the lesion site following treatment for spinal cord injury.
20
QIMR Annual Report 2009/10
CANCER AND CELL BIOLOGY DIVISION
MEMBRANE TRANSPORT Laboratory Head: Associate Professor Nathan Subramaniam
This laboratory studies how iron metabolism is regulated by the liver. Identification of the molecules involved in iron metabolism, and defining the way they work has major implications for the treatment of iron-related disorders such as hereditary haemochromatosis and anaemia. HIGHLIGHTS •
Established that loss of both HFE and transferrin receptor 2 genes causes severe iron loading similar to that observed in juvenile haemochromatosis.
•
Demonstrated that hepcidin is misregulated in the absence of HFE and transferrin receptor 2 genes.
•
Showed that chronic inflammation may not be the primary cause of the anaemia seen in schistosomiasis.
•
Demonstrated that increased availability of iron may lead to increased disease severity in schistosomiasis.
•
Established that mutations leading to the macrophage cell iron phenotype of ferroportin disease affect its iron transport activity.
•
Showed that differences in the functional consequences of mutations in ferroportin are responsible for the phenotypic variability of ferroportin disease.
•
Demonstrated that ferroportin disease mutations cluster in specific regions according to phenotype.
The major focus is aimed at understanding how iron levels in the body are regulated, the genes involved, their mechanism of action and the role iron plays in various disorders including cancer.
In the first study of its kind, it was shown that deletion of the genes HFE and TFR2, mutations of which cause hereditary haemochromatosis, lead to severe iron loading typical of juvenile haemochromatosis. The loss of these genes also causes the abnormal regulation of the iron hormone hepcidin. In collaboration with Dr Jon Harris (Queensland University of Technology), it was shown that mutations leading to the macrophage cell iron phenotype of ferroportin disease affect ability to transport iron and not its localisation. In addition, mutations which affect the function of ferroportin are responsible for the phenotypic variability of ferroportin disease. Protein modelling suggested that ferroportin disease mutations cluster in specific regions according to phenotype. In collaboration with the Parasite Cell Biology Laboratory, a study was conducted into the effect of schistosomiasis infection in the presence of increased iron. These studies suggest that chronic inflammation may not be the primary cause of the anaemia observed in schistosomiasis and that increased iron during infection causes increased liver scarring. A collaborative study with Dr Kerry Richards and Professor Robin Mortimer (Conjoint Endocrine Laboratory, RBWH) showed that the human placenta secretes and internalises the serum protein transthyretin. This internalisation is increased in the presence of thyroid hormone which enters as a complex with transthyretin. Denny Muslim, PhD student, Membrane Transport Laboratory
21
CANCER AND CELL BIOLOGY DIVISION
CANCER COUNCIL QUEENSLAND (CCQ) TRANSGENICS Laboratory Head: Associate Professor Graham Kay
The CCQ Transgenics Laboratory studies the epigenetic mechanisms that modulate gene expression and the role of tumour suppressor genes in preventing cancer during normal development. HIGHLIGHTS •
Revealed a role for Smchd1 in the control of both autosomal and X-linked gene expression.
•
Created a mouse model that contains different combinations of pocket protein loss in their melanocytes.
Epigenetic control of gene expression is mediated by mechanisms that modulate access of the transcription machinery to the genome. Previously, the Laboratory showed that Smchd1 play an essential role in X-inactivation, an epigenetic process that involves silencing one of the two X chromosomes in females. Using microarray expression analysis, results show that Smchd1 is also involved in silencing the expression of numerous autosomal genes in both males and females. Some of these genes are regulated in a manner akin to that involved in X-inactivation, suggesting that Smchd1 may regulate autosomal and X-linked gene expression through a common mechanism.
Using next generation sequencing to compare changes in DNA and chromatin modifications in the presence and absence of Smchd1, researchers are now endeavouring to determine the mechanism by which SmchD1 regulates gene expression. Other studies in the Laboratory are concentrating on the role of tumour suppressor genes in the cascade of events leading to cancer with an emphasis on melanoma. One of the most frequently mutated tumour suppressor genes in familial melanoma is Cdkn2a, which can act to simultaneously deregulate both the pocket protein family of proteins (Rb1, p107 and p130) and the Arf/p53 regulatory pathway. To evaluate the tumour suppressive interactions of each pathway in melanoma formation, a mouse model was created containing different combinations of pocket protein loss, both alone and in combination with Arf/p53, and the phenotypes of these mouse strains and their melanocytes are being determined.
Live cell imaging showing single green spot of Smchd1-GFP localising to the inactive X chromosome in female cells.
22
QIMR Annual Report 2009/10
CANCER AND CELL BIOLOGY DIVISION
RADIATION BIOLOGY AND ONCOLOGY Laboratory Head: Professor Martin Lavin
The focus of this laboratory is DNA damage response and its role in maintaining the integrity of DNA to minimise the risk of cancer and neurodegeneration. HIGHLIGHTS •
Described a novel activity for senataxin defective in ataxia with oculomotor apraxia type 2 (AOA2).
including ataxia with oculomotor apraxia type 1 and 2 (AOA1 and AOA2).
•
Generated a mouse model for AOA2.
•
Investigated the role for aprataxin defective in ataxia with oculomotor apraxia type 1 (AOA1) in oxidative stress.
•
Described the role for aprataxin in DNA double strand break repair.
•
Developed a sensitive probe for oxidative stress.
•
Generated a mouse model for SMG1 involved in non-sense mediated decay of abnormal mRNAs.
Progress has been made in describing additional autophosphorylation sites important in the activation of ATM. In collaboration with Thilo Dork (Hannover Medical School), the first Rad50 deficient patient has been identified. Rad50 represents a member of the Mre11 complex that acts as a sensor of DNA double strand breaks, and is a new substrate for ATM. Studies are underway to investigate the functional significance of Rad50 phosphorylation in response to DNA damage.
The major objective of this laboratory is to investigate the mechanisms that maintain the integrity of the genome to minimise the risk of cancer and other pathologies. Over the years, the Laboratory has focused on the human genetic disorder ataxia-telangiectasia (A-T) as a model system to investigate cancer development and neurogeneration. More recently, these studies have been extended to include several other disorders that overlap with A-T in their clinical phenotype
The first comprehensive description of the characteristics of senataxin, the protein defective in AOA2, has been reported. This protein has a role in protecting cells against this form of stress and is also involved in transcriptional control and mRNA splicing. A mouse model for AOA2 has been generated, which will be of great assistance for investigating neurodegeneration. In collaboration with Professor Gardiner (UQ), important progress has been made in developing biomarkers for prostate cancer. Professor Martin Lavin, Head of Radiation Biology and Oncology Laboratory
23
CANCER AND CELL BIOLOGY DIVISION
RBWH GASTROENTEROLOGY Laboratory Head: Professor Barbara Leggett
This laboratory identifies genetic changes which define distinct subtypes of colon cancers and premalignant polyps with the aim of predicting the clinical behaviour of these tumours. HIGHLIGHTS •
Completed a genome-wide expression profiling study of 38 serrated colorectal polyps and 100 colorectal cancers.
•
Established a protocol for genome-wide methylation profiling and completed a proof of principle pilot study of ten colorectal cancers.
•
Identified frequent chromosomal instability in tumours with a BRAF mutation that are microsatellite stable.
•
Commenced a new study to examine molecular changes underlying the development of colorectal polyps.
•
Initiated a BRAF mutant mouse model to investigate colon cancer development.
Different types of colorectal polyps may progress to cancer and this is accompanied by defined molecular changes. A better understanding of the molecular changes that underlie the development of different types of colorectal polyps and cancers will improve patient management and ultimately lead to better therapy options. Recent research efforts have focused on a particularly aggressive form of colorectal cancer that has mutation of the BRAF oncogene in the absence of microsatellite instability. The Laboratory has found that chromosomal instability is common in this cancer type and this may contribute to the worse outcome observed for these patients. A large, genome-wide study is currently underway using expression and methylation microarrays to evaluate key molecular pathways altered in these cancers. Analysis of methylation status of IGFBP7 and CIMP in serrated polyps showed that IGFBP7 methylation is associated with large, proximal, advanced serrated polyps (ASPs). In addition, IGFBP7 methylation was observed in 68.4% of BRAF mutant/ CIMP positive ASPs. The Laboratory also generated inducible shRNA IGFBP7 knockdown retroviral vectors to analyse IGFBP7 senescence function in vitro. A BRAF mutant mouse model that has inducible colon-specific Braf V600E mutant overexpression is being assessed to determine the contribution of BRAF to the initiation or progression of colon cancer. Immunohistochemical staining of colorectal cancer
24
QIMR Annual Report 2009/10
CANCER AND CELL BIOLOGY DIVISION
SIGNAL TRANSDUCTION Laboratory Head: Professor Kum Kum Khanna
This laboratory researches signal transduction pathways involved in the detection, signalling or repair of DNA damage and seeks other genes in these pathways which might have similar involvement in cancer susceptibility by preventing the generation of mutations in DNA. HIGHLIGHTS •
Found that hSSB1 and hSSB2 may have a function in the maintenance of genomic stability.
•
Identified a novel role of Pin1 in the regulation of the final stage of cell division cycle that might provide an explanation for the link between dysregulated Pin1 levels and cancer.
•
Identified DNA damage-induced phosphorylation of Exo-1 and its role in the regulation of DNA damage repair.
•
Characterised centrobin as a novel regulator of the cell division cycle, and in particular mitosis.
•
Demonstrated that cells deficient in SBP2 accumulate oxidative damage that might predispose them to cancer, neurodegeneration and premature ageing.
In collaboration with Michele Pagano and Weidong Wang, integrator subunit 3 (INTS3) was identified as a major partner of hSSB1 and hSSB2. The complex also contains many additional proteins that are suggestive of a role for hSSB1 in damageinduced transcription. Experiments are currently underway to investigate the pathophysiological roles of SSB1 and SSB2, having generated conditional knockout mice for these proteins.
A novel role was identified for Pin1, a peptidyl-prolyl isomerase which is deregulated in many tumours, in cytokinesis. Furthermore, there is evidence that Pin1 regulates the final stages of cytokinesis by binding to centrosome protein 55 kDa (Cep55), an essential component of the cytokinetic ring discovered previously. These data are the first evidence that Pin1 regulates cytokinesis and may provide a mechanistic explanation as to how pathologic levels of Pin1 can stimulate tumour formation. Centrobin, a recently identified centrosomal protein, was found to have a novel role as a regulator of centrosome and spindle integrity. Centrobin-depleted cells have unfocused spindle poles and they fail to satisfy spindle assembly checkpoint. Furthermore, interphase microtubules were observed to be clustered around the centrosome in centrobin-depleted cells compared to more diffused localisation seen in control cells. The microtubule instability phenotype might be due to an indirect effect of centrobin on microtubule growth.
25
CANCER AND CELL BIOLOGY DIVISION
SKIN CARCINOGENESIS Laboratory Head: Dr Graeme Walker
This laboratory is interested in the interaction of genetic and environmental factors in melanoma development and in particular how ultraviolet radiation (UV) initiates melanoma. HIGHLIGHTS •
Discovered that naevus (mole) development in mice is caused by mutation of the same gene (CDK4) that is responsible for melanoma susceptibility in melanoma-prone families.
•
Investigated how melanocytes move up to the burnt area of skin after sunburn.
The development of naevi (moles) is the strongest risk factor for the development of melanoma. The laboratory has studied mice that have gene mutations that are important in human melanoma. One gene, CDK4, was found to predispose mice to the developing naevi. This gene regulates cell proliferation in general, and investigations are ongoing as to why its deregulation has such a special effect on melanocytes. In addition to mechanisms of tumourigenesis, the laboratory is interested in how melanocytes respond to ultraviolet (UV) radiation. Sun exposure results in inflammation and the release of molecules (cytokines) that create chemical gradients to attract immune cells into or out of the skin.
26
QIMR Annual Report 2009/10
It was discovered that some of these cytokines also influence melanocytes, which can migrate out of hair follicles to the sunburnt area of skin. These cytokines may be important in the development of a melanoma subtype (lentigo maligna) that is caused by chronic sun exposure and proposed emanate from follicular melanocytes. In contrast, this melanocyte activation may be helpful for vitiligo (loss of melanocytes). Although not associated with excess skin cancer, white patches can create psychological and social stigma especially for darker skinned individuals. Repigmentation involves activation of follicular melanocytes and their migration up into and outwards along the epidermis. Treatments such as phototherapy (UV) and corticosteroids are often not successful, and rarely long lasting. Therefore knowing which cytokines activate follicular melanocyte precursors may be of considerable help to vitiligo patients.
Multiple-label immunofluorescence image of a melanoma from a mouse model.
GENETICS AND POPULATION HEALTH DIVISION DIVISION CHAIR: PROFESSOR EMMA WHITELAW The Genetics and Population Division encompasses 13 laboratories and over 150 scientists. There continues to be an emphasis on working with large human cohorts and many of these cohorts are being collected at both national and international levels. A number of the laboratories are using classic epidemiological approaches to identify the environmental causes of various cancers, including those of the skin, the pancreas, the ovaries and the oesophagus. Others are involved in finding the underlying genetic factors associated with increased susceptibility to cancer, in particular breast, ovarian, endometrial, colorectal cancer and melanoma. Other laboratories are using similar strategies to identify genes that predispose people to migraine, dementia, depression and addiction. Improvements in the technologies available to study DNA both in the germline and in tumour tissues has revolutionised this area of research. The acquisition of a Genome Analyzer II at QIMR has provided us with additional on-site capabilities in this area. The success of the genome-wide association studies (GWAS) means that studies must now try to understand at a functional level why particular sequence changes in particular parts of the genome predispose to disease. These studies are beginning and a number of laboratories are now investigating this using transcriptome analysis and animal models. The former requires analysis of extremely large datasets and the Division is delighted to welcome Dr Lutz Krause, an experienced bioinformatician. Dr Krause is the recipient of a QIMR Fellowship and moved here from Switzerland in June 2010.
27
Science for me has always been about the search for knowledge, asking new questions and addressing them the best we can. With 10-15% of Australians suffering from asthma, we hope our research will ultimately lead to improved disease prevention and management gement and allow asthma sufferers to live normal llives. ives. Dr Manuel Ferreira from the Genetic Epidemiology Laboratory is heading the largest Australian study of asthma genetics.
28
QIMR Annual Report 2009/10
GENETICS AND POPULATION HEALTH DIVISION
CANCER AND POPULATION STUDIES Laboratory Head: Professor Adèle Green
The Cancer and Population Studies Group investigate the causes and natural histories of cancers and seek to generate evidence for their prevention. HIGHLIGHTS •
Launched a new study (D-Health) to assess the feasibility of conducting a large-scale randomised trial of vitamin D.
•
Completed a study of office-based workers in Brisbane showing that the general population is confused about how sun exposure is needed to provide vitamin D.
•
Investigated health resource use in relation to oesophageal cancer and Barrett’s oesophagus.
•
Showed that persistence of betapapillomavirus infections in the skin is a risk factor for actinic keratoses, a potential precursor tumour to skin cancer.
•
Demonstrated that moderate intake of oily fish (average of one serving every five days) and of wine (average of half glass per day) may decrease the acquisition of actinic keratoses.
•
Determined that people who have relatively high levels of serum selenium have a lower risk of both basal and squamous cell carcinoma in the eight years following blood collection.
•
Showed over a 16 year period that clinical signs of chronic sun damage to the skin are associated with developing multiple basal cell carcinomas over time.
The Cancer and Population Studies Group investigates the role of environmental factors and personal characteristics, including genetically-determined, in the causation of cancer and its precursors, and in cancer prognosis. A major project continues to be the 20-year follow-up study of almost 1,000 residents of the township of Nambour, Queensland.
This study focuses on the common skin cancers and associated pre-malignant skin conditions. Besides solar radiation, the effects of diet and of human papillomavirus (HPV) infection are also being studied and further investigation of the economic burden of skin cancer in the Queensland community continues. Since June 2007, the Queensland Pancreatic Cancer Study has been conducted to understand the genetic and environmental risk factors of pancreatic cancer. A new project this year involves middle-aged people with colorectal cancer. The aim is to investigate the changes in employment and work-life while dealing with a lifethreatening condition and managing treatment demands. This case-control study is the first in Australia and the goal is to enrol 400 men and women with cancer and follow them up at one year. The highly active QIMR/RBWH Statistics Unit is situated within the Group. The biostatisticians collaborate with scientists and clinicians on projects including development of vaccines and treatment for malaria; human papillomavirus and skin cancer; Indigenous health; radiation oncology; and obstetrics and gynaecology. A new study, D-Health, aims to assess the feasibility of conducting a large-scale randomised trial of vitamin D for the prevention of chronic disease in the general population. D-Health is recruiting approximately 600 people aged 60-85 from across the four eastern states of Australia. D-Health is launching in August this year. 29
GENETICS AND POPULATION HEALTH DIVISION
CANCER CONTROL GROUP Laboratory Head: Associate Professor David Whiteman
The Cancer Control Group conducts research aimed at reducing the burden of cancer. The need for such research is clear, given that almost one in three deaths in Australia is due to cancer. HIGHLIGHTS •
Identified that infection with Helicobacter pylori decreases the risk of oesophageal adenocarcinoma.
•
Discovered people who experience frequent symptoms of gastro-oesophageal acid reflux have seven times higher risk of oesophageal adenocarcinoma.
•
Found that obese people have lower risks of oesophageal squamous cell carcinoma, the converse of that observed for oesophageal adenocarcinoma.
The Group’s mission is to identify those factors that cause cancer, and then to find ways of applying such knowledge to prevent cancer. Research is conducted into other aspects of cancer control, including defining pathways to diagnosis, mapping patterns of care and identifying determinants of survival from cancer. In collaboration with Brisbane pathologists, the current epidemiological study in melanoma has recruited more than 600 patients. Data analysis will commence in 2011.
The Group has long-standing collaborations with researchers at Dartmouth Medical School (USA) and University of Toronto (Canada) to perform pooled analyses of 12 melanoma datasets. An international consortium headed by Tom Vaughan (Fred Hutchinson Cancer Research Center, Seattle, USA) and David Whiteman (Cancer Control Group, QIMR) was awarded a US$7.6 million grant by the US National Cancer Institute to conduct a genome-wide scan of Barrett’s oesophagus and oesophageal adenocarcinoma. The Group’s other major focus is oesophageal cancer. With QIMR colleagues, the Group has undertaken the largest studies of oesophageal cancers and pre-cancers yet conducted. These studies have led to new insights about the causes of these conditions. Analyses will continue for many years, enhanced by the productive collaborations with clinicians and researchers across Australia, USA, UK and Europe.
A photomicrograph of Barrett's oesophagus, the metaplastic precursor for oesophageal adenocarcinoma.
30
QIMR Annual Report 2009/10
GENETICS AND POPULATION HEALTH DIVISION
CANCER GENETICS Laboratory Head: Professor Georgia Chenevix-Trench
This laboratory investigates why some people get cancer, and how these cancers develop from a normal cell, particularly breast, ovarian and stomach cancer which are often found together in the same families. HIGHLIGHTS •
Discovered that mutations in the breast cancer predisposition gene, BRCA1, appear to alter the pattern of methylation in breast tumours.
These findings are providing novel insights into the aetiology of these cancers, and will soon allow risk prediction models to be developed, particularly in mutation carriers.
•
Identified the type of mutations in the ATM breast cancer predisposition gene that are most likely to cause breast cancer.
•
Identified the first, validated ovarian cancer susceptibility locus.
Analysis of GWAS for chemoresponse is also underway, and the study is expected to identify several novel genes that predict a patient’s response to treatment. In addition, analysis of expression, copy number and methylation profiles of familial breast tumours has shown that BRCA1-related breast tumours have a distinct methylation profile. This suggests that the BRCA1 gene may play a direct or indirect role in de novo methylation.
The genome-wide association study (GWAS) revolution continues, with dozens of genetic variants found to be identified with cancer risk. The Cancer Genetics Laboratory has played an important role in international consortia that have identified about 20 susceptibility genes for breast cancer, seven for ovarian cancer, and nine that modify the risk of cancer in BRCA1 and BRCA2 mutation carriers. Some of these loci, like the one that codes for the telomerase gene, and another at 8q24 near the MYC oncogene, appear to be pan-cancer susceptibility loci that affect risk of many different cancers.
In addition, detailed analysis of the ATM gene in a large number of breast cancer families, and controls, has shown that rare evolutionarily unlikely missense substitutions confer increased risk of breast cancer.
31
GENETICS AND POPULATION HEALTH DIVISION
EPIGENETICS Laboratory Head: Professor Emma Whitelaw
The Epigenetics Laboratory aims to understand the basic mechanisms of disease at a molecular level. The Laboratory focuses on chromatin, the proteins that package DNA. HIGHLIGHTS •
Identified a number of novel genes involved in epigenetic reprogramming.
•
Detected hyperactivity in adult mice that were exposed to ethanol in utero.
•
Began a thorough characterisation of the small RNA population in sperm in the hope of identifying the drivers of non-DNA based transgenerational inheritance.
•
Developed a mouse model for fetal alcohol spectrum disorder.
Biologists across many disciplines have known that there is a surprising degree of variation in physical traits even among genetically identical individuals and even when the environmental influences, in the strict sense of the word, are controlled. Genetic textbooks acknowledge this fact and refer to it as intangible variation or developmental noise.
32
QIMR Annual Report 2009/10
The Epigenetics Laboratory suggests that this intangible variation results from the variable establishment of epigenetic modifications to the DNA nucleotide sequence in early development. These modifications, which involve DNA methylation and chromatin remodelling, result in alterations in gene expression, which affect the physical form of the organism. Work from a number of laboratories suggests that these epigenetic states can be influenced by the environment, raising the possibility that they are involved in the developmental origins of some disease states. The Laboratory has recently shown that the consumption of 10% ethanol during the first half of gestation in the mouse alters the DNA methylation levels at a gene that is particularly sensitive to epigenetic state. This study has led to the development of a mouse model of fetal alcohol spectrum disorder.
The Familial Cancer Laboratory examines the genetic changes that make some families more susceptible to colorectal and other cancers.
GENETICS AND POPULATION HEALTH DIVISION
FAMILIAL CANCER Laboratory Head: Dr Joanne Young
HIGHLIGHTS •
Demonstrated that approximately half of the patients who carry Lynch syndrome mutations and who develop breast cancer will show DNA mismatch repair deficiency.
Research published by the Laboratory in early 2010 clearly shows that breast cancers may also be sentinels for Lynch syndrome in some families.
•
Identified a novel syndrome of young-onset (less than 45 years old) colorectal cancer associated with sparse polyps in the patient and their siblings.
•
Found that in about half of the patients with serrated polyposis the polyp which causes cancer is an adenoma.
•
Showed that the smoking paradox in patients with serrated polyposis differs according to gender.
Currently, efforts are focused on the significance of skin cancers and small intestinal cancers in Lynch syndrome; examining the pathology and molecular features which may be associated with this condition; characterising the types of inheritance of Lynch syndrome mutations in families with these unusual tumours; and looking for evidence of independent genetic segregation.
•
Discovered that genetic background is important in how the disease is expressed in patients with MUTYH mutations.
The Familial Cancer Laboratory concentrates on inherited susceptibility to colorectal and other cancers. This year, the Laboratory has studied some of the cancers which occur outside the colon in patients with a condition called Lynch syndrome. The results of this work can lead to a diagnosis of Lynch syndrome at routine examination, thereby alerting the clinical team that the patient and half of their relatives are at increased risk for cancers and should undergo preventive screening. Similarly to colon and endometrial cancers, breast cancers which arise in Lynch syndrome mutation carriers were found to be more likely to show many infiltrating lymphocytes, and half of the breast cancers in these patients will demonstrate loss of DNA repair proteins. Though cancer of the colon is most common in Lynch syndrome, there has been debate as to whether cancers of the breast can also occur in this condition.
Serrated adenoma and adjacent cancer
33
GENETICS AND POPULATION HEALTH DIVISION
GENETIC EPIDEMIOLOGY Laboratory Head: Professor Nick Martin
This laboratory investigates the pattern of disease in families to assess the relative importance of genes and environment in a variety of important health problems and to locate the genes responsible using genome-wide association analysis. HIGHLIGHTS •
Discovered a new gene, IRF4 predisposing to moliness and melanoma on chromosome 6.
•
Investigated new genes for blood cell characteristics including monocyte count, erythrocyte volume and that the latter also affects iron status.
•
Showed that top alleles for CD4/CD8 ratio (an important marker of AIDS susceptibility) are also associated with type 1 diabetes, and HIV-1 immune control.
•
Uncovered a new gene for hair curliness in Europeans, with possible applications for forensics and cosmetics.
•
Found the top gene for finger-length ratio, a putative marker of prenatal testosterone exposure, is also the top gene affecting age at menarche.
•
Replicated new gene variants for lipids, smoking, and eye colour.
•
Published the first genetic study of gambling addiction.
This has been an exciting year for the Genetic Epidemiology Laboratory with intensive analysis of genome-wide association studies (GWAS) on 17,000 study participants, in which half a million or more single nucleotide polymorphisms (SNPs)
34
QIMR Annual Report 2009/10
are typed from thousands of twins and their family members who have previously been measured for hundreds of diverse genotypes. There have been major breakthroughs in two of the principal domains of research interest. For melanoma and its most important risk factor, nevus density (moliness), the influence of new genes on chromosomes 9, 20 and 22 have been shown. Participation in an international consortium found new genes for hair and eye colour, both of which influence melanoma risk. In the domain of depression, the Laboratory contributed to a large international consortium that has found strong (but not quite significant) evidence for several new genes, and this is now being combined into a yet larger analysis through the Psychiatric Genetics Consortium. The Genetic Epidemiology Laboratory also played a leading role in initiating the ENIGMA consortium (Enhancing NeuroImaging Genetics through Meta-Analysis) to combine GWAS studies of brain imaging phenotypes, with a view to unravelling the genetic influences on brain structure and function as a window into psychiatric diseases – particularly depression.
GENETICS AND POPULATION HEALTH DIVISION
GYNAECOLOGICAL CANCER Laboratory Head: Dr Penny Webb
This laboratory investigates all aspects of gynaecological cancer from aetiology to diagnosis, patterns of care, quality of life and survival. The main goal is to identify ways to prevent these cancers and to improve outcomes for the women they affect. HIGHLIGHTS •
Showed that high intake of processed meat may be linked to elevated risk of ovarian cancer while women who eat more poultry and fish may have a lower risk.
conducted ten years earlier. Other ongoing investigations into risk factors for endometriosis have identified that childhood weight and menstrual characteristics are associated with risk.
•
Identified that women who drink two or more cups of tea a day may have a 30% lower risk of getting ovarian cancer than women who do not drink tea, and that both black and green tea seem to confer a similar benefit.
•
Found that women with ovarian cancer continue to prioritise tumour response as the most important outcome of chemotherapy despite disease progression over time and women's realistic understanding of the low likelihood of cure.
Data collection for two national studies (the Ovarian Cancer Patterns of Care Study and Endometrial Cancer Clinical Follow-Up and Quality of Life Study) is progressing well and is due for completion in early 2011. Analysis of data from the recently completed Australian National Endometrial Cancer Study has begun.
•
Shown that women who maintained or increased their physical activity after a diagnosis of ovarian cancer have decreased depression and improved quality of life.
The Gynaecological Cancer Laboratory has continued investigations into the causes of ovarian cancer and endometrial cancer through the Australian Ovarian Cancer Study (AOCS) including investigating the role of diet in ovarian cancer risk using data from both AOCS and a similar study
Also nearing completion is a pilot study assessing the feasibility of implementing a home-based walking intervention in women with ovarian cancer who are undergoing adjuvant chemotherapy. The Laboratory has continued the contribution to the international Ovarian Cancer Association Consortium which has recently identified a new gene implicated in the development of ovarian cancer, and, for the first time, have also contributed data to collaborative studies conducted through the Epidemiology of Endometrial Cancer Consortium. 35
GENETICS AND POPULATION HEALTH DIVISION
INDIGENOUS HEALTH RESEARCH PROGRAM Laboratory Head: Associate Professor Gail Garvey
The Program seeks to increase the number of research projects developed in partnership with Aboriginal and Torres Strait Islander communities and to increase the number of Aboriginal and Torres Strait Islander postgraduate students and researchers working on these projects. HIGHLIGHTS •
Conducted a cross-sectional study of Indigenous children residing in the Torres Strait to assess the prevalence of obesity and the metabolic syndrome.
•
Evaluated and asthma education intervention for Indigenous children with asthma.
•
Found that Indigenous people’s understanding of dementia is poor.
•
Conducted the Spotlighting Careers in Indigenous Health and Science Program in August 2009. 15 Indigenous students and two teachers attended the program from various areas of South East Queensland.
The Program is validating the cultural sensitivity of an existing supportive care needs survey and adapting it for use with Australian Indigenous people with cancer. This work has been carried out in 2009 and early 2010. A cross-sectional study is about to commence to assess the baseline support needs of all adult Indigenous patients hospitalised for their cancer. The results from the asthma study and the metabolic syndrome and obesity study among children and youth of the Torres Strait have been published. 36
QIMR Annual Report 2009/10
The Multicentre Bronchiectasis Study continues to recruit study subjects. 89 children in Australia and 41 in Alaska have been enrolled in the observational study and 45 children in Australia and 37 in New Zealand are enrolled in the randomised controlled trial. Data collection will end in 2011. The study on the understanding of dementia was a collaborative project conducted between QIMR and CRC Dementia (QUT), Centre for Rural and Remote Health (USQ) and Alzheimer’s Australia. This project found that Indigenous people’s understanding of dementia was poor, which highlights the need for culturally appropriate awareness campaigns and targeted education interventions on dementia among Indigenous communities. Spotlighting Careers in Indigenous Health and Science Program aspires to showcase science and enhance students’ understanding of Indigenous health. The program allows students to explore and gain experience in real laboratories and participate in other learning activities specific to Indigenous health and culture. In 2009, 15 Indigenous students, one teacher and one Aboriginal Counsellor attended.
GENETICS AND POPULATION HEALTH DIVISION
MOLECULAR CANCER EPIDEMIOLOGY Laboratory Head: Dr Amanda Spurdle
This laboratory studies breast, ovarian, endometrial, colon and prostate cancer with a focus on identifying molecular signatures of normal and tumour tissue that can point to the genetic and environmental causes of these cancers. HIGHLIGHTS •
Developed a quantitative classification scheme for colorectal-endometrial cancer mismatch repair gene variants, to apply to a large international database.
tumour information in this database will assess the predictive capacity of tumour features, developing another component of the MMR gene multifactorial classification model.
•
Provided information on tumour features in developing a model for the clinical classification of sequence variants in the colorectal-endometrial cancer mismatch repair genes.
•
Found that some gene sequence variants predicted to cause benign protein changes may alter RNA splicing to severely affect protein structure and function.
In addition, work is continuing on classifying variants in breast cancer genes BRCA1 and BRCA2, with emphasis on assessing possible splicing aberrations. The Laboratory’s research has shown that some gene sequence variants predicted to cause benign protein may actually alter RNA splicing to severely affect protein structure and function. This has important implications for bioinformatic components of prediction models, which currently do not consider the effect of splicing for variants that lie within the coded protein.
The Molecular Cancer Epidemiology Laboratory has continued work on unclassified variants in mismatch repair (MMR) genes. More that 14,900 variants in an international dataset were re-asssessed (identifying error for 3% of entries), and provided a qualitative classification scheme to provide consistent evaluation across the dataset. This provided a framework for future research, and also resulted in the reclassification of variants in 429 families recruited into the study. Analysis of
The Laboratory has also continued work assessing the role of common sequence changes in risk and prognosis of breast, ovarian, endometrial and prostate cancer, in large consortia. This has identified further variants that are associated with disease risk and progression, and might be incorporated in prediction models in the future.
37
GENETICS AND POPULATION HEALTH DIVISION
MOLECULAR EPIDEMIOLOGY Laboratory Head: Professor Grant Montgomery
The Molecular Epidemiology Laboratory investigates complex diseases using high throughput genomics platforms to identify genes and pathways contributing to disease risk. HIGHLIGHTS •
Discovered novel genetic variants contributing to risk for endometriosis.
•
Discovered age-specific effects of IRF4 variants for mole count leading to novel insights in how moles contribute to melanoma risk.
•
Discovered new genes for a range of diseases including coronary heart disease, inflammatory bowel disease, nicotine dependence, and eye diseases.
Endometriosis is a common gynaecological disease that affects up to 10% of women in their reproductive years. It causes pelvic pain, severe dysmenorrhea, and sub-fertility. The Molecular Epidemiology Laboratory is a leading member of the International Endogene Consortium in collaboration with researchers from Oxford University, UK and the Harvard School of Public Health, USA. Recent analysis of a large genome-wide screen of 3,400 endometriosis cases (2,200 from Australia) identified a novel region on chromosome 7
38
QIMR Annual Report 2009/10
and implicate several other regions in risk for endometriosis. Replication studies are being completed to confirm the results and understand the mechanisms. Current studies of gene expression in melanoma cell lines are searching for the mechanism for increased risk of moles and melanoma on chromosome 9. Variants in a gene called IRF4 were recently demonstrated to have age-specific effects on mole count and predispose to melanoma. A genome-wide search for new genes contributing to melanoma risk was recently completed identifying several new leads to follow up. The Laboratory has contributed to new gene discoveries including genes for coronary heart disease, inflammatory bowel disease, nicotine dependence, and eye disease through collaborations with a range of international groups. Followup from these discoveries will lead to greater understanding of mechanisms increasing disease risk and improve future diagnosis and treatment.
GENETICS AND POPULATION HEALTH DIVISION
MOLECULAR PSYCHIATRY Laboratory Head: Dr Corinne Lendon
This laboratory seeks to identify and understand the actions of the genes and environmental factors involved in disorders of mental health. These include dementia and cognitive ability, anxiety and depression. HIGHLIGHTS •
Completed second phase of genotyping from Longitudinal Ageing Womens (LAW) cohort.
•
Completed European GWAS collaboration, findings published in Nature Genetics 2009.
•
Completed transcriptomic study that identified IL-33 gene in dementia, findings published Molecular Psychiatry 2009.
The Dementia Group is headed by Dr Corinne Lendon with local researchers and collaborators Dr Antonia Pritchard, Associate Professors Gerard Byrne and Nancy Pachana. Data collection is complete for the study of cognitive function, anxiety and depression in an Australian healthy ageing cohort. Candidate gene associations and functional studies are being carried out on RNA. Analyses continue and publications are in preparation. As a member of the European Consortium Genome Wide Association Study of Dementia the Laboratory has completed the first screen of Alzheimer patients and
Normal, healthy brain tissue
controls in search for disease associated genes. A genome wide association studies report of the two candidate genes CRI and CLU1 (in addition to APOE) was published in Nature Genetics. Evidence was found in support of the role of these genes in Alzheimer’s disease (AD) in replication studies, and this was convincingly confirmed by a back-to-back publication by the UK/US collaboration in the same issue of Nature Genetics. The Australian-European collaboration continues and using GWAS to identify genes predisposing to cognitive decline and probably to late life dementia. This is most timely because biomarkers for presymptomatic testing for dementia are becoming a reality. A collection of blood samples is being prepared to take part in replication of such studies. In addition to searching for genes, the program of functional studies on the differential control of APOE (a proven risk factor of AD) allele and isoform expression is ongoing, using human blood and brain cell models.
Brain tissue of Alzheimer's sufferer with amyloid plaques
39
GENETICS AND POPULATION HEALTH DIVISION
NEUROGENETICS Laboratory Head: Dr Dale Nyholt
The Neurogenetics Laboratory studies the role of genetics in the development and mechanism of the nervous system to identify genes that cause neurological disorders. A particular focus is on migraine, a frequent, debilitating and painful headache disorder that normally affects people during their most productive years. HIGHLIGHTS •
Conducted ten large-scale projects examining genetic markers across the human genome in over 17,000 individuals.
•
Confirmed a genetic association between migraine and anxious depression.
•
Identified the first locus influencing risk of migraine with aura.
•
Completed the first Australian genome-wide association study of the more common forms of migraine.
In close collaboration with colleagues both within and outside of QIMR, investigations have been performed on traits including erythrocyte volume, monocyte counts, hair morphology (curliness), lymphocyte ratio (and risk of type 1 diabetes and HIV-1 immune control), finger-length ratio (a putative retrospective biomarker of prenatal testosterone exposure), and dizygotic twinning.
40
QIMR Annual Report 2009/10
The Laboratory has contributed to the development of novel bioinformatic approaches (powerful gene-based tests) and sophisticated quantitative genetic studies that have provided novel insight in the genetic architecture of common complex traits. Studies examining comorbid migraine and anxious depression were conducted and most recently robustly identified the first locus influencing susceptibility to common migraine with aura. The first Australian genome-wide association (GWA) study of the more common forms of migraine (migraine with and migraine without aura) has produced some exciting results that are currently undergoing replication studies by international collaborators. Additional large-scale meta-analysis studies are currently underway, where the Australian migraine GWA data is being combined with multiple international migraine casecontrol cohorts. The next year will produce even more exciting results in which novel genes and pathways influencing migraine susceptibility will be identified.
Bright field fluorescence showing insulin-producing cells in the pancreas
GENETICS AND POPULATION HEALTH DIVISION
ONCOGENOMICS Laboratory Head: Professor Nicholas Hayward
This laboratory identifies novel cancer genes and studies the way in which defects in these genes are associated with cancer predisposition or development. HIGHLIGHTS •
Identified key genes that are involved in tumour development in the hormone-producing cells of the pancreas.
•
Identified a small nucleic acid that is switched off in melanoma, resulting in invasion.
•
Developed a melanoma specific mutation panel that potentially can predict the response and effectiveness of emerging therapeutic strategies treating melanoma.
Work to characterise the genetic and molecular changes that occur in the development of tumours in endocrine organs is progressing well using new tools and state-of-the-art methods that were developed in the last year. Work continues on the biology of the gene responsible for the disease multiple endocrine neoplasia type 1 (MEN1), which will help to understand its normal function and provide clues that may lead to better treatments for endocrine tumours. There are currently no effective treatments for advanced melanoma. Once melanoma cells have spread through the body the disease is usually fatal within 6–9 months.
The Laboratory is looking for ways to control the spread of these tumour cells by focusing on a gene that has been found to be lost from cells as the disease progresses. This year, the key target of this gene has been identified and studies to determine the function of the gene in normal cells and in melanoma are underway. Future investigations are hoped to uncover new avenues for possible therapeutic intervention to treat melanoma. Research using gene arrays to profile copy number (CN) changes in oesophageal cancer has been extended to include pre-cancerous tissues. Whole genome CN profiles have revealed the most frequent regions of loss involve two well-known tumour suppressor genes, disruption of which is very frequent in the pre-cancer tissue from cancer patients; the surprise was detecting these changes in patients with no history of cancer. The results will be integrated with those of others, leading to a possible diagnostic test. These genes are believed to be important in the function of these cells normally, and may therefore be important not only in preventing tumours but also in diabetes.
41
GENETICS AND POPULATION HEALTH DIVISION
QUEENSLAND STATISTICAL GENETICS Laboratory Head: Professor Peter Visscher
Queensland Statistical Genetics (QSTAG) specialises in quantitative and statistical genetics, population genetics, human genetics and bioinformatics to investigate the genetic basis of differences in risk to disease and other phenotypes between individuals. HIGHLIGHTS •
Illuminated the 'missing heritability' problem in complex trait genetics.
•
Developed new statistical methods for the prediction of genetic risk to common disease.
The Laboratory has shown that genetic variation in human height, a classical complex trait, is due to many genes with small effect sizes. This result has implications for the discovery of genes affecting all complex traits, including disease.
42
QIMR Annual Report 2009/10
In collaboration with the Genetic Epidemiology, Neurogenetics, and Molecular Epidemiology Laboratories, a genome-wide association study on iron metabolism phenotypes measured in blood identified a number of genetic variants that in total explain a substantial proportion of genetic variation in iron status. The Queensland Statistical Genetics Laboratory published review articles in Nature and Journal of the American Medical Association.
IMMUNOLOGY DIVISION DIVISION CHAIR: PROFESSOR GEOFF HILL The Immunology Division has a significant focus on tumour and infectious disease-based immunology. In particular, a central theme of the Division is that of preclinical modelling as a prelude to prospective clinical trials of vaccine and cellular therapies. By expanding this knowledge base, the ultimate aim is to provide improved diagnostics and treatments for infectious diseases and malignancies. The Division’s research continues to provide vital insight into a range of diseases including graft-versus-host disease, breast cancer and melanoma. Early stage preclinical and clinical studies of cellular therapy continue for a number of malignancies including leukaemia, lymphoma, nasopharyngeal carcinoma, breast cancer and melanoma. Studies linking the pathophysiology of EBV infection to autoimmunity (multiple sclerosis) and cancer (lymphoma) are underway. The progressive developmental testing of novel vaccines for infectious agents human cytomegalovirus, Epstein-Barr virus, malaria and streptococcus continues. With over one million people dying every year from malaria and 500,000 of rheumatic heart disease and rheumatic fever (a possible consequence of streptococcus A infection), this work has the potential to save the lives of many people across the globe. In collaboration with an Australian biotech company, a new blood diagnostic kit has been developed that will allow clinicians to easily and efficiently monitor transplant patients at risk of developing cytomegalovirus disease and improve the outcome of patients post-transplant. A new mouse line has been established to test new vaccines and treatments of chikungunya virus arthritis and a novel way to active T cells to alleviate experimental visceral leishmaniasis has potential applications for a more efficient treatment.
43
One of the great things about my job is mentoring the next generation of medical researchers. The enthusiasm and energy that talented PhD students like Kimberley bring to the lab is infectious! The future of Australian Health and Medical Research appears to be in very good hands. Associate Professor Maher Gandhi, Head of Clinical Immunohaematology and Kimberley Jones, PhD student
44
QIMR Annual Report 2009/10
Brendan Parkes and family
IMMUNOLOGY DIVISION
BONE MARROW TRANSPLANTATION Laboratory Head: Professor Geoff Hill
The Bone Marrow Transplantation Laboratory works towards understanding the mechanisms by which transplant recipients eradicate leukaemia but also develop life-threatening complications, particularly graft-versus-host disease. HIGHLIGHTS •
Found that chronic graft-versus-host disease (GVHD) is an IL-17A dependent process.
(GVHD) and graft-versus-leukaemia effects after haematopoietic stem cell transplantation.
•
Demonstrated the ability of the inflammatory cytokine, lymphotoxin, to mediate GVHD.
•
Discovered a new suppressive pathway (SOCS3) that limits both acute and chronic GVHD, opening the door to new potential therapeutics.
In the last year, new work on the previously unknown pathogenic pathways of chronic GVHD found that it is an IL-17A dependent process. This opens the way for studies of new inhibitors to prevent and treat this complication that currently lacks any effective therapy. The Laboratory also established that soluble lymphotoxin (TNF-related inflammatory cytokine) is involved in acute GVHD, providing a rationale for selecting TNF antagonists for the treatment of disease.
Over 10,000 Australians are diagnosed with a blood cancer each year, accounting for 10% of all cancers and cancer deaths. The transplantation of healthy stem cells from a donor of the same genetic background into the recipient with leukaemia (stem cell transplantation) is the most effective curative therapy for the majority of these blood cancers. Unfortunately, this process results in side effects which can be fatal including infection, a rejection process known as graft-versus-host disease and in some patients, the leukaemia still recurs. The Bone Marrow Transplantation Laboratory continues to investigate the mechanisms of graft-versus-host disease
New studies have progressed on antigen presenting cells and their role in GVHD. Using newly generated transgenic lines, effector T cell responses can be imaged in vivo and in real time to quantify the important sites of antigen presentation after bone marrow transplantation. In partnership with the Tumour Immunology Laboratory an experimental treatment was used to help a bone marrow transplant overcome a life threatening infection. The research teams are now embarking on a formal prospective clinical trial to thoroughly test the procedure.
45
IMMUNOLOGY DIVISION
CANCER IMMUNOTHERAPY Laboratory Head: Dr Chris Schmidt
The focus of research in this laboratory is on understanding how the immune system succeeds in its fight against malignancies which is central to the future development of cancer immunotherapies. HIGHLIGHTS •
Established a novel technology for examining antigenspecific immune responses.
killer T cells efficiently. The technology will be expanded to include known melanoma antigens.
•
Commenced the first assessment of anti-tumour immune responses in patients with minimal residual disease following melanoma removal.
•
Established a bank of matched normal and cancer cell lines from melanoma patients.
This will allow refinement of preliminary studies on the immune responses against melanoma in patients who have recently had most of their tumour removed, and relate the results to their eventual clinical outcome. Few validated cancer targets exist for other cancers, and T cells isolated from patients with prostate cancer and glioblastoma will be tested for responses to proposed antigens using this lentivirus system.
Two major impediments to successful cancer immunotherapy are that it is currently not known which molecules on cancer cells should be targeted by the immune system, nor what kind of immune response is required for successful resolution of metastatic disease. In both cases, a convenient technology for detecting immune responses to any given protein is essential, but currently lacking. Lentivirus vectors encoding model antigens have been developed, and found they could stimulate both helper and Computer model of a dendritic cell courtesy of medicagraphics.com
46
QIMR Annual Report 2009/10
Basic genetic studies in cancer require malignant and matched normal tissue from a large number of patients with well characterised clinical histories. Previous clinical trials provide such a patient base, and cell lines have been generated from their cancers and matched normal cells. This resource will be made available to researchers through an Enabling Grant from the NHMRC to the Australasian Biospecimens Network, of which the Laboratory is a member.
The main focus of the Cellular Immunology Laboratory is the cytotoxic T lymphocyte (CTL) and factors controlling its primary function in recognising and killing virus-infected cells. IMMUNOLOGY DIVISION
CELLULAR IMMUNOLOGY Laboratory Head: Associate Professor Scott Burrows
HIGHLIGHTS •
Discovered that polymorphisms in the T cell receptor genes influence immune responses in humans.
•
Discovered strains of Epstein-Barr virus that occur at higher frequencies in multiple sclerosis patients.
T cells play a pivotal role in the immune system by recognising virus-infected tissue through the use of highly specific cell surface receptors. These T cell receptors (TCR) recognise viral peptides presented by MHC molecules on the surface of virusinfected cells. For a TCR to be successfully triggered, it must lock onto an exact 3-dimensional structure. In this way, any given TCR must simultaneously recognise both the viral peptide and the MHC presenting it. Such recognition must be sensitive and precise, since a false positive could result in destruction of healthy tissue. This year, the Laboratory has investigated how natural mutations in TCR genes across the human population affect individual responses to viruses. Studies have provided proof of concept that differences in the TCR genes between individuals can influence how they respond to viral infection. This year, the controversy over whether there is a link between infection with Epstein-Barr virus (EBV) and the development of multiple sclerosis (MS) has also been investigated. Results have contributed to the mounting evidence in support of a link. Examination of the stains of EBV infecting MS patients versus controls, found that some strains occur at different frequencies in MS patients. A common mutation within a T cell receptor influences recognition of virus-infected cells
47
IMMUNOLOGY DIVISION
CLINICAL IMMUNOHAEMATOLOGY Laboratory Head: Associate Professor Maher Gandhi
The major research area in this laboratory is the immunobiology of lymphoma. Interests include biomarkers, immuno-evasion, microRNA expression and cellular immunotherapies for virus associated lymphomas. HIGHLIGHTS •
Continued the second year of an NHMRC / NCRIS funded Phase I clinical trial of adoptive immunotherapy in EBVpositive lymphomas.
•
Performed the first in-depth profile of viral microRNAs in a range of primary samples from histologically diverse EBVpositive lymphomas.
•
Completed the first year of a multi-centre Phase II lymphoma trial, specifically performing a correlative laboratory study.
•
Identified a previously uncharacterised immune defect that leads to fulminant infectious mononucleosis.
•
Completed specimen collection of a multi-centre Phase II study of immune thrombocytopenic purpura.
•
Characterised the clinical and immunobiological characteristics of a new and highly aggressive EBV-positive lymphoma.
•
Demonstrated that EBNA1 is not immunologically silent and can be utilised as a target for vaccines against posttransplantation lymphoproliferative disorders.
Researchers Dr Jamie Nourse and Kimberley Jones with patient Katie Pulling.
48
QIMR Annual Report 2009/10
The Laboratory supports a range of translational studies that will heighten understanding of the biology of lymphoma. Highly detailed functional immunoassays are performed and genetic biomarkers on healthy individuals are studied as well as clinical samples obtained from lymphoma sufferers. This work has led to disease insights and therapeutic advances. The transforming abilities of the Epstein-Barr virus (EBV) have been used to establish a model system for investigating key events in the pathogenesis of lymphoma. Physiologically relevant human models that imitate the various stages of B cell differentiation are lacking. Using high efficiency EBV infection of isolated naive B cells, this laboratory has recently demonstrated that the use of EBV infection of isolated human naive B cells provides a highly relevant in vitro model that mimics the GC reaction. From a therapeutic perspective, a novel Phase I clinical trial of autologous EBV-specific T cell therapy in patients with relapsed and refractory EBV-positive lymphomas has begun in collaboration with the Tumour Immunology Laboratory and investigators at the Peter MacCallum Cancer Centre. To date, three patients have been enrolled.
IMMUNOLOGY DIVISION
DENDRITIC CELLS AND CANCER Laboratory Head: Associate Professor Alejandro López
This laboratory explores the function of dendritic cells (DC) in patients with breast cancer and investigates the role of breast cancer stem cells in the generation of tumours. Resulting findings will yield novel DC-based immunotherapy. HIGHLIGHTS •
Defined properties of breast cancer stem cells that differ from the commonly acknowledged markers.
•
Established that the markers commonly associated with breast cancer stem cells (BCSC) described distinct subtypes of breast cancer.
•
Identified molecules that appear to be specific for luminal BCSC.
•
Establishing a correlation between a functional characteristic of BCSC (long-term proliferating cells symmetric division rate) and tumour growth.
In collaboration with Professor Brent Reynolds (University of Florida) the Laboratory has provided further support for a mathematical modelling of how cancer stem cells contribute to tumour growth, specifically looking at how symmetric division rate of BCSC correlates with tumour growth.
Defining what makes breast cancer stem cells (BCSC) different to other cells contained in a growing cancer would allow a more tailored therapy that specifically targets the cells responsible for tumour initiation and growth. Relatives of the adult somatic breast stem cells, BCSC are responsible for the initiation of the tumour and the regrowth after clinical relapses. Research on these cells has been fuelled by the description of two surface markers originally defined as expressed by BCSC in a defined pattern (named CD24-CD44+). In collaboration with the group of Professor Sunil Lakhani, research has now disclosed that those markers are, instead, specific for cells derived from breast cancer of the basal type and not present in other cells originated from cancer of the luminal type. Following an extensive study of cell lines established from breast cancer tissues, the distribution of these two and other markers have been defined as present in both cells with and without BCSC properties.
Primary breast cancer tissue
49
Researchers at Q-Gen
IMMUNOLOGY DIVISION
EPSTEIN-BARR VIRUS BIOLOGY Laboratory Head: Professor Denis Moss
This laboratory is committed to understanding the biology and immunology of two clinically important human pathogens, Epstein-Barr virus (EBV) and vaccinia virus, and capturing laboratory findings and using them in human clinical trials. HIGHLIGHTS •
Began a peptide-based clinical trial in nasopharyngeal carcinoma (NPC) patients in collaboration with Princess Alexandra Hospital.
•
Defined the immune response in healthy individuals and NPC patients using the SAVINE vaccine encoded within adenovirus.
•
Screened bioactive compounds for immunological activity.
A new formulation (SAVINE) has been designed that includes all of the possible immunogenic determinants of proteins expressed within NPC biopsies. The EBV Biology Laboratory is currently performing preclinical testing on this formulation. Results indicate that SAVINE, when delivered in a replicationdeficient adenovirus, is capable of activating immune responses from both healthy individuals and NPC patients. These results provide a platform for future clinical trials.
50
QIMR Annual Report 2009/10
A clinical trial has begun using NPC patients recruited from the Head and Neck Clinic at Princess Alexandra Hospital in collaboration with Professor Bill Coman and colleagues. This trial involves adoptive transfer of in vitro activated T cells from NPC patients. Activation of T cells involves the use of a peptide encoded within a protein associated with NPC. This procedure is conducted within the Q-Gen facility at QIMR, and to date, two patients have been treated. In collaborative with the Drug Discovery Group, a library of compounds derived from natural sources is currently being screened for immunological activity. The overall aim is to identify compounds that might have clinical applications, particularly those with immunosuppressive or anti-herpes virus activity.
IMMUNOLOGY DIVISION
IMMUNOLOGY AND INFECTION Laboratory Head: Associate Professor Christian Engwerda
This laboratory studies the host immune response during malaria and leishmaniasis, and aims to distinguish host immune responses that control parasite growth from those that contribute to disease. HIGHLIGHTS •
Discovered a novel way to activate the immune system during experimental visceral leishmaniasis to improve the efficacy of anti-leishmaniasis drugs and improve disease outcome.
•
Discovered a polymorphism in the galactin-2 gene that increases susceptibility to cerebral malaria in highland Papuan children, but not adults.
•
Discovered a way to expand regulatory T cells in an experimental cerebral malaria model to protect from disease.
•
Started studies on volunteers infected with malaria for analysis of T cell responses during infection.
In the past year, the Immunology and Infection Laboratory continued to identify host immune responses during malaria and leishmaniasis that control infection, and to distinguish these from those that cause disease. Discovery of a novel way to activate T cells during experimental visceral leishmaniasis has resulted in rapid disease resolution and more efficient drug treatment. This strategy will be tested on cell samples taken
from human visceral leishmaniasis patients in India, in collaboration with Indian scientists. Methods have been developed to prevent experimental cerebral malaria by expanding regulatory T cells during infection. The findings from this research have important implications for understanding the pathogenesis of severe malaria syndromes in humans. In collaboration with Professor James McCarthy (Clinical Tropical Medicine, Laboratory, QIMR), a study has begun of T cells from volunteers infected with Plasmodium falciparum, the parasite responsible for most malaria morbidity and mortality. This work forms part of a wider program of research being conducted at QIMR to develop drugs and vaccines to prevent and treat malaria. A satisfying outcome from the Laboratory’s hard work was the award of a NHMRC New Investigator Project Grant to Ashraful Haque. This is Ash’s first major grant and his first step towards establishing an independent research career. Alex Mulherin maintained the perfect record of Honours students from the Laboratory, achieving First Class awards.
Green fluorescent malaria parasites sequestered in lung tissue.
51
IMMUNOLOGY DIVISION
IMMUNOVIROLOGY Laboratory Head: Professor Andreas Suhrbier
The Immunovirology Laboratory is exploiting new knowledge about interactions between viruses and the immune system to develop novel anti-viral and anti-cancer strategies. HIGHLIGHTS •
Developed a mouse model of chikungunya virus arthritis.
•
Discovered that chikungunya virus persists long term in vivo in macrophages.
•
Discovered that SerpinB2 modulates Th1/Th2 immune responses, allowing for the first time an understanding of the role of this protein in diseases like asthma and pre-eclampsia.
Chikungunya virus is a mosquito transmitted virus related to Ross River virus that has recently emerged in the Indian Ocean and India to produce the largest epidemic ever seen for this virus. The disease results in debilitating arthritis that can persist for months. In collaboration with Dr Pierre Roques (Commissariat à l'Énergie Atomique, Paris, France), the Laboratory has discovered that the disease is due to recruitment and activation of white blood cells called macrophages, with the virus also able to persist in these cells for extended periods. A mouse model of chikungunya virus arthritis has been developed for testing of new vaccines and treatments for this emerging disease. This model will also help unravel how the virus can evade the immune response for such extended periods.
SerpinB2 is a protein that the body usually makes in very large amounts during inflammation. What SerpinB2 actually does remains controversial. The Laboratory’s research discovered that a physiological function is regulation of the immune response; SerpinB2 suppresses a pro-inflammatory immunity called Th1 immunity. This activity may explain why too little SerpinB2 results in pre-eclampsia where Th1 responses are excessive, and too much SerpinB2 results in asthma where Th1 responses are insufficient. The Immunovirology Laboratory has continued its collaboration with Peplin Ltd., who has developed a new topical treatment for non-melanoma skin cancer (ingenol mebutate, or PEP005). The treatment has shown very promising results in human trials. Peplin was recently sold for US$287.5 million to LEO Pharma, including several patents with QIMR staff as inventors.
Professor Andreas Suhrbier, Head of Immunovirology Laboratory
52
QIMR Annual Report 2009/10
IMMUNOLOGY DIVISION
MOLECULAR IMMUNOLOGY Laboratory Head: Professor Michael Good
The Molecular Immunology Laboratory studies the immune response to pathogens, principally Plasmodium and group A streptococcus (GAS), with the goals of understanding pathogenesis and developing vaccines. HIGHLIGHTS •
Completed preclinical studies of malaria vaccines.
•
Group A streptococcus (GAS) vaccine entering clinical trials.
The Molecular Immunology Laboratory studies the immune response to pathogens with the goals of understanding pathogenesis and developing vaccines. The Laboratory is interested in immunity, pathogenesis and vaccine development for some infectious agents of global importance principally malaria parasites and group A streptococcus (GAS). The low dose malaria vaccine is entering clinical trials in early 2011. This was the culmination of several years of research by Professor Michael Good and his vaccine research team (with Dr Alberto Pinzon-Charry) in collaboration with Professor James McCarthy (Clinical Tropical Medicine Laboratory, QIMR). The molecular mechanism of the vaccine was published in the highly prestigious Journal of Clinical Investigation. The malaria pathogenesis team identified a novel potential treatment to generate long-term protection against malaria. The treatment is novel, as it addresses the immunological changes induced by Plasmodium that prevent natural longterm immunity. The vaccine for GAS is also entering clinical trials in 2010. This project was again the result of several years of research headed by Professor Michael Good, in close collaboration with Dr Michael Batzloff (Bacterial Vaccines Laboratory, QIMR). Professor Michael Good, Head of Molecular Immunology Laboratory
53
IMMUNOLOGY DIVISION
MOLECULAR VACCINOLOGY Laboratory Head: Professor Denise Doolan
Research in this laboratory investigates the molecular basis of immunity to disease, with a focus on malaria and model systems that can inform the basic immunology, mechanisms and antigenic targets of immunity, and evaluation of candidate vaccines. HIGHLIGHTS •
Identified 17 novel Plasmodium falciparum sporozoite and liver stage antigens strongly associated with sterile protective immunity against malaria.
•
Identified 21 novel P. falciparum blood stage specific antigens that may represent good targets for a malaria vaccine to reduce blood stage parasite burden and minimise symptoms.
•
Identified a subset of P. falciparum antigens targeted by cross-species immunity against malaria, which may represent good targets for a vaccine capable of protecting against multiple parasite species.
•
Developed a high throughput approach to identify, from the entire proteome of complex pathogens, the antigenic targets of cellular immunity for a rational vaccine design.
•
Developed a sensitive high throughput quantitative method for assessing Plasmodium parasite burden from very small blood volumes.
•
Identified an adjuvant capable of augmenting cell-mediated immune responses.
The Molecular Vaccinology Laboratory uses genome-wide approaches to identify novel target antigens for malaria vaccine development, since vaccines to date have been based on only a handful of antigens. Using protein microarrays, novel
sporozoite and liver antigens strongly associated with sterile protective immunity, novel blood-stage antigens, and crossspecies reactive antigens have been identified. The vaccine potential of a subset of these antigens is currently being evaluated. A complementary study using a high throughput approach to identify novel antigens recognised by cellmediated immune responses has been established. Laboratory models have been established to assess the immunogenicity and protective efficacy of candidate malaria vaccines, with a particular focus on the liver-stage where clinical symptoms do not occur. Evaluation of candidate vaccines and demonstrated effects on parasite burden have been carried out. Work is also underway to identify potential human-use compatible adjuvants capable of augmenting cell-mediated immunity, since no such adjuvants have been licensed, and have identified one adjuvant that preferentially induces robust CD8+ T cell responses. To understand how an effective immunity can be generated by vaccination, investigation of the factors that may modulate the function and phenotype of effector T cells, and in particular the acquisition of effector function by CD8 T cells, is underway. Unexpected insights into the effect of vaccination on immune function have been obtained that have important implications for vaccine development.
Hepa 16 cells treated with IFNg
54
QIMR Annual Report 2009/10
IMMUNOLOGY DIVISION
TUMOUR IMMUNOLOGY Laboratory Head: Associate Professor Rajiv Khanna
This laboratory seeks a deeper understanding of the mechanisms by which an immune response to tumours may be generated, augmented and applied to the inhibition of tumour growth. HIGHLIGHTS •
Initiated a Phase I clinical trial on nasopharyngeal carcinoma in collaboration with University of Hong Kong.
•
Developed novel T cell-based therapy for the treatment of cytomegalovirus treatment in stem cell recipients.
•
Completed preclinical studies on a prophylactic vaccine for human cytomegalovirus.
•
Determined the influence of mRNA structure on the antigen presentation to cytotoxic T cells.
•
Developed a novel immune-based diagnostic tool for human cytomegalovirus.
This laboratory is involved in developing immune-based therapies and novel diagnostic tools for human herpes virus associated diseases. These studies are primarily focused on two viruses, namely Epstein-Barr virus (EBV), which causes glandular fever and Hodgkin’s lymphoma (HL), and cytomegalovirus. EBV is also associated with a number of cancers including nasopharyngeal carcinoma (NPC).
This therapy is based on a propriety technology (referred to as E1-LMPpolyTM) developed by this laboratory. The possibility of expanding this therapy for other EBV-associated cancers, such as HL and non-Hodgkin’s lymphomas, is also being explored. In addition, a collaborative agreement has been signed with a UK-based biotech company to jointly develop a therapeutic vaccine for both NPC and HL. Another aspect of research is focused on developing novel immune-based diagnostic tools for human cytomegalovirus, which is a major cause of morbidity and mortality in transplant patients. In collaboration with an Australian biotech company, a new whole blood diagnostic kit has been developed that will allow identification and prediction of which transplant patients are at the highest risk of developing cytomegalovirus disease after organ transplantation. This diagnostic kit has recently been registered in the European Union as a clinical immune monitoring kit. It is anticipated this kit will also available at most pathology centres in the United States and Australia within the next 12–18 months.
A large clinical study has been initiated in collaboration with colleagues at the University of Hong Kong to test a killer T cell-based therapy for advanced NPC patients.
QuantiFERON-CMV (QF-CMV) is a novel whole blood assay that was developed by the scientists at the QIMR and Melbourne-based diagnostic company, Cellestis Limited.
55
INFECTIOUS DISEASES DIVISION DIVISION CHAIR: PROFESSOR JAMES MCCARTHY The 13 laboratories that comprise the Infectious Diseases Division study how a range of important pathogenic organisms cause illness, search for better ways to diagnose and treat them, as well as developing vaccines to prevent infections. A major emphasis of work undertaken in the Division is on infections that disproportionately affect people living in the developing world and the tropics. Pathogens studied include viruses such as HIV and mosquitoborne viruses; bacteria such as Streptococci; and parasites such as malaria, intestinal protozoa, worms and scabies. One laboratory in the Division focuses on the application of proteomic technology to biomedical science. In the last 12 months, members of the Division have successfully secured funding for their work from prestigious bodies including the National Institutes of Health (NIH), National Health and Medical Research Council (NHMRC) program and project grant system, as well as the Gates Foundation. Three new laboratories have been added to the Division in the past year, headed by Drs Kathy Andrews (Tropical Parasitology), Katja Fisher (Scabies), and Colleen Olive (Immunity and Vaccinology). The Division has achieved many research milestones, including sequencing of the genome of the Asian blood uke (Schistosoma japonicum); successful completion of two PreINDs with the US FDA for ďŹ rst-in man vaccine trials in group A streptococcus and malaria; demonstration that if the Aedes aegypti mosquito is infected with an endosymbiont bacteria called Wolbachia, it can no longer transmit the dengue fever virus; and assisting the World Health Organization identify the best malaria rapid diagnostic tests for use in the effort to control malaria.
56
QIMR Annual Report 2009/10
My research is ever evolving so each day is different. I love to know and understand why something happens and mathematical modelling is the perfect tool for me to explore hypotheses about disease transmission. The collaborations I have with WHO have direct public health impacts, particularly for malaria diagnosis, and it is rewarding to know that this work will help improve the health care of many people. Dr Michelle Gatton, Head of Malaria Drug Resistance and Chemotherapy Laboratory, Infectious Diseases Division
57
INFECTIOUS DISEASES DIVISION
BACTERIAL PATHOGENESIS Laboratory Head: Professor Kadaba Sriprakash
This laboratory undertakes research into streptococci, staphylococci, and other medically important bacteria. HIGHLIGHTS •
Isolated streptococcal species from school children in India.
•
Developed rapid diagnostic tests to distinguish between group A streptococci (GAS) and group G streptococci (GGS).
•
Conducted a study analysing GGS isolates collected from around the world.
The group C and group G streptococci (GGS) are close genetic relatives of GAS. Traditionally recognised as commensal organisms, these organisms are emerging as significant human pathogens. Despite high rates of rheumatic fever, GAS is rarely isolated from the throats of individuals in the Northern Territory. However, GGS is. Recent research has demonstrated that DNA can be transferred between group A streptococcus and closely related group G streptococcus. This transfer is mediated by bacteriophages, the equivalent of a bacterial virus. The Laboratory is investigating how commonly
58
QIMR Annual Report 2009/10
this occurs, and fully characterising these bacteriophages. Such information may help us to understand the rates at which streptococci undergo large scale genetic drift and help us to predict the emergence of new patho-varieties from commensal organisms. Many bacteria, some commensal and some disease-causing, can inhabit the throat. A molecular approach to identify all major species in these bacterial communities is being investigated. The Laboratory’s multi-locus sequence typing study using GGS isolates (collected from around the world) demonstrate that a degree of genetic diversity is present in the population. This diversity is driven by lateral transfer of DNA, not point mutation. Although Streptococcus pyogenes (group A streptococcus, GAS) is generally more virulent than S. dysgalactiae subsp. equisimilis (group G streptococcus, GGS), the isolation rates of the latter from school children in India far exceeds that of S. pyogenes.
INFECTIOUS DISEASES DIVISION
BACTERIAL VACCINES Laboratory Head: Dr Michael Batzloff
The focus of this laboratory is the identification, characterisation and evaluation of potential vaccine candidates for group A streptococcus (GAS) specifically Streptococcus pyogenes, and other bacterial pathogens. HIGHLIGHTS •
Demonstrated J8-DT mediated protection against group A streptococcus is antibody mediated and the lead vaccine candidate can induce a protective immunological memory response.
•
Demonstrated a novel pathway for Burkholderia pseudomallei infection of the nasal cavity leading to direct infection of the brain.
•
Highlighted new interactions with the host tissues, allowing the identification of target molecules for future vaccine research.
Over the previous year, the Bacterial Vaccines Laboratory has made significant progress towards a vaccine for group A streptococcus and associated diseases. Using a variety of techniques including passive transfer and T cell depletion, it has been demonstrated that J8-DT/alum induced protection
is antibody mediated. This observation has a large impact on vaccine design and adjuvant selection. More recently, the lead vaccine candidate has been shown to induce a protective immunological memory response which is critical for vaccine efficacy. Burkholderia pseudomallei is another bacterial pathogen that is a serious problem in tropical countries including northern Australia. In collaboration with Griffith University through the Griffith Medical Research College, research has demonstrated a possible new route of infection resulting in direct infection of the brain following intranasal exposure in mice. Traditionally, this bacteria was thought to colonise the lung, progress into the blood and then cross the blood-brain barrier. Further investigation of various tissues that the bacteria targets in this new infection pathway has allowed identification of new target proteins for future vaccine development.
An electron micrograph of a pair of bacteria (Streptococcus pyogenes)
59
INFECTIOUS DISEASES DIVISION
CLINICAL TROPICAL MEDICINE Laboratory Head: Professor James McCarthy
This laboratory undertakes translational research in tropical infectious diseases. A particular focus is the study of drug resistance, identification of new drugs, and the development of novel diagnostic techniques. HIGHLIGHTS •
Showed that scabies mite glutathione S-transferase enzymes are involved in the development of resistance to the two most commonly used treatments for scabies.
•
Commenced studies on the clinical pathology and immunology of scabies using a recently developed pig model.
•
Initiated scabies drug discovery research by investigating mite-killing properties of natural product extracts and pure compounds derived from plants.
•
Developed a field-based assay to detect glucose 6-phosphate dehydrogenase enzyme deficiency in malaria patients.
•
Commenced a clinical study using experimental human malaria infection.
•
Demonstrated that rapid tests for malaria may fail in some circumstances because some parasites lack the target protein.
•
Completed a large multicentre study of efficacy of antihelmintics.
•
Successful completion of two Pre-IND applications to the US FDA.
This laboratory explored the contribution of glutathione S-transferases to drug resistance in scabies. In collaboration with scientists from the Eskitis Institute (Griffith University) work on the acaricidal activity of natural products was undertaken.
New bioassay methodologies for screening drugs for activity against scabies is ongoing. A trial of scabies infection using a newly developed pig model of human scabies has been completed. This work lays the foundation for world-first prospective studies of scabies immunology. The Laboratory participates in several multicentre national and international collaborative research projects. These include: investigating factors influencing performance of rapid diagnostic test (RDT) kits for malaria; using serological tools to monitor malaria epidemiology; developing a glucose 6-phosphate dehydrogenase assay applicable for large scale field study for better management of Plasmodium vivax malaria; and field trials of antihelmintics and diagnostic methods for helminth infections. The Laboratory also collaborates with a number of other laboratories at QIMR to research new targets for antimalarial drugs, and investigate the interaction between HIV and malaria. Translational clinical studies are in various stages of progress. These include work with Professor Michael Good on a vaccine for group A streptococcal infection and blood stage malaria. Exciting projects underway include experimental human malaria infections to test new drugs, and experimental hookworm infections to study the relationship between allergy and helminth infections.
Professor James McCarthy, Head of Clinical Tropical Medicine Laboratory with Dr Cielo Pasay and Mei-Fong Ho
60
QIMR Annual Report 2009/10
INFECTIOUS DISEASES DIVISION
HIV MOLECULAR VIROLOGY Laboratory Head: Associate Professor David Harrich
The principal focus in this laboratory is detailed analysis of HIV replication. This includes the processes by which HIV is able to convert its genetic material, composed of RNA, into a form compatible with human DNA. Understanding the role of viral and cellular factors in regulating HIV replication is a primary goal. HIGHLIGHTS •
Isolated and identified several previously unrecognised host proteins that play a vital role in HIV replication.
•
Created a mutant form of a viral protein, referred to as Nullbasic, to inhibit HIV reproduction in infected cells.
•
Developing a gene therapy approach using Nullbasic that could be used for HIV infected people experiencing treatment failure.
Human immunodeficiency virus (HIV) is the cause of acquired immunodeficiency syndrome (AIDS). No cure exists for HIV infection. Globally, an estimated 33 million people are living with HIV and approximately 2.7 million new infections occur annually. In total, over 60 million people have been infected by HIV since the beginning of the pandemic resulting in 25 million deaths. At the end of 2008, over 17,000 people were living with HIV in Australia. The number of new infections in Australia is now approaching 1,000 annually. There are currently 20 different drugs available to treat HIV infection, which extend average life expectancy by up to 40 years. Unfortunately, HIV is able to rapidly mutate so that some therapies become less effective over time.
The Laboratory studies the HIV life cycle at the molecular level and seeks to find new means to stop the virus through a detailed analysis of viral interactions with the host cell. Many host cell proteins are required by the AIDS virus to infect a cell. A novel assay was used to isolate and identify host cell proteins used by HIV to facilitate its reproduction. Experiments are under way to determine how these host proteins affect a key HIV process called reverse transcription. A recent discovery found that the host enzyme PRMT6 is required to stably maintain the HIV Tat protein within a cell. Targetting Tat is critical as it plays key roles in HIV infection and AIDS. Understanding how these proteins interact at the molecular level may reveal a means to stop HIV reproduction in infected cells. Recently, the Laboratory showed that a mutant viral protein called Nullbasic could potently protect human cells from HIV infection. Testing is currently underway for methods to deliver Nullbasic into human cells using a gene therapeutic strategy.
Nullbasic causes HIV Rev protein to move out of nucleus into cytoplasm - disrupting HIV growth
61
INFECTIOUS DISEASES DIVISION
IMMUNITY AND VACCINOLOGY Laboratory Head: Associate Professor Colleen Olive
The Immunity and Vaccinology Laboratory investigates the immunological mechanisms of pathogen recognition and intracellular signalling pathways that culminate in host immunity, with the objectives of developing new vaccines for infectious diseases. HIGHLIGHTS •
Showed that dendritic cells stimulated by different Tolllike receptor agonists induced different signature profiles of cytokines that may influence the type of adaptive immunity.
•
Demonstrated that dual stimulation of Toll-like receptors enhanced the potency of immune responses.
•
Identified a role for different mitogen-activated protein kinases in the regulation of Toll-like receptor signalling in dendritic cells.
Vaccination has long been recognised as a prevention strategy for infectious diseases. However, there remain many pathogens for which suitable vaccines have not been developed. One such pathogen, group A streptococcus is the cause of rheumatic heart disease (RHD) and has been the focus of research for a number of years. RHD, while being a global health problem, is more prevalent in Australia's Aboriginal population. Established in February 2010, the Immunity and Vaccinology Laboratory is investigating new approaches to design and deliver high potency tailored peptide vaccines by triggering Toll-like receptor (TLR) signalling in dendritic cells (DCs). DCs are critical to bridging the induction of an innate immune
Jyothy Nair, Research Assistant, Immunity and Vaccinology Laboratory
62
QIMR Annual Report 2009/10
response to a pathogen and adaptive immunity, and they also have an important role in controlling the type of immunity generated. Research has determined the cytokine signature profiles of DCs induced by stimulation with various TLR agonists, and identified those which have the potential to favour a particular type of immune response. Further research showed that the immune response can be amplified by triggering more than one TLR simultaneously. Research in progress is identifying the cell signalling pathways involved in TLR signalling in DCs. This may lead to novel ways to manipulate the immune response. In collaboration with scientists at the University of California, the Laboratory is investigating various chemical approaches in conjunction with liposome technology to engineer TLRagonist peptide vaccines, which will be evaluated for protection in animal models of infectious diseases including group A streptococcus.
INFECTIOUS DISEASES DIVISION
MALARIA BIOLOGY Laboratory Head: Associate Professor Donald Gardiner
This laboratory uses transgenic approaches to investigate antimalarial drug targets, mechanisms of antimalarial drug action and antimalarial drug resistance. These studies are essential in the current era of multi-drug resistant malaria parasites. HIGHLIGHTS •
Determined the crystal structure of the Plasmodium falciparum M17 aminopeptidase.
•
Published the first study on the effect of antimalarial drugs on the transmission stages of the malaria parasite P. falciparum.
•
Undertook three high throughput screens in the USA to identify novel antimalarial drugs.
•
Identified the first inhibitors of the P. falciparum M18 aminopeptidase.
Malaria remains a leading cause of morbidity and mortality worldwide, with at least one to two million deaths per annum directly attributable to this disease. The Malaria Biology Laboratory has several ongoing projects which focus on rational drug targeting and novel intervention strategies. Production of sexual stages or gametocytes is essential for transmission of the malaria parasite through the mosquito vector. However, little is known about this life cycle stage.
The Laboratory is examining the effect of antimalarial drugs on gametocytes and looking at basic gametocyte biology with a particular focus on potential intervention strategies. A unique technique has been developed that will allow identification of new and novel inhibitors of malaria transmission. In collaboration with colleagues at University of Technology, Sydney, it has been shown that aminopeptidases are promising drug targets. Current studies are characterising these enzymes and investigating the activity of specifically designed inhibitors in vitro and in vivo. Screening of the National Institutes of Health (USA) 300,000 compound library has been completed. Investigation of the antimalarial activity of antiretroviral protease inhibitors both alone and in combination with other drugs continues. Research has presented evidence to suggest that these drugs target an uncharacterised P. falciparum aspartic protease and future plans are to determine the function and structure of this enzyme so that new potent and specific inhibitors can be developed.
Smiley Faced Killers - ring stage parasites of Plasmodium falciparum
63
INFECTIOUS DISEASES DIVISION
MALARIA DRUG RESISTANCE AND CHEMOTHERAPY Laboratory Head: Dr Michelle Gatton
This laboratory studies the mechanisms and factors influencing the development and spread of drug resistance in malaria parasites, and investigates ways to improve the diagnosis, treatment and control of malaria. HIGHLIGHTS •
Demonstrated that the dormancy of the malaria parasite following artemisinin treatment in vitro is a possible mechanism of artemisinin treatment failure in vivo.
•
Demonstrated that the amplification of large chromosomal segments occur when parasites develop resistance to artelinic acid in vitro, but the amplifications are unstable when drug pressure is removed.
•
Participated in the Round II WHO-Malaria Rapid Diagnostic Tests (RDT) product testing and investigated factors influencing the performance of malaria RDTs.
•
Investigated the impact of malaria transmission intervention strategies in different transmission settings using a mathematical model.
•
Compared the performance of malaria diagnostics in Temotu province, Solomon Islands to discover a large proportion of asymptomatic Plasmodium infections with low and submicroscopic parasite densities.
•
Developed a real-time web-base surveillance system for Ross River virus and Barmah Forest virus diseases in Queensland.
Artemisinin combination therapy is the recommended first line treatment of P. falciparum malaria, however treatment failure is common for artemisinin monotherapy.
64
QIMR Annual Report 2009/10
The Laboratory demonstrated that parasites arrest development for up to 20 days (dormancy) following artemisinin treatment and that up to 2% of these parasites recover in vitro. Repeated dosing, or combination treatment, led to a reduction and delay in recovery. Using a mathematical model of P. falciparum infection and the dormancy recovery rates and profile, treatment failure rates that mirror those observed in the field were predicted, indicating that dormancy is a key factor in treatment failure. The development of artemisinin resistance is a major concern. The resistance mechanism was investigated using laboratory-selected resistant parasites. Amplification events in the chromosomes of resistant parasites were found, and demonstrated to be unstable when drug pressure is withdrawn. The results have practical implications for the containment of resistance. Rapid and accurate diagnosis is fundamental to the success of malaria control and elimination programs. The Laboratory participated in the WHO Round II Product Testing of malaria RDTs which provides a direct performance comparison of malaria RDTs. The results help ensure only quality RDTs are deployed in the field. The global diversity of parasite antigens were investigated. Research found parasites in the field lack the antigens that are targeted by malaria RDTs, which is an important finding for the selection of effective RDTs for malaria diagnosis.
INFECTIOUS DISEASES DIVISION
MOLECULAR GENETICS Laboratory Head: Professor Peter Upcroft
This laboratory works on the three most medically important anaerobic protozoan parasites, the sexually transmitted Trichomonas vaginalis, the intestinal parasite Giardia duodenalis and the invasive Entamoeba histolytica. HIGHLIGHTS •
Assembled the DNA sequence of the gut protozoan parasite Giardia into five chromosome linkage groups.
•
Revealed errors in the two longest constructs in the Giardia genome database and proposed how these should be corrected.
It has long been thought that the mechanism of action of the drug, metronidazole, used to treat infections of anaerobic organisms was via activation to its toxic form by two parasite proteins, pyruvate:ferredoxin oxidoreductase (PFOaR) and ferredoxin. The Molecular Genetics Laboratory has shown that Giardia resistant to metronidazole has fully functional PFOR and ferredoxin. Current investigations have shown that the mechanism of action of metronidazole in anaerobes is via a new mechanism. In response to the Laboratory’s 2006 publication detailing new 5-nitroimidazole (5-NI) drugs which are active against metronidazole-resistant Giardia, bulk synthesis of one of the compounds, C17, was arranged allowing detailed research using a highly active 5-NI compound. With great difficulty, C17resistant Giardia lines were developed which were also highly cross-resistant to metronidazole. Over the last year, the focus has been how C17 is activated in drug-susceptible isolates and how cells become resistant to C17 and metronidazole.
Previously, research showed that the enzyme pyruvate: ferredoxin oxidoreductase (PFOR), which is involved in metronidazole activation with ferredoxin, was downregulated in a metronidazole-resistant line. However, new studies now show that the C17-resistant lines have both active PFOR and ferredoxin and that reduction of metronidazole can be achieved in cell free assays with PFOR and ferredoxin purified from the C17-resistant lines. Reduction of metronidazole is followed spectrophotometrically but this is not possible for C17. Thus, metronidazole and C17 have been separately reduced in cell free assays and tested on live cells to show that both metronidazole and C17 can be reduced in vitro by the PFOR-ferredoxin couple. This leaves the possibility that the PFOR-ferredoxin pathway does not activate these drugs in the live parasite or that drug-resistant cells can compartmentalise drugs or exclude them. The Giardia DNA sequence was assembled into five chromosome linkage groups. The previous longest contiguous Giardia DNA sequence was around one million base pairs (1Mb) while the maps now extend this to around 3 Mb. In the process of mapping and assembling the genome into chromosomes, errors were revealed in the two longest constructs in the genome database. Thus, corrections were proposed for these errors and the new maps are being incorporated into the genome database for Giardia.
Dr Kenia Krauer, Senior Research Officer, Molecular Genetics Laboratory
65
INFECTIOUS DISEASES DIVISION
MOLECULAR PARASITOLOGY Laboratory Head: Professor Don McManus
This laboratory researches the biology, pathogenesis and epidemiology of parasitic worms that infect humans with the aim of developing new public health interventions, including vaccines, and diagnostic procedures that will lead to their elimination through integrated control. HIGHLIGHTS •
Published the completed draft genomic sequence for Schistosoma japonicum as a cover article in Nature.
•
Identified and cloned the schistosome-insulin receptor as a new vaccine target of S. japonicum.
•
Manufactured the first schistosome protein microarray and probing to identify further targets for vaccine intervention.
The publication of the completed genomic sequence for S. japonicum provides a global insight into the host interaction of this complex pathogen, revealing that it can exploit host nutrients, neuroendocrine hormones and signalling pathways for growth, development and maturation. This is first reported for any flatworm and the genomic information serves as a valuable platform to facilitate development of new interventions for schistosomiasis control. The Laboratory’s recent published data on apical membrane proteins expressed on the surface of the schistosomulum larva and adult worm support the hypothesis that these are
66
QIMR Annual Report 2009/10
logical vaccine targets. One such protein identified is the schistosome-insulin receptor, which has been recently cloned and characterised from S. japonicum. Formulated with Quil A, the vaccine provides more than 70% protection in mice in terms of reduced faecal egg output. This is the highest protective efficacy reported for any schistosome recombinant protein to date. Future plans are to field test the vaccine in challenge experiments with water buffaloes and if the vaccine efficacy is verified, undertake extensive field testing in China and the Philippines. The first schistosome protein microarray was manufactured with 172 S. japonicum and 50 S. mansoni cell free expressed proteins. The array is being probed with sera from people from schistosomiasis-endemic areas who are naturally resistant to schistosome infection, and also with sera taken from animals experimentally protected against schistosomiasis to identify new targets for vaccine intervention. Franziska Bieri, PhD student in Molecular Parasitology Laboratory
INFECTIOUS INFE IN NFE FECT CT TIO OUS US D DISEASES ISEA IS EASE EASE ES DI D DIVISION IVISI IVI VISI VI SION ION N
MOSQUITO CON CONTROL NTRO OL Laboratory Head: Dr Peter Ryan
Research in this laboratory focuses on the biology and control of mosquito-borne viruses such as dengue, Ross River and Barmah Forest. With the global increase in mosquito-borne diseases such as dengue, new approaches to control are urgently needed. HIGHLIGHTS •
Provided sustainable delivery of health benefits to rural communities in Vietnam through community-based dengue control programs, with ongoing costs of between 0.28 to 0.89 international dollars per person per year.
•
Identified several new fungi that may be used as biological control agents against Aedes aegypti – the global dengue mosquito.
•
Demonstrated that household water storage practices encouraged by local, state and federal governments can directly increase mosquito productivity in urban areas and may lead to increased risk of dengue and Ross River virus transmission.
•
Identified several mosquito proteins as candidate age biomarkers.
•
Showed that a Wolbachia endosymbiont blocks replication of all four dengue viruses in Aedes aegypti mosquitoes.
The major research focus is the development of contemporary approaches for the control of the global dengue mosquito – Aedes aegypti. Although dengue is a major problem in most tropical areas, there is also potential for emergence of dengue in cooler sub-tropical areas due to changing patterns of
household water storage. Households in southern Queensland had a high abundance of different types of containers, including rainwater tanks, and many of these containers have emerged as key habitats for mosquitoes, supporting the belief that some of these areas may be at high risk for invasion of exotic mosquitoes, including dengue mosquitoes. To address this dengue threat, a range of new biological approaches to control Ae. aegypti mosquitoes have been investigated, including Wolbachia endosymbionts and entomopathogenic fungi. The Laboratory’s research has shown that mosquitoes that have been infected with Wolbachia have a greatly reduced ability to support infection with dengue virus and this demonstrates an alternative approach to control of dengue, without the need for insecticides. A range of fungi were evaluated for control of Ae. aegypti. Infected mosquitoes were less likely to be active and find a host than were uninfected mosquitoes. This suggests that fungus infected Ae. aegypti may have reduced biting behaviour and therefore less likely to transmit pathogens such as the dengue virus.
67
INFECTIOUS DISEASES DIVISION
PARASITE CELL BIOLOGY Laboratory Head: Associate Professor Malcolm Jones
The Parasite Cell Biology Laboratory researches three specific parasites: schistosomes, the hydatid tapeworm Echinococcus granulosus and the malaria parasite Plasmodium, particularly their host interactions which can be exploited in control strategies. HIGHLIGHTS •
Completed and published a gene atlas of Schistosoma japonicum.
•
Deployed gene silencing technologies to interrupt expression of schistosome tetraspanin, a major vaccine candidate of schistosomiasis, demonstrating major alteration in tegument architecture as a result of this gene silencing.
•
Completed molecular characterisation of families of proteins controlling uptake of the essential trace element zinc in schistosomes.
The Parasite Cell Biology Laboratory specialises in cell biological aspects of the biology of helminth parasites afflicting humans. Major progress was achieved in functional studies of tetraspanin, a novel surface-associated vaccine target in Schistosoma mansoni. Schistosomes, or blood flukes, reside in the blood vessels surrounding the liver and bowel of their human hosts. The parasites cover themselves in a unique cytoplasmic layer, called the tegument.
Through gene knockdown studies using short interfering RNAs, it was shown that tetraspanin is integral to the proper formation of the tegument and subsequent survival of the parasite in its human host. This finding provides a potential mechanism by which a vaccine based on Sm-TSP-2 protects immunised hosts. Recently published genomic sequence datasets for schistosomes has revealed many molecules expressed by the schistosome parasites where no functional information is available. The lack of information extends to ignorance of where in the complex multicellular schistosome parasites the genes are expressed. To rectify this deficiency, techniques of laser microdissection microscopy and microarray analyses were combined, to dissect out and define the transcriptome of highly important tissues involved in nutrition and reproduction from sections of female Schistosoma japonicum. This approach enabled the basic formulation of a gene atlas for schistosome parasites, defining the expression repertoire of specific tissues. This atlas will help clarify roles of specific schistosome tissues in host interaction and disease and lead to better identification of vaccine targets.
Micrograph of a schistosome
68 6
QIMR A Annual n Report 2009/10
INFECTIOUS DISEASES DIVISION
PROTEIN DISCOVERY CENTRE Laboratory Head: Professor Jeff Gorman
The Protein Discovery Centre aims to discover the identities of proteins involved in or affected by physiological and disease processes and the influence of post-translational modifications on the ways proteins function and interact. HIGHLIGHTS •
Participated in a study that showed that the asparaginyl hydroxylase responsible for controlling the transcriptional activity of hypoxia inducible factor plays a major role in regulating mammalian metabolism.
respiratory syncytial virus (RSV) in collaboration with Dr Kirsten Spann (Sir Albert Sakzewski Virus Research Centre) and Dr Peter Collins (National Institute of Allergy and Infectious Diseases, US National Institutes of Health).
•
Made major contributions to understanding the process of cartilage development.
•
Developed a strategy for comprehensively quantifying proteomic changes in cells that accompany disease and developmental pathways.
•
Gained a detailed understanding of how human respiratory syncytial virus manipulates protein interactions and metabolic pathways in the infected cell.
Another major focus has been on regulation of signal activated transcription factors by post-translational modification pathways in collaboration with Drs Murray Whitelaw and Daniel Peet (The University of Adelaide). Strong collaborations have also continued with Professor John Bateman (The Murdoch Children’s Research Institute) involving the proteomic analysis of cartilage development and disease. Future expansion of the PDC research portfolio is anticipated to include prostate cancer research in collaboration with Professor Judith Clements and her associates (QUT).
The QIMR Protein Discovery Centre (PDC) is a specialty node of the national proteomics consortium, Proteomics Australia. The role of the PDC is to provide Australian researchers collaborative access to specialist proteomics capabilities in the fields of analysis of post-translational modification and infectious disease agents. The PDC obtains substantial funding from the National Collaborative Research Scheme via Bioplatforms Australia and the Queensland Government. Professor Jeff Gorman was appointed as the convenor of Proteomics Australia in 2009. This year, the Centre continued successful involvement in major activities involving the serious paediatric respiratory pathogen,
At QIMR, a series of in-house collaborations include identification of biomarkers of mosquito age, characterisation of the phenotype of breast cancer cells and the analysis of the malarial proteome. The Centre has invested in the latest mass spectrometry hardware including two state-of-the-art LTQ-Orbitrap mass spectrometers from Thermo and two high performance MALDI-TOF/TOF mass spectrometers from Bruker Daltonics. Additional mass spectrometers include two Bruker Qq-TOF and one 3D-Ion Trap instruments from Bruker. This equipment is complemented with a range of ancillary proteomic equipment.
Professor Jeff Gorman, Head of Protein Discovery Centre and The Honourable Nicola Roxon, MP, Minister for Health and Ageing
69
INFECTIOUS DISEASES DIVISION
SCABIES Laboratory Head: Dr Katja Fischer
Skin infection with scabies mites is a serious problem among Aboriginal communities, providing sites for colonisation by pathogenic bacteria which lead to serious complications. This laboratory aims to investigate the underlying molecular mechanisms. HIGHLIGHTS •
Created a series of functional knockout mutants of specific scabies mite complement inhibitors.
•
Transferred complement research methodologies to QIMR from a complement laboratory at Lund University in Malmö.
•
Revealed whole blood bactericidal assays increased bacteria survival rates in the presence of scabies mite molecules under physiological conditions.
•
Developed a pig model for scabies which will be instrumental in extrapolating in vitro data into an in vivo setting.
•
Discovered multiple classes of scabies mite molecules that prevent the immune system from killing group A steptococcus bacteria.
Based on high resolution structures generated in collaboration with researchers at Monash University, PhD student Simone Reynolds has created a series of functional knockout mutants, which will serve as a tool to determine the binding mechanism between specific scabies mite complement inhibitors and human complement factors. Dr Angela Mika visited a complement laboratory at the Lund University in Malmö, Sweden to transfer complement research methodologies to QIMR which are instrumental in demonstrating anti-complement activities of scabies mite molecules.
70
QIMR Annual Report 2009/10
In collaboration with the Bacterial Pathogenesis Laboratory, whole blood bactericidal assays revealed increased bacteria survival rates in the presence of scabies mite molecules under physiological conditions. The lack of either an animal model or an in vitro culture has limited scabies research previously. The Laboratory has developed a pig model for scabies which will be instrumental in extrapolating in vitro data into an in vivo setting. In early 2010, the Scabies Laboratory had a change of Laboratory Head. Dr Katja Fischer is now heading the Laboratory while Professor Dave Kemp remains as an overall scientific advisor, acting as a major resource in supervision, planning and fund raising for projects within the Laboratory. Image courtesy of Priscilla Goh Shi Min, Honours student.
The Tropical Parasitology Laboratory is working towards a better understanding of parasite biology, in particulary transcriptional regulation. The focus is investigating new antimalarial drugs, drug targets and parasite biology.
INFECTIOUS DISEASES DIVISION
TROPICAL PARASITOLOGY Laboratory Head: Dr Kathy Andrews
HIGHLIGHTS •
Identified new antimalarial compounds from plants and fungi.
•
Shown for the first time some HIV protease inhibitors have antimalarial activity against sexual stage malaria parasites.
Malaria continues to be one of the world’s most devastating diseases, particularly in under-developed regions. Around one million people die each year from malaria, with children under five years of age being a most risk. There is currently no vaccine for malaria, and prevention and treatment rely on drugs and public health measures such as bed nets. Unfortunately, drug resistance is a major problem in the fight against malaria which means that new drugs are urgently needed. To address this, the Tropical Parasitology Laboratory is using different approaches to investigate new antimalarial compounds and potential new drug targets. In a piggy
back approach, anti-cancer and anti-HIV drugs (and related compounds) are being investigated for their ability to kill malaria parasites. In collaboration with chemists at the Griffith University Eskitis Institute, compounds derived from natural sources, such as plants and fungi, are being studied for antimalarial activity. This project has been funded by the Medicines for Malaria Venture since 2007 and has resulted in the identification of several interesting new antimalarial compounds that are being further investigated. In parallel to drug discovery approaches, the Laboratory is also using molecular and biochemical approaches to identify and validate the targets of antimalarial compounds and to better understand essential processes, such as transcriptional regulation, in malaria parasites.
71
MENTAL HEALTH RESEARCH DIVISION CHAIR: PROFESSOR MICHAEL BREAKSPEAR The Division of Mental Health Research is a new initiative to undertake cutting-edge research into the nature, causes, diagnosis and outcome of the major mental illnesses, with a particular focus on schizophrenia, bipolar disorder, depression and autism. By combining recent advances in neurosciences with QIMR's existing strength in genetics and population health, the Mental Health Research Division has the potential to become one of Australia's leading centres for mental health research. Through improvements in diagnosis and management, the research aims to reduce the burden of mental illness to society and improve the quality of life for those with a mental illness. By working in collaboration with clinicians and other researchers in Brisbane, the Division will pursue a broad and integrative approach to mental health research. The aim is to work very closely with mental health services to recruit patients into research when they first present for assessment – prior to receiving treatment. The information collected will provide better understanding of the impact these mental illnesses have on brain function and help identify causes of disturbances in basic cognitive processes. The Division currently encompasses two laboratories – the Systems Neuroscience Group led by Michael Breakspear and the Psychiatric Genetics Laboratory led by ARC Future Fellow Naomi Wray. Systems Neuroscience is a rapidly growing field that seeks the basic principles of brain organisation, dynamics and function across a hierarchy of spatial and temporal scales in health and disease. Family studies show that genetic factors contribute an important risk for all psychiatric disorders. The Psychiatric Genetics Laboratory focuses on combining detailed symptom data with detailed genetic data to unravel the genetic etiology of these disorders. One of the major events on the near horizon is the establishment of a state-of-the-art brain imaging facility through a collaboration between QIMR, The University of Queensland and the Royal Brisbane and Woman’s Hospital. This will enable translational research into mental health diagnosis and treatment on the Herston campus. Beyond 2010, new laboratories will be established within the Division with the opening of the Smart State Research Centre, building on the existing strengths and new initiatives within QIMR in Mental Health Research.
72
QIMR Annual Report 2009/10
Our research aims to reduce the burden of mental illness to society and improve the quality of life for those with a mental illness. We will utilise the latest brain imaging and computer modelling techniques to help understand the impact these mental illnesses have on brain function and help identify causes of disturbances in basic cognitive processes. Professor Michael Breakspear, Chair of QIMR Mental Health Division
73
JOINT RESEARCH
74
QIMR MR Annual Annua Report 2009/10
JOINT RESEARCH
AUSTRALIAN CENTRE FOR INTERNATIONAL TROPICAL HEALTH (ACITH) The Australian Centre for International Tropical Health (ACITH)
•
Dr Peter Ryan, Professor Brian Kay and team with Professor Scott O’Neill (UQ), have shown that the symbiotic bacterium Wolbachia can affect life expectancy, feeding behaviour and susceptibility to a range of arboviruses including dengue. With public health researchers in Vietnam and the Australian Foundation for Peoples of Asia and the Pacific, Professor Brian Kay and Dr Peter Ryan have now protected over 500,000 people in over 50 communes from dengue disease, using a communitydriven biological control strategy. In collaboration with Associate Professors Peter Hill and Theo Vos (UQ) and three MPH students, the strategy was shown to be lowcost and sustainable.
•
Professor Andreas Suhrbier, with Professor Alex Khromykh (UQ), has established patented Replikun technology for more effective vaccine delivery.
•
Professor Andreas Suhrbier, with Dr Pierre Roques (France) and others, has created the first mouse model to understand the immunopathology and possible treatment modalities for chikungunya virus which swept through the Indian Ocean islands and India, causing over 1.6 million cases.
•
Professors Michael Good and Sri Sriprakash and others have developed vaccines for malaria and streptococcus which are currently being trialled.
•
Professor James McCarthy is overseeing the Phase I malaria trial and made a considerable contribution to the success of Pacific Malaria Support Centre.
•
Professor Alex Loukas (now at JCU, Cairns) demonstrated that celiac disease, among others, could be treated with parasites.
aims to improve the health of populations in Australia and internationally through excellence in education, research and service including high level representation on major international and tropical health committees, editorial panels and review bodies. The Centre also supports postgraduate coursework and research training in international global and tropical health. ACITH obtains core operating income from the Public Health Education and Research Program of the Australian Government Department of Health and Ageing. This income supports staff critical to the public health effort and is matched by funds from the two parent institutions – QIMR and UQ. ACITH and QIMR have consolidated their international position in tropical health with strong grant support from the Gates Foundation, NHMRC, NIH and others including The Atlantic Philanthropies, several Commonwealth Departments and the Queensland Government. Following a 2008 application to the Smart State Building Infrastructure Fund for expanded collaborative facilities for JCU, QIMR, QUT and GU, $19.45 million was provided for the Queensland Tropical Health Alliance (QTHA) which formally commenced in 2010.
HIGHLIGHTS •
•
Professor Don McManus with Professor Gail Williams (UQ) and Yuesheng Li (Hunan, China), has made major advances with respect to public health policy and practice in China regarding schistosomiasis and hydatid disease. With significant collaboration, the genomes of Schistosoma japonicum (Professor Don McManus) and Giardia (Professor Peter Upcroft, Dr Jacqui Upcroft) were decoded.
QIMR will continue to support UQ with respect to ACITH although other funding models will need to be identified. The new QTHA model, however, probably offers ACITH greater opportunities to expand its mission as part of this alliance.
75
JOINT RESEARCH
AUSTRALIAN CENTRE FOR VACCINE DEVELOPMENT (ACVD) The Australian Centre for Vaccine Development (ACVD) at QIMR is one of the largest vaccine research centres in Australia. It provides opportunities for its members to develop
HIGHLIGHTS •
Developed an adenoviral vector-based vaccine to prevent birth defects in new born babies.
•
Developed a novel strategy for malaria vaccine based on Toll-like receptor agonists.
•
Developed novel blood test to predict viral diseases in transplant patients.
•
Phase I clinical studies aimed at testing novel immunebased therapies for human cancers (nasopharyngeal carcinoma, Hodgkin’s lymphoma, post-transplant lymphomas, glioblastoma, and prostate cancer).
•
Screened natural compounds for novel adjuvants for human vaccine formulations.
•
Signed collaborative agreements with major international vaccine development companies to co-develop vaccines for infectious diseases and virus-associated cancers.
•
Described critical characteristics of breast cancer stem cells identified in established breast cancer cell lines.
•
Identified novel tumour associated antigens in melanoma.
collaborative links with national and international academic institutions and the biotech industry and also provide a platform for young Australian and international scientists to learn and develop new techniques in the field of vaccine research. During 2009/10, ACVD and the Emory Vaccine Centre at Emory University in Atlanta (USA) established the QueenslandUS Vaccine Technology Alliance with a three-year grant of $1.8 million from the Smart Futures Fund of the Queensland National and International Research Alliances Program. Additional funding has been provided by QIMR and the Emory University, with total project funding from all sources equalling $8.5 million over three years. Under this collaborative program, a number of projects on novel vaccine design have been funded and training opportunities for postgraduate students will be provided. ACVD scientists have made a number of contributions towards vaccine and immunotherapy development.
76
QIMR Annual Report 2009/10
JOINT RESEARCH
•
Tina Skinner-Adams and Michael Williams. Delocalised lipophilic cationic anti-malarial conjugates.
COOPERATIVE RESEARCH CENTRE FOR ABORIGINAL HEALTH (CRCAH)
GMRC staff continue to be successful in attracting external funding. Grants and Fellowships from the ARC and NHMRC awarded Dr Louisa Gordon and Professor Michael Good, administered through the GMRC, amounted to $4.2 million in 2009/10.
The CRCAH finished in December 2009 and its successor, the Lowitja Institute (incorporating the CRC for Aboriginal and Torres Strait Islander Health) commenced in January 2010. The Lowitja Institute is a collaborative research organisation that brings together Aboriginal organisations, research institutions and government agencies to facilitate evidencebased research into Aboriginal and Torres Strait Islander health. QIMR is a Research Participant and Foundation member.
Q-PHARM
The Institute will host the Cooperative Research Centre for Aboriginal and Torres Strait Islander Health (CRCATSIH) and will eventually take over its research program in June 2014, thereby providing a permanent organisation for Indigenous health research. Beyond June 2014, the Institute will fund research and implement programs in its own right.
•
Commenced a collaborative study with Professor James McCarthy on the validation of a human malaria challenge model.
•
Completed successful recruitment for an international, multicenter influenza vaccine study, as lead site.
•
Continued its leading role in professional education activities with Australian Research Collaborative Service, British Association of Research Quality Assurance and Queensland Clinical Trials Network.
GRIFFITH MEDICAL RESEARCH COLLEGE (GMRC) The Griffith Medical Research College (GMRC) is a joint initiative of QIMR and Griffith University that aims to promote collaboration between researchers of both organisations. The GMRC achieves these aims by providing seed funding for collaborative initiatives, supporting research higher degree students, and promoting professional interaction between staff. This year Professor Michael Good, the founding Director of the GMRC stepped down to take up an Australia Fellowship at Griffith University. Professor Good’s vision and drive were instrumental in the founding and promotion of the strategic goals of the GMRC. Professor Alex Loukas also stepped down from the committee after taking up a new position at James Cook University. His place on the Committee was taken by Associate Professor David Whiteman.
Q-Pharm is a specialist contract research organisation that conducts early phase clinical trials of pharmaceutical and biotechnology products spanning the areas of therapeutic, diagnostic and disease prevention agents.
HIGHLIGHTS
The company offers the best appointed early phase clinical trials facilities in Australasia which include recruitment and outpatient clinics, a specialised 18 bed clinic for the conduct of the most medically demanding trials and an open plan 24 bed facility for larger healthy volunteer trials. Q-Pharm concluded its eighth year of trading as a private company on 30 June 2010. As in previous years, the company’s international client base continued to diversify and accounts for greater than 60% of revenue. Despite challenging trading conditions continuing into the 2009/10 financial year, the company has consolidated its place as one of the leading early phase clinical trial organisations in Australasia.
The GMRC currently includes 66 staff and six students. Biniris (Aust) Pty Ltd continues their generous financial support of GMRC research higher degree students. This year, the GMRC directly awarded funding of $104,500 for three collaborative research projects: •
Jeremy Brownlie, Jonathan Darbro and Peter Ryan. Characterisation of fungal pathogen kinetics in Aedes aegypti the global dengue vector.
•
Jin Gao, Newell Johnson, Peter Parsons and Glen Boyle. Role of transforming growth factor-beta (TGF-beta1) and the matrix metalloproteinases (MMP-2 and -9) cascade in the formation of oral squamous cell carcinoma (OSCC) stem cells via epithelial-mesenchymal transition.
77
CORPORATE
78
QIMR Annual Report 2009/10
Front row Left to Right: Michael Creevey, IT Manager with members of the IT team: Tomomi Tomlin and Robert Taylor Back Row Left to Right : Archie De Guzman, Luke Lowrey, and Vincent Mar
CORPORATE DIVISION The role of the Corporate Division is to ensure the Institute operates effectively and to provide the high level of support services required to keep QIMR at the forefront of medical research. It provides these services in an increasingly challenging and complex regulatory and commercial environment. Consisting of Scientific Support Services, Finance, Procurement, Grant Management, Human Resources, Information Technology, Regulatory Affairs, Safety, Records and Information Services, Building Services, External Relations and Business Development, the dedicated corporate staff are committed to providing its researchers with access to the best staff and students, as well as cutting edge scientific equipment, technologies and processes. It has been a very productive year for the Corporate Division as we prepare for an anticipated period of rapid growth for the Institute with the construction of the Smart State Medical Research Centre. The Division’s recent focus has been on streamlining and improving QIMR’s systems and processes to provide researchers with better quality information at their fingertips; managing construction of the new facility; and raising awareness of QIMR among the general public.
SMART STATE MEDICAL RESEARCH CENTRE The landscape is changing dramatically at QIMR with construction of a new 13-floor research facility underway on the site of the old Queensland Radium Institute (QRI). Set between the existing Bancroft Centre and Clive Berghofer Cancer Research
Centre, the new building will serve as the integrating hub for the existing buildings and provide an inviting street profile and focal point for QIMR. The demolition of the Queensland Radium Institute was completed on time and all demolition items were removed from site for recycling as appropriate. Construction has begun and building is on schedule for completion on time and within budget.
SYSTEMS Following a comprehensive review and analysis of existing corporate systems, this year saw the implementation of a suite of new online systems. The new systems, which were progressively released over a period of nine months, streamline the interface for corporate functions and have made significant impact on the turnaround time for core services and the level of access to critical operating information. Scientists and staff alike have been very positive about the new systems and the efficiency gains from online access to services. The new payroll and HR system, Aurion, replaces manual paper processes with secure web access for staff to their HR information and services. The online requisition and ordering system WebGet was designed by QIMR’s IT team to meet the Institute’s specific ordering needs. WebGet also provides improved efficiency of inventory processes and order life cycles. The new fundraising database, The Raiser’s Edge, allows the fundraising team to better manage donor relationships and implement more effective coordination of fundraising approaches. A new version of the WebReporting Suite was introduced which gives even more real-time on-line information to scientists to assist with managing their research.
Smart State Medical Research Centre under construction
79
High School students learning about vaccination from Dr Wayne Schroder
BIOINFORMATICS The Corporate Division is also supporting QIMR’s new Bioinformatics Laboratory, with the implementation of a high performance computer cluster. Bioinformatics is the analysis of large volumes of research data such as studies of the human genome. This processing capacity will ultimately bring QIMR researchers a step closer to understanding the underlying genetic causes of a range of diseases.
QIMR also hosted two well attended public health forums on skin cancer (in partnership with Melanoma Australia) and men’s health. Media relations were another priority as reflected in the increased national and international coverage of QIMR’s research programs. The department’s education program continues to inspire the scientists of tomorrow with some 1,400 senior students attending the High School Lecture Series in 2009-10.
RESEARCH SUPPORT
FUNDRAISING
Preparations are underway for the commissioning of the SSMRC and the extra demand for services that will follow. These include scaling up of the microscopy, DNA sequencing, tissue preparation and tissue culture capacity of the Institute. These service laboratories are getting an upgraded laser for flow cytometry that will allow users to perform better protein analysis on live cells and new customised filters have been installed to the Deltavision microscope allowing specific proteins and parts of the live cell to be studied.
We would like to sincerely thank everyone who has made a donation to QIMR and helped make our important research happen. We rely on community support to maintain our position as a leading medical research institute and to pioneer new research. Thank you to our many loyal supporters including our corporate partners such as Suncorp and Xstrata, and philanthropists Mr Clive Berghofer, AM and Mr Royce Blackburne.
COMMUNITY ENGAGEMENT The External Relations department’s efforts to raise community awareness of QIMR and the calibre and breadth of its research have included the re-development of the QIMR website. The new site reflects the new QIMR branding and ensures information is more easily accessible. QIMR was on display for the second consecutive year at the Government House Open Day hosted by QIMR Patron, Queensland Governor Ms Penelope Wensley AO. Some 46,000 people visiting the QIMR display at the Science Pavilion at the 2009 Brisbane Ekka had the opportunity to try their hand at some laboratory procedures.
80
QIMR Annual Report 2009/10
Mr Sean Ryan, Founder of the Knights of the Round Table event that has raised over $500,000 for QIMR.
Mr Clive Berghofer AM
We also recognise the wonderful contribution made by our monthly donors and the planned givers who kindly made provision for QIMR in their wills. Medical research is an investment with long term potential. The new treatments we develop can save lives and potentially improve the health of everyone now and in the future. Each year QIMR acknowledges some extraordinary people whose support of medical research has been outstanding and who share our vision and values. The recipients of 2009-10 Ambassador awards were Mrs Norma Schwarz, Mr Bob Rice, Ms Robyn Bailey and Mrs Ailsa Zinns. Mrs Fitton and Mr Michael Gambaro were announced as joint winners of the QIMR Humanitarian Award at the 2009 Derrick-Mackerras Memorial Lecture. Another important source of funding is generated by individuals and businesses who organise events for which QIMR is the beneficiary. We are very appreciative of their support and acknowledge their dedicated efforts. They include people such as Sean Ryan (Knights of the Round Table), Sunny Drescher (Happy Face Cent Auctions), Jones Lang La Salle and the tenants of the Riverside Centre (Corporate golf day), our friends at Tattersall’s, employees of Witchery who sell pink ribbons throughout their Queensland stores, the organisers of the All British Classic Day and our many friends in Toowoomba including Fitton Insurance Brokers and all those who contribute to the success of the Fitton Charity Race Day and Darling Downs Equine Extravaganza.
THE ATLANTIC PHILANTHROPIES The Smart State Medical Research Centre is only possible thanks to the generous support of The Atlantic Philanthropies (AP). The $27.5 million Founding Chairman’s grant from Atlantic Philanthropies is our largest-ever philanthropic gift and brings AP’s total commitment to QIMR over the last ten years to $57 million. Mr Charles “Chuck” Feeney, the Founding Chairman of AP, has been involved in the conceptualisation and planning of the new building for some time and played an active role in encouraging the financial support from both the Federal and State governments. Mr Feeney demonstrated his belief in giving while living when he gave away the vast majority of his wealth to start The Atlantic Philanthropies in 1984. Atlantic Philanthropies hopes to inspire individuals at widely varying levels of wealth to embrace giving while living: to approach philanthropy as a calling to which they can, during their lifetimes, actively devote their funds, skills and time, and receive enormous satisfaction in the process.
Donna Hancock Acting General Manager/Secretary
Artist’s impression of completed Smart State Medical Research Centre
81
WE THANK AND ACKNOWLEDGE THE SUPPORT OF THE FOLLOWING VALUED FRIENDS AND MAJOR DONORS: The Atlantic Philanthropies
Ryan Saunders Foundation Limited
Mr Clive Berghofer AM
Mr Kevin and Mrs Dallas Bedford
Estate of Mr Peter Lipscombe
Mr George Landers
Estate of Mr John Francis Pickering
Estate of Ms Heather Daphne Livesey
Suncorp Metway
Queensland Community Foundation
Estate of Miss Violet Maud Lingard
Selwyn Thomas Fassifern Ozanne and Doreen Elaine
Visiting Medical Officers (VMO) Committee (AMAQ)
Ozanne Trust
Estate of Ms Cathryn Janet Christensen
Gambaro’s Restaurant
Xstrata Copper
NOVA 106.9
Estate of Ms Lillian Jenvey
Sidney Richard and Beryl Lillian Early Trust
Estate of Mr Kevin H Makins
Barbara Rhoda Phyllis Dalton Perpetual Charitable Trust
Estate of Ms Sheila Beatrice Harrison
Mr Tim and Mrs Kym Reid
Estate of Mr Camrin Anthony Reeve
Mr P R Rowland
Roycorp Pty Ltd (Mr Royce Blackburne)
Mrs Heather Jordan
Port Glaud Limited
The Cory Charitable Foundation
Estate of Miss Marjorie Grace Dunn
All British Classics Car Club Inc
BT Investment Management Pty Ltd Witchery Mr Barry and Mrs Maureen Stevenson Estate of Ms Flora Ethel Box E M Squires Charitable Trust Mr Karl Morris Tattersall's Club The Henry Cyril Robjohns and Stella May Robjohns Memorial Trust Biniris Pty Ltd Happy Face Cent Auction (Mrs Sunny Drescher) Estate of Mr Geoffrey John Shepherd
82
Mr Stuart Bishop Spaceframe Buildings Qld Ex-Service Women's Association Jameson Charitable Foundation Mr Rod Wylie Reuben Pelerman Benevolent Foundation Mr Dan Holzapfel Dr James Aylward The White Foundation Pty Ltd Mr Henry and Mrs Joan Daniel Community Supporting Police Inc
Fitton Insurance Brokers
Mr Douglas and Mrs Helen Cowlishaw
Mrs Brenda Holdway
G T Burgess Investments Pty Ltd
Estate of Ms Margaret Rudder
Mrs M J Gibson
Mrs Helen Gow
Ms Barbara McKay
J J Richards and Sons Pty Ltd
Mr Damien Cavallucci
Mr Kevin and Mrs Elsie Hayes
Mr Peter Rasey
Mr Ivan Mitchell
Estate of Mr Robert Kenneth Gregory
Mr Norman and Mrs Marjorie Ongley
FGF Developments Pty Ltd
Estate of Ms Marjorie Blanche Baxter
Mr Leigh Ainsworth
Sherrin Investments Pty Ltd
Mrs Jacqueline Pascual
QIMR Annual Report 2009/10
TRUST REPORT It has been an important year for the Institute, and for Trust. Once again, the past 12 months has seen many changes, and these will form the basis of growth and development for many years to come. The announcement of an increase in recurrent operational funding in the recent State Budget was good news for Council and Trust, with the size and capacity of QIMR about to increase substantially once the Smart State Research Centre is completed. In particular, it will give Trust the capacity to rebuild capital lost in the recent global financial crisis, and will give Council confidence that it can support an additional 400 of the world’s best scientists in our new facility. The improved, but still volatile, financial conditions have resulted in an increase in Trust investment earnings, increasing the value of our reserves from the low point reached during the crisis. However, the climate for fundraising and sponsorship is still difficult and highly competitive. Against this background, our External Relations Department has performed very well. I would like to congratulate them on a very good year, which has seen our database resources vastly improved and the launch of our new website. The team is supported by a wonderful band of volunteer fundraisers, who have held boardroom lunches, race days, golf days and other high profile events, of which QIMR is a beneficiary. During the year, we identified an opportunity to host a major fundraising event, a two day bike ride, which is planned to take place in August for the next three years, commencing in 2011. ‘The Ride to Conquer Cancer’ will be our signature event over this period.
I would also like to thank our individual and corporate donors for their support of QIMR over the past year. In particular, I would like to acknowledge the ongoing generosity of Mr Clive Berghofer. Clive’s support over many years has resulted in the development of new treatment methodologies for many forms of cancer, which will benefit current and future generations. The work of Trust is done by a small number of dedicated members, supported by an experienced and competent staff. During the year, we welcomed Professor John Hay to our ranks, upon his taking the role of Chair of Council. John has been a supportive and valuable member of Trust, and an inspirational Council Chair. We also farewelled David Stirling who resigned because of work and family commitments. David has been an important contributor to Trust, particularly in the Investment Committee, and his business experience and contribution will be greatly missed. The remaining members of Trust, Rod Wylie and Patricia McCormack, have continued to play a vital role, and their hard work and guidance is appreciated and highly valued. The review and amendment of the Queensland Institute of Medical Research Act, has not yet occurred, but we are hopeful that this will occur later in 2010. This will provide a larger base for Council and Trust, to enable us to further support and guide the wonderful efforts of our staff, partners, donors and volunteers to continue QIMR’s vital research. Jane Seawright Chair
83
TRUST MEMBERS
Patricia McCormack BA (Psych and IR) FAHRI, MAICD
Jane Seawright
Patricia McCormack is a highly
BA LLB(Hons) MBus (Marketing) Acting Chair
regarded People Management
Jane Seawright is a lawyer with
experience in all facets of Human
professional with extensive Resource Management. She
extensive experience in marketing and strategy. She established a
established People Focus in 2002 with the aim of providing HR
freelance marketing consultancy,
services specialising in organisation development and human
Seawright Consulting, in 2000 and held the position of
resources management. Ms McCormack is a member of the
Independent Chair of the Queensland Furnishing Industry
QIMR Personnel Administration Committee and the QIMR
Superannuation Trust for 13 years. She practices in corporate
Marketing Committee.
and commercial law, and is also a Law Society-accredited mediator and registered adjudicator, pursuant to the Building
David Stirling
and Construction Industry Payments Act 2004. She has been
David Stirling has had extensive
the Convenor and Acting Chair of The Queensland Institute of
commercial experience over the past
Medical Research Trust since February 2008, and is a member
40 years in the areas of banking,
of the QIMR Marketing Committee.
merchant banking and investments. Before joining the QIMR Trust, David was Managing Director of a financial
Professor John Hay AC BA (Hons)
services firm and a Partner of an international Chartered
(Western Australia and Cambridge),
Accounting firm. He has been a member of a considerable
MA (Cambridge), PhD (Western
number of professional organisations including the Institute of
Australia), Hon LittD (Deakin), Hon
Engineers, Commercial Law Association, Institute of Chartered
DLitt. (UWA); Hon DU (QUT); Hon
Accounts affiliate, FPA, Securities Institute of Australia and a
LLD (Queensland); FAHA; FACE;
Fellow of the Australian Institute of Company Directors. David
FAIM; FQA (Chair from 24/09/09)
is a member of the QIMR Investment Committee.
Professor Hay was Vice Chancellor of The University of Queensland from 1996-2007. In that time he led the
Rodney Wylie
development of many major new research institutes including the Institute for Molecular Bioscience, the Australian Institute
OBE B Comm BA FCA FAICD
of Bioengineering and Nanotechnology and the Queensland
Rod Wylie is a Brisbane-based
Brain Institute. He was also instrumental in securing funding for
Chartered Accountant with
the Translational Research Institute to be built at the Princess
substantial experience in investment,
Alexandra Hospital. He has led both Deakin University and The
company management and
University of Queensland to be named Australian universities
corporate governance issues across
of the year by the Good Universities Guide. Professor Hay
a wide range of organisations, in many cases with nationwide
is Chair of nine boards, including QIMR to which he was
and international activities. He has been involved through
appointed by the Queensland Government in September 2009.
Board/Council membership in the administration of a number of professional and community non-profit groups. Mr Wylie chairs the QIMR Investment Committee and is a member of the QIMR Finance and Audit Committee and QIMR Personnel Administration Committee.
84
QIMR Annual Report 2009/10
POSTGRADUATE TRAINING QIMR’s postgraduate students have continued to make an impressive impact on the wider scientific community this year receiving numerous notable awards Today’s students are the scientists of the future so postgraduate students are an important part of the research effort at QIMR and the mentoring of students remains a high priority. The excellent research facilities, support services, extensive network of international and national research collaborations and internationally-ranked quality of QIMR scientists combine to provide an outstanding environment for advanced training in health and biomedical research. Overall, 2009-2010 was an excellent year for students at QIMR with a total of 24 PhD students, four Research Masters and 14 Honours students successfully graduating from their degree programs. During the year, the Institute admitted 26 new PhD, two Research Masters and 21 Honours students; PhD admissions in particular were greatly increased from only 14 in 2008-2009. QIMR also hosted 52 visiting students during the year, many from overseas; again a considerable increase from the 28 students who visited the Institute in the previous year. The highly successful QIMR Summer Vacation Scholarship program again attracted a significant number of applications and the 14 successful Vacation Scholars gained valuable experience working with QIMR scientists between December 2009 and February 2010.
Kimberley Jones was awarded the ASMR Medal as winner of the Australian Society of Medical Research Postgraduate Student Category; Kate Markey, won the Young Researcher Award from the Australian Academy of Sciences to attend the 2010 Meetings of Nobel Laureates in Lindau, Germany and Karin Verweij won a prize for the best poster presentation at the International Congress on Twin Studies in Seoul, South Korea. QIMR students also did very well in receiving travel awards to attend international conferences including Miriam Mosing and Karin Verweij who won Behaviour Genetics Association travel Fellowships and Daniel Worthley who won a Royal Australian College of Physicians Overseas Travelling Fellowship. The Higher Degrees Committee (HDC) evaluates students prior to their acceptance as candidates at the Institute, monitors their progress during their candidature, provides education programs and offers a number of travel awards, Honours and PhD Top-Up Scholarships to the top students. As in previous years, HDC members have devoted considerable time to the review of students during their study program with more than 33 reviews conducted in 2009-2010.
85
Being a PhD student at QIMR has been extremely rewarding. I’ve been very well supported by my supervisors and the other members of the lab. The expertise and technology available within the lab, and the institute as a whole, has been critical for the success of my PhD project. QIMR has provided me with signiďŹ cant p personal holarships support in terms of top-up scholarships and travel funding. Kate Markey, PhD student, Bone Marrow Transplantation Laboratory, Immunology Division
86
COMPLETED STUDENTS 2009-2010 STUDENT
UNIVERSITY QIMR SUPERVISOR
THESIS
PHD Julie BALEN
School of Population Health, UQ, Don McManus
Daniel BUCHANAN
Medicine UQ, Joanne Young and George Mellick
Genetic risk factors in Parkinson's disease
Melissa BURKE
School of Population Health, UQ, Don McManus/Geoff Gobert
Transcriptomics of Schistosoma japonicum-induced immunopathology
Enda BYRNE
School of Medicine, UQ, Peter Visscher and Allan McRae
Mitochondrial and autosomal genetic analyses in the Australian Population
Justin CHAPLIN
QUT, Grant Montgomery
Molecular genetics of reproductive disorders
Teong CHUAH
UQ, Martin Lavin
Amber GLANFIELD
Public Health, University of Queensland, Malcolm Jones
Iron Biology of schistosomes: molecular characterization and vaccine potential of iron homeostasis proteins
Davina GORTON
School of Veterinary and Biomedical Sciences, James Dr Colleen Olive (co-supervisor) Cook University,
T cell and B cell Responses in a rat Model of Rheumatic Heart Disease
Matthew JONES
UQ School of Medicine supervisors: D. Krause
Understanding the role of tousled-like kinases in cell cycle progression
Marina KVASKOFF
School of Population Health, University of Queensland and Ecole Doctorale ED420, Université de Paris XI, France, David Whiteman
Nelson LEE
Medicine, UQ, James McCarthy and Qin Cheng
Towards the Optimisation of Malaria Rapid Diagnostic Tests
Hong Yon LIM
School of Molecular and Microbial Sciences, UQ, Kathy Andrews
Identification of P. falciparum histone deacetylase 1 (PfHDAC1) interacting proteins
Penelope MCBRIDE
UQ, Adele Green
Cutaneous squamous cell carcinoma & its determinants
Luke MEREDITH
GMRC, Griffith University, David Harrich
The role of viral and cellular factors in regulating HIV-1 reverse transcription
Daniel MORGAN
School of Medicine, UQ, Emma Whitelaw
Epigenetic Modifiers of Transgene Silencing
Nirmala PANDEYA
School of Population Health, University of Queensland, David Whiteman
Risk factors for cancers of the oesophagus: histological subtypes, temporal effects and bias
Naomi RICHMONDSINCLAIR
QUT, Adele Green
The Epidemiology of Basal Cell Carcinoma
Kienan SAVAGE
UQ School of Medicine Primary Supervisor KK Khanna; Cosupervisors: G.Chenevix-Trench & D.J. Richard
BRCA1, KAP1 and DNA damage response
Meru SHEEL
Life Science, QUT, Michael Batzloff
Immunogenicity and protective efficacy of an anti-Streptococcus pyogenes vaccine candidate in multiple animal species
Nadia WHITELAW
School of Medicine, UQ, Emma Whitelaw
The characterisation of three MOMMEs
Daniel WORTHLEY
School of Medicine, The University of Queensland, Barbara Leggett
DNA methylation throughout the human colorectum: person, place and pathology
Hong YOU
School of Population Health, UQ, Don McManus/Geoff Gobert/ Wenbao Zhang
Cloning, characterisation and vaccine efficacy of schistosoma japonicum insulin receptors
Christine ZHANG
Griffith University, Grant Montgomery
Molecular genetics of endometriosis
Gu ZHU
Medicine UQ, Nick Martin
The Quantitative Genetics of Nevus Count and Other Pigmentary Characteristics of the Skin
Brendan ZIETSCH
Psychology, UQ,Nick Martin
Causes of covariation between personality, psychiatric symptoms, and sexual behaviour
Michelle BAUER
Cell and Molecular Biosciences , QUT, David McMillan
Evaluation of a multi-epitope group A streptococcal vaccine
Priscilla GOH SHI MIN
Moleculas Biosciences, University of Queensland, Dr Katja Fischer and Dr Angela Mika
The role of peritrophins in scabies mite immunity
Thomas HARDING
Cell and Molecular Biosciences , QUT, David McMillan
Characterisation of the arsenic resistance locus in group G streptococcus
Krystal LIANOS
B. Appl Sc Hons, Life Sciences, QUT, Emma Whitelaw
Dicer effects on epigenetically-sensitive alleles
Laken MCGARVEY
School of Chemistry and Molecular Biosciences, UQ, Don McManus/Geoff Gobert
Gene Expression Profiling and Flow Cytometry of the Lungs of Naïve and Rechallenged Mice During Migration of Schistosoma japonicum Schistosomula
Rachael MCGEORGE
Griffith University, Tina Skinner-Adams
Examining the Antimalarial Activity of the HIV Protease Inhibitors
Sean MORGAN
Cell and Molecular Biosciences , QUT, David McMillan
Multilocus Sequence Typing of invasive group G streptococcal isolates from Fiji
Alex MULHERIN
SBMS, UQ, Christian Engwerda
Defining the role of dendritic cells in the activation of T cells in response to Leishmania donovani infection.
Nurual OSMAN
UQ, McDonald/Hill
Chronic GVHD
Jillian PACKHAM
Nan Yang Singapore, Don Gardiner
Functional Studies of Ring Exported Protein 1 (REX1) in Plasmodium falciparum
Meera PERUMALPILLAIMCGARRY
School of Chemical and Molecular Biosciences, University of Queensland, Malcolm Jones
Proteomic analyses of egg secretions of schistosomes
Ben RUTHERFORD
QUT, Leon Hugo and Peter Ryan
Development of Proteomic Techniques for Analysis of Ae. aegypti Proteome
Primary Supervisor KK Khanna; Co-
Determinants of Schistosoma japonicum and soil-transmitted helminth infections, and associated morbidity in Hunan province, China: an epidemiological assessment
Endometriosis and naevus-associated gene variants in relation to risk of cutaneous melanoma
BSC HONOURS
87
COMPLETED STUDENTS 2009-2010 CONTINUED STUDENT
UNIVERSITY QIMR SUPERVISOR
THESIS
Leigh SCHULTE
School of Chemical and Molecular Biosciences, University of Queensland, Malcolm Jones
Molecular characterization of zinc transporters of schistosomes
Hong YON LIM
School of Molecular and Microbial Sciences, University of Queensland, Kathy Andrews
Identification of P. falciparum histone deacetylase 1 (PfHDAC1) interacting proteins
Abraham JOHN
MSc Honours, School of Biomolecular and Physical Sciences , Griffith University, Nathan Subramaniam
Role of ATM (ataxia telangiectasia mutated) in iron metabolism
Mariska MIRANDA
School of Chemistry and Molecular Biosciences, The University of Queensland, Kevin Spring
Investigating the role of IGFBP7 in serrated neoplasia of the colon
MASTERS
Klara UNOSSON
Linköpings University, Sweden, Christian Engwerda
Defining early immune events following Plasmodium berghei infection.
Renate ZELGER
Universitäftür Bodenkultur Wien, Don Gardiner
Protein trafficking within the malaria parasite
STUDENT AWARDS 2009-2010 RECIPIENT Enda
Byrne
Patrick
Driguez
Imogen
Gillions
Kimberley
Jones
Muhsin
Karim
Yi
Lu
BESTOWER
DATE
AWARD
Jan-10
Dr. Diana Cavaye scholarship
Top-up scholarship
Aug-09
ACVD Josephine Mackerras Training Scholarship
Excellence in PhD research
ACVD
Oct-09
Josephine Mackerras Training Scholarship
QIMR
Jul-10
QIMR PhD TopUp Award
Jun-10
Winner, Post-Graduate Student Category
Jul-09
MC Ainsworth Scholarship in Neurosciences
QIMR Australian Centre for Vaccine Development
Australian Society of Medical Research Australian Neuroscience Society
Best student oral presentation award in the 5th
Nov-09
Australian Twin Registry
Jun-10
Travel award
Jun-10
Young researcher award
Jun-10
Young investigator
High ranking abstract at annual meeting
Jun-10
KHA Laboratory Award
Highest ranking abstract at annual meeting
May-10
Travel award
Jun-10
Travel award
Meetings of Nobel
International Student Research Forum
Laureates Transplantation Society of Australia and NZ Markey
Best Postgraduate Essay
Griffith University
Council of the Lindau
Kate
REASON
Transplantation Society of Australia and NZ Australian Society of Immunology The Transplantation Society
Laureates
Award to present at World Transplant Congress, Vancouver Top student abstract submitted to World Transplant Congress
Nico
Martin
ANZ Banking Corporation
Brian
Morrison
QIMR
Jan-10
QIMR PhD TopUp Award
Relinquished
ANZ Banking Corporation
Jun-09
NZ Trustees PhD Scholarship
Postgraduate Stipend
Jun-10
BGA Travel Fellowships
2010 BGA Seoul Conf Travel
Nov-09
Best Student Presentation
Mar-10
Honours Scholarships
Jul-09
Runner Up PhD Talk Prize 2009
Jul-09
Student Travel Award 2009
Jul-09
Student Travel Award 2009
Miriam
Mosing
Behavior Genetics Associaton
Michelle
Neller
Shu
Qin Toh
Australasian Flow Cytometry Group QIMR The East Coast Protein Meeting The East Coast Protein
Simone
Reynolds
Meeting
Jun-09
ANZ Trustees PhD scholarship in Medical
Chosen Attended Lindau Meetings of Nobel
Research
Postgraduate Stipend
The ASP and ARC/ NHMRC Network for Parasitology Celestine
Rickman
RBWH Research Foundation Brisbane Immunology
Renne
Robb
Group Australian Center for Vaccine Design
88
QIMR Annual Report 2009/10
Oct-09
Royal Brisbane and Women’s Hospital Research Foundation Basic Sciences Prize, $1000.
Aug-09
Peter Doherty Medal
Jul-09
Josephine Mackerras Training Scholarship
RBWH Research Week Best student presentation Merit award to attend World Transplant Congress
STUDENT AWARDS 2009-2010 CONTINUED RECIPIENT
BESTOWER Behavior Genetics
Verweij
Psychology UQ
Jun-10
Annandale Bequest Awardee
2010 Seoul ICTS/BGA Conf Travel
Psychology, UQ
Jun-10
International Conf Travel
Seoul ICTS/BGA Conf Travel
ANZ Banking Corporation
Jan-10
Twin Studies (ICTS) Warren
Phillip
Whiley
Australasian HIV/AIDS conference
ANZ Trustees PhD scholarship in Medical Research
Jun-10
Best Poster Presentation, Seoul Meeting
Sep-09
Best student oral presentation
Aug-09
Poster Prize
Familial Cancer Conference 2009 RBWH Research Foundation
Worthley
Oct-09
RACP
Jan-10
RACP
Jan-10
NHMRC
Jan-10
2010 BGA Seoul Conf Travel
Postgraduate Stipend RUNNER UP -ICTS Seoul
Poster: BRCA2 sequence variants causing missense alterations and spli
Committee
Daniel
REASON
BGA Travel Fellowships
International Congress on
Kylie
AWARD
Jun-10
Association
Karin
DATE
Royal Brisbane and Women’s Hospital Research Foundation Clinical Sciences Prize, $1000. Royal Australasian College of Physicians Cottrell Fellowship, $60,000. Royal Australasian College of Physicians IMS Overseas Travelling Fellowship, $15,000.
RBWH Research week Fellowship Travelling Fellowship
NHMRC/CJ Martin Biomedical Overseas Fellowship: to Columbia University, NY, US:
Postdoctoral Training Fellowship
$429,022. NHMRC
Jan-10
NHMRC/R.G. Menzies Fellowship:
Postdoctoral Training Fellowship
QIMR AWARDS 2009-2010 THE DERRICK-MACKERRAS MEMORIAL LECTURE
RALPH DOHERTY QIMR SCIENCE PRIZE
Each year, an eminent person is invited to deliver the DerrickMackerras Memorial lecture, named after the founding Director and Deputy Director of QIMR. This year, the Honourable Barry Jones, AO, gave the lecture titled: My life and times: the factors that made me an advocate for science.
The prestigious Ralph Doherty Science Prize for outstanding achievement and leadership in medical research was given to Professor Nick Hayward for his leadership in the field of melanoma genetics and his dedication to QIMR as a researcher, mentor and ambassador for science in the public arena.
BANCROFT MEDAL
POSTDOCTORAL PRIZE
The Bancroft Medal is awarded annually to those who have made an outstanding contribution to the Institute. This year’s recipient was Ms Joy Black. Joy has been an outstanding employee with QIMR for the last 23 years. As Executive Assistant to the Director, Joy has been at the forefront of contact with staff, students, external stakeholders, dignitaries and the public and has performed her role with enthusiasm, dignity and hard work.
This year’s winner of the QIMR Postdoctoral Prize was Dr Manuel Ferriera of the Genetic Epidemiology Laboratory for his published work on bipolar disorder, autism and schizophrenia risk. These papers reshaped the research landscape not just in psychiatry but for other complex diseases as well and will influence the research agenda for years to come.
FELLOWS OF THE INSTITUTE
This annual award has been designed to recognise people within the community who tangibly and actively raise awareness and/or revenue for the Institute and our research program. This year we awarded two individuals with the Humanitarian Award in honour of their significant contributions towards our vision to improve human health and longevity. They are Del Fitton and Michael Gambaro. Del Fitton is a QIMR Ambassador who has raised over $200,000 for QIMR since 1998 as founder and driving force behind the Darling Downs Equine Extravaganza.
Each year, outstanding individuals are named as Fellows of the Institute and this year, Dr Peter Roeser and Professor Peter Brooks were named. Dr Roeser was awarded the fellowship in recognition of his contribution as Chair of the QIMR Clinical Trial Protocol Committee since 2003 and his work to ensure that QIMR maintains its high reputation in translational research. Professor Peter Brooks was awarded the fellowship for his contribution to QIMR as NHMRC nominee on the QIMR Council, Chair of the Appointments and Promotions Committee and the Medical Advisory Board and his work in cementing research partnerships between UQ and QIMR.
HUMANITARIAN AWARD
Michael Gambaro has supported QIMR for many years through the Knights of the Round Table event and has helped raise over $1 million for charities in Queensland including QIMR.
89
OTHER AWARDS 2009-2010 BESTOWER OF AWARD
RECIPIENT
90
DATE
AWARD
REASON
Dr Barrie Anthony
University of Salford, UK
June 2010
Hugh Mulligan prize for work of outstanding merit on a thesis for a PhD or MSc in the field of parasitology, bacteriology or tropical medicine
Dr Beben Benyamin
Heart Foundation
November 2009
Best student oral presentation award in the 5th International Student Research Forum
Prof Michael Breakspear
QLD Office and Health and Medical Research
June 2010
Health Research Fellowship
Successful Application
Dr Manuel Ferreira
QIMR Derek Mackerras Awards
October 2009
QIMR Postdoctoral Prize
Winner
Assoc Prof Maher Gandhi
Australian Society of Medical Research
June 2010
Winner, Clinical Researcher Category
Assoc Prof Gail Garvey
Queensland Government
November 2009
Our Women Our State Awards
Promoting Indigenous Women in Science Award
Prof Michael Good
Australian Museum
September 2009
CSIRO Eureka Prize for Leadership in Science
Leadership in Science
NHMRC
December 2009
NHMRC Australia Fellowship
Queensland Government
June 2010
2010 Queensland Great
Excellence in PhD research
A renowned national and international health leader who has made a life-long contribution
Dr Darren Gray
Griffith University
August 2009
Griffith University Postdoctoral Fellowship
Three year fellowship
Dr Motoko Koyama
Transplantation Society of Australia and NZ
June 2010
Young investigator award
High ranking abstract at annual meeting
Dr Marina Kvaskoff
des Labaoratoires SVR
December 2009
Jean Darier Award
For an epidemiological study project in Dermatology
Fondation de France
October 2009
Laureate Postdoctoral Award
Research excellence
Dr Yuesheng Li
Australian Research Council
January 2010
Future Fellowship
Four year fellowship
Assoc Prof J. Alejandro López
Griffith University
July 2009
Graduate Certificate of Higher Education
Dr Stuart Macgregor
Australian Academy of Science
March 2010
Ruth Stephens Gani Medal
Prof Don McManus
World Health Organisation
August 2009
Expert Advisory Panel on Parasitic Diseases (Schistosomiasis)
WHO Panel Membership
UNICEF/UNDP/World bank/ WHO Special Programme for Research and Training in Tropical Diseases (TDR)
November 2009
Member of the Disease Reference Group on Zoonoses and Marginalized Infectious Diseases of Poverty
Member of Reference Group
Joint International Tropical Medicine
December 2009
Member of the Scientific Program Committee
Member of the Scientific Committee
Regional Network for Asian Schistosomiasis and Other Helminth Zoonoses (RNAS+)
November 2009
Elected as Board Member
Board Membership
International Association of Hydatidology
December 2009
Awarded Cerificate of Merit
Excellence in hydatid research
American Society of Tropical Medicine and Hygiene
May 2010
Conferred with honorary membership
Assoc Prof Colleen Olive
DEEDI
May 2010
Queensland International Fellowship
Dr Nirmala Pandeya
National Health and Medical Research Council
January, 2010
Post doctoral fellowship
Research excellence
Dr Alberto Pinzon-Charry
The Australian Institute of Policy and Science
November 2009
2009 Queensland Young Tall Poppy Science Award
For excellence in research and public engagement
Dr Celestine Rickman
RBWH Research Foundation
October 2009
Royal Brisbane and Women’s Hospital Research Foundation Basic Sciences Prize, $1000.
RBWH Research Week
Dr Richard Ruddell
Australian Liver Foundation
January 2010
Career Development Research Fellowship
3yr Fellowship
Dr Tina Skinner-Adams
CASS Foundation
Oct 2009
Travel Award
Travel USA
Dr Brett Stringer
2nd Eph/Ephrins and Cancer Meeting
June 2010
Travel Award
Outstanding Abstract Prize
Dr Patricia Valery
Australian Society for Medical Research
January 2009
Queensland Premier’s Award for Health and Medical Research (Senior Researcher category) – selected as a finalist
Presentation on education intervention for childhood asthma
Prof Peter Visscher
Australian Academy of Science
March 2010
Fellow
Dr Logan Walker
Genesis Oncology Trust, NZ
December 2009
John Gavin Postdoctoral Research Fellowship
Competitive post-doctoral fellowship application
Assoc Prof David Whiteman
Australian Research Council
September 2009
Future Fellowship
Research excellence
Dr Michelle Wykes
Queensland State Government
February 2010
Smart Futures Fellowship
Dr Zhen Zhen Zhao
Cancer Council Queensland
June 2009
Travel Award
BIT’s 2nd Annual World Cancer Congress
GRANTS AND FUNDING Major new Grants Awarded 2009-2010 (over $100,000) SOURCE
CHIEF INVESTIGATORS AND PROJECT TITLE
TERM
PERIOD
TOTAL FUNDING
ALF
ALF - Hospitality Industry Career Development Fellowship
3 yrs
2010 - 2012
$270,000
ARC
RICHARD D: The role of human single-stranded binding protein
4 yrs
2010 - 2013
$686,400
ARC
NYHOLT D: Elucidating the molecular mechanisms underlying migraine
4 yrs
2010 - 2013
$686,400
ARC
WRAY N: Dissecting the shared genetic architecture of psychiatric &
4 yrs
2010 - 2013
$686,400
ARC
LI Y:Development of new interventions and treatment
4 yrs
2010 - 2013
$686,400
ARC
WHITEMAN D: Studies in Cancer Control
4 yrs
2010 - 2013
$891,200
ARC
ANDREWS K: New Drugs for Malaria that Target Histone Deacetylases (Adminsitered by Griffith University)
4 yrs
2010 - 2013
$154,000
ARC
GORDON L: Work Life after a diagnosis of breast, prostate and colorectal cancer (Administered by Griffith University)
3 yrs
2010 - 2012
$240,000
ARC
KHANNA K: Functional characterization of SSB2: a novel single stranded DNA binding protein (Administered by Griffith University)
3 yrs
2010 - 2012
$310,000
ARC
LAVIN M et al: To investigate the role of the protein kinase SMG-1 in the stress response (Administered by University of Queensland)
3 yrs
2010 - 2012
$285,000
ARC
LAVIN M: Characterisation of the novel mitochondrial protein (CABC1/ADCK3) (Administered by University of Queensland)
3 yrs
2010 - 2012
$300,000
ARC
MARTIN N: Identifying genes for cognition (Administered by University of Queensland)
3 yrs
2010 - 2012
$328,000
CCQ
SCHMIDT C: Analysis of the ant-tumour immune response and its target antigens
2 yrs
2010 - 2011
$192,500
CCQ
BOYLE G: Functional interplay between hSSBI and the NRM Complex
2 yrs
2010 - 2011
$100,000
CCQ
MacDONALD K: Analysis of a novel regulatory T cell induced by allore activity
2 yrs
2010 - 2011
$200,000
CCQ
RICHARD D: Functional interplay between hSSBI and the NRM Complex
2 yrs
2010 - 2011
$200,000
DEEDI
KHANNA R: Australia - US Vaccine Alliance
4 yrs
2009 - 2012
$1,272,000
GOT
WALKER L: The role of germline DNA copy number variation in familial breast cancer risk
2 yrs
2010 - 2011
NZ$140,000
LFA
CHARMSAZ S: EphA proteins may be therapy targets for Leukaemia
3 yrs
2010 - 2012
$120,000
LRC
SUBRAMANIAM N: Study of alcohol and iron interactions, non HFE haemochromatosis and hepatic fibrosis (Administered by University of Queensland)
3 yrs
2010 - 2012
$202,592
NBCF
CHEVENIX-TRENCH G:Towards targeted treatments for advanced basal breast cancer
2 yrs
2010 - 2011
$199,996
NHF
BATZLOFF M et al: Protection mediated by a vaccine candidate for rheumatic heart disease
2 yrs
2010 - 2011
$129,000
NHMRC
MOUNSEY K: Molecular mechanisms of ivermectin resistance in the ectopar
2 yrs
2010 - 2011
$142,500
NHMRC
Practioner Fellowship (Administered by University of Tasmania)
5 yrs
2010 - 2014
$271,133
NHMRC
MACGREGOR S: Statistical Methods for Gene Mapping
4 yrs
2010 - 2013
$417,000
NHMRC
McMANUS D: Impact of the Three Gorges Dam on transmission and future control of human schistosomiasis in China
5 yrs
2010 - 2014
$1,347,500
NHMRC
GARDINER D et al: Trafficking of the major virulence protein tp the host cell surface in malaria parasite infceted erythrocytes (administered by LaTrobe University)
3 yrs
2010 - 2012
$188,500
NHMRC
FISCHER K: Functional Analysis of Novel Scabies Mite Serpins
3 yrs
2010 - 2012
$321,518
NHMRC
HAYWARD N: Ongogenic fusions in melanoma
3 yrs
2010 - 2012
$417,375
NHMRC
ANDERSON G et al: Assessment of oxidant stress and mitochondrial dysfunction in younf adults with iron loading diseases
3 yrs
2010 - 2012
$580,500
NHMRC
ANDERSON G et al: Red cell disorders and the regulation of iron homeostasis
3 yrs
2010 - 2012
$583500
NHMRC
FERREIRA M et al: Finding the genetic causes of asthma: the Australian Asthma Genetics Consortium
3 yrs
2010 - 2012
$1,659,013
NHMRC
VISSCHER P et al: Explaining the Dark Matter of Genome-wide Association Studies for Complex Disease
2 yrs
2010 - 2011
$264,750
NHMRC
MULVENNA J: Unravelling the tetraspanin web in the schistosome tegument
3 yrs
2010 - 2012
$288,750
NHMRC
GATTON M et al: Development & application of theoretical models of Plasmodium transmission to guide Malaria elimination
3 yrs
2010 - 2012
$304,125
NHMRC
CHEVENIX-TRENCH G et al: Identification of the gene for a novel syndrome of gastric adenocarcinoma and promal polyposis of the stomach
3 yrs
2010 - 2012
$364,875
91
GRANTS AND FUNDING CONTINUED SOURCE
CHIEF INVESTIGATORS AND PROJECT TITLE
TERM
PERIOD
TOTAL FUNDING
NHMRC
BURROWS S et al: Investigations into the biology and functionality of the T Cell Receptor
3 yrs
2010 - 2012
$409,125
NHMRC
NEALE R et al: Does vitamin D supplementation reduce mortality for for older Adults - a pilot trial
3 yrs
2010 - 2012
$427,700
NHMRC
MONTGOMERY G et al: Defining the mechanism of melanoma & naevus risk on Chromosome 9p21
3 yrs
2010 - 2012
$505,300
NHMRC
SUBRAMANIAM N et al: Examining the relationship between MATRIPTASE-2 & HEMOJUVELIN, two essentials regulators of iron homeostasis
3 yrs
2010 - 2012
$514,500
NHMRC
ENGWERDA C et al: Tissue specific antigen presenting cell functions during infection
3 yrs
2010 - 2012
$535,500
NHMRC
SUHRBIER A: The role of macrophage SerpinB2 in inflammation
3 yrs
2010 - 2012
$563,500
NHMRC
HAQUE A: IL-2/anti-IL-2 complexes in immunity to blood stage malaria infection and prevention of cerebral immunopathology
3 yrs
2010 - 2012
$565,500
NHMRC
OLIVE C et al: A dual antigen sythentic peptide subunit vaccine approach to prevent streptococcal associated cardiovascular disease
3 yrs
2010 - 2012
$582,450
NHMRC
NEALE R et al: Patterns of care and quality of life in patients with pancreatic cancer
3 yrs
2010 - 2012
$655,213
NHMRC
SUHRBIER A: Inhibition of interferon-alpha/beta by chikungunya virus and the induction of arthritis
3 yrs
2010 - 2012
$683,875
NHMRC
WRAY N et al: Towards an etiological understanding of the comorbidity of psychotic disorders
3 yrs
2010 - 2012
$845,938
NHMRC
NYHOLT D: Elucidating the molecular mechanisms underlying migraine and endometriosis via genetic dissection
5 yrs
2010 - 2014
$618,750
NHMRC
WRAY N: Dissecting the shared genetic architecture of psychiatric & psychological traits with application to prediction of genetic risk
5 yrs
2010 - 2014
$560,000
NHMRC
MONTGOMERY G: Identification of rare autosomal copy number variant (CNV) events from SNP and CNV probes
5 yrs
2010 - 2014
$677,500
NHMRC
KHANNA K: Functional analysis of hSSB1 and hSSB2, two newly discovered singlestranded DNA binding proteins
5 yrs
2010 - 2014
$766,250
NHMRC
VISSCHER P: Quantify and partition the contribution of common variants, rare variants and CNV to genetic risk of disease susceptibility
5 yrs
2010 - 2014
$766,250
NHMRC
HILL G: Immunological therapies for cancer,chronic infection & autoimmunity (Administered by University of Queensland)
5 yrs
2010 - 2014
$2,026,000
NHMRC
LAVIN M et al: Rad50 protects the integrity of the genome to minimise disease risk (Administered by University of Queensland)
3 yrs
2010 - 2012
$505,500
NHMRC
LAVIN M: Role of Senataxin in protecting against neurodegeneration (Administered by University of Queensland)
3 yrs
2010 - 2012
$520,500
NIAID
DOOLAN D: Proteome-wide cellular immunity approach to P. falciparum
4 yrs
2009 - 2013
US$2,479,629
NIH-WU
MARTIN N et al: Genetic Epidemiology of Acoholism AND Comorbidity - Project 7
5 yrs
2009 - 2014
US$1,264,016
NIH-WU
RAMM G et al: Continuation, Expansion & merging of the Biliary Atresia Research Consortium
5 yrs
2009 - 2014
US$162,000
RISS
SCHMIDT C: Dendritic Cell Immunotherapy for Glioblastoma
1 yrs
2009 - 2010
$100,000
TGEN
HAYWARD N: Identification of novel melanoma risk genes using high throughput genomics
1 yrs
2009 - 2010
$293,020
UNI MELB
YOUNG J: UniMelb Colobrative Research - Colorectal Cancer
2 yrs
2009 - 2011
$146,000
LEGEND FOR SOURCE OF FUNDS ALF
92
Australian Leukaemia Foundation
NHF
National Heart Foundation
ARC
Australian Research Council
NHMRC
National Health and Medical Research Council
CCQ
Cancer Council Queensland
NIAID
National Institute of Allergy and Infectious Disease
DEEDI
Dept of Employment, Economic Development & Innovation
NIH-WU
National Institutes of Health
GOT
Genesis Oncology Trust
RISS
NCRIS - Research Infrastructure Support Services Limited
LFA
Leukaemia Foundation Australia
TGEN
Translational Genomics Research Institute
LRC
Leukaemia Research Centre
Uni Melb
University of Melbourne
NBCF
National Breast Cancer Foundation
QIMR Annual Report 2009/10
QIMR PATENTS TITLE
INVENTOR(S)
APPLICATION NUMBER
Patent Families Managed By QIMR Novel molecules
Toni Antalis; John Hooper
PCT/AU1998/000085
Immunogenic agent and pharmaceutical composition for use against
Michael Good; Mary Stevenson
PCT/AU2004/000870
G-CSF derivative for inducing immunological tolerance
Geoff Hill; Kellie MacDonald; Edward Morris
PCT/AU2004/001116
Polytope vaccines
Andreas Suhrbier; Scott Thomson;
PCT/AU1995/000461
homologous and heterologous pathogens
Rajiv Khanna; Scott Burrows; Barbara Coupar; Denis Moss Synthetic peptides and vaccines comprising the same
Juan Cooper; Wendy Relf; Michael Good; Allan Saul
PCT/AU1995/000681
Cytotoxic T-cell epitopes
Denis Moss; Scott Burrows; Rajiv Khanna;
PCT/AU1995/000140
Beverley Kerr; Jacqueline Burrows; Andreas Suhrbier EBV CTL epitopes
Rajiv Khanna; Beverley Kerr; Ihor Misko;
PCT/AU1997/000328
Denis Moss; Scott Burrows CTL epitopes from EBV
Martina Sherritt; Scott Burrows; Rajiv Khanna
PCT/AU1998/000531
EBV peptide epitopes, polyepitopes and delivery system therefor
Rajiv Khanna; Jaikumar Duraiswamy
PCT/AU2003/001451
Novel hCMV cytotoxic T cell epitopes, polyepitopes, composition comprising
Rajiv Khanna; Rebecca Elkington; Susan Walker
PCT/AU2002/000829
same and diagnostic and prophylactic and therapeutics uses therefor Human cytomegalovirus immunotherapy
Rajiv Khanna
PCT/AU2005/001798
Peptide compounds
Istvan Toth; William Gibbons
PCT/GB1993/001558
Novel human ssDNA binding proteins and methods of cancer diagnosis
Kum Kum Khanna; Derek Richard;
PCT/AU2008/000181
Malcolm White Therapeutic antibodies, antibody fragments and antibody conjugates
Michael Good; Michael Batzloff;
US 11/950,217
Manisha Pandey Synthetic chimeric peptides
Katin Nordstrom; Michael Good;
US12/333,222
Michael Batzloff Cancer drug targets and methods of diagnosis
Andrew Boyd; Bryan Day; Brett Stringer
Human cytomegalovirus immunotherapy
Rajiv Khanna
PCT/AU2009/000672 61/347,352
QIMR Patent Families Managed Outside QIMR Materials and methods relating to stem cell mobilization by multi-pegylated
Geoff Hill
PCT/US2009/062471
Detection of genes
Catherine Hyland
PCT/AU1994/000506
Receptor ligand system and assay
Andrew Boyd
US 1998/104340
Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis
Andrew Boyd
PCT/AU2004/000142
A method of treatment
Andrew Boyd
PCT/AU1999/000931
Differentiation modulating agents and uses therefore
Johannes Prins
PCT/AU2005/000008
Treatment for EBV associated disease
Denis Moss
PCT/AU2006/001854
granulocyte colony stimulating factor
Vaccine
Michael Batzloff
Melanoma-associated MHC Class 1 Associated oligopeptide and its use
Chris Schmidt
PCT/EP2006/008533
US 2003/706275
Method for screening for anticancer agents
Kum Kum Khanna
PCT/GB2008/003390
A novel growth factor and a genetic sequence encoding same
Nicholas Hayward
PCT/AU1996/000094
Patent Families Resulting from Industry Sponsored Contract Research Performed at QIMR Treatment of virally induced lesions
Andreas Suhrbier
PCT/AU2008/000596
Use of angeloyl-substituted ingenones in combination with other agents to
Andreas Suhrbier; Peter Parsons
PCT/AU2006/001700
Treatment of solid tumours
Andreas Suhrbier
PCT/AU2005/001827
Chaperonin 10 modulators of toll-like receptors inducible cytokine and
Andreas Suhrbier
PCT/AU2005/000041
treat cancer
cytokine secretion Treatment of prostate cancer
Peter Parsons
PCT/AU2001/000966
Therapeutic agents I
Andreas Suhrbier; Peter Parsons
PCT/AU2001/000679
Therapeutic agents II
Andreas Suhrbier; Peter Parsons
PCT/AU2001/000680
Therapeutic agents III
Andreas Suhrbier; Peter Parsons
PCT/AU2001/000678
93
QIMR PATENTS
CONTINUED
TITLE
INVENTOR(S)
APPLICATION NUMBER
Patents Families Managed by QIMR as Trustee for the CRC-Vaccine Technology T helper epitopes
David Jackson
PCT/AU2000/000070
Novel immunogenic lipopeptides comprising T-helper and cytotoxic T
David Jackson
PCT/AU2003/001019
David Jackson
PCT/AU2003/001018
lymphocyte (CTL) epitope Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes Truncated LHRH formulations
David Jackson
PCT/AU2005/001383
Immunogenic molecules
David Jackson
PCT/AU2006/000162
MARK
STATUS
AUSTRALIAN TRADE
Queensland Institute of Medical Research
Registered/Protected
Trade Marks Managed by QIMR
MARK NUMBER 1233303
QIMR
Registered/Protected
1233307
Hexagons device
Registered/Protected
1233317
Dividends Defeating Disease
Registered/Protected
1116557
OFFICIAL COMMITTEES 2009-2010 QIMR COUNCIL ProfessorJohn Hay (Chair from 24/09/09) Mr Christopher Coyne (Acting Chair to 23/09/09) Professor Emeritus Bryan Campbell Professor Judith Clements Mr Paul Fennelly Professor Lyn Griffiths Assoc Professor Paula Marlton Dr Jeannette Young COMMITTEES REPORTING TO COUNCIL Finance and Audit Committee Mr Paul Fennelly (Chair) Professor Emeritus Bryan Campbell Mr Rod Wylie Professor John Hay (From 24/09/09) Appointments and Promotions Committee
Animal Ethics Committee (AEC)
Dr Andrew Redmond
Scientific Sub-Committee (AEC)
Dr Tom Sculley
Human Research Ethics Committee (HREC)
Professor Julie Campbell Professor Lyn Griffiths Professor James McCluskey Dr Jurgen Michaelis Professor Joe Trapani Professor Michael Good (ex officio) (To 30/06/10)
Professor Kadaba Sriprakash Dr Brett Stringer
Dr Ian Wilkey (Chair)
Dr Marion Woods
Dr Roger Allison
Mrs Rebecca Lacey – Secretary (To 25/06/10)
Ms Madeline Brennan
Mr Angus Edmonds Ms Clare Endicott (To 01/11/09)
Dr Peter Roeser (Chair)
Mr Colin Forrest (From 15/06/10)
Dr Graham Radford-Smith (Deputy Chair) (To 30/06/10)
Mrs Mary Mackenzie Mr David Russell Dr Christopher Schmidt Dr Katharine Trenholme Dr Tom Sculley
Dr Geoff Beadle Professor Andrew Boyd Dr Suzanne Elliott Mr Paul Fahey (To 26/03/10)
QIMR Annual Report 2009/10
Professor John Hay (Chair) (From 24/09/09) Mr Chris Coyne (Chair) (To 24/09/09) Mr Rod Wylie Mr John Parnell
Ms Rosemary Hood Dr Rick Andrew Ms Karen Thompson Ms Donna Hancock Ms Beatrix Wanrooy - Secretariat COMMITTEES REPORTING TO THE DIRECTOR
Professor James McCarthy
Senior Executive Team (To 30/06/10)
Dr Agnieszka Mitchell
Professor Michael Good (Chair)
Dr Agnieszka Mitchell (ex officio)
Dr Michael Moore
Professor Adèle Green
Ms Rebecca Lacey – Secretary (To 25/06/10)
Professor Denis Moss
Professor Andrew Boyd
Dr Lesley Ross-Lee
Ms Donna Hancock
Dr Christopher Schmidt
Professor Brian Kay
Dr Joanna Youngson
Professor Martin Lavin
Mrs Rebecca Lacey – Secretary (To 25/06/10)
Dr Agnieszka Mitchell (01/02/10 to 31/03/10)
Council Personnel Administration Committee
Professor Emma Whitelaw
Dr Julie-Anne Tarr (ex officio) (To 18/12/09)
Scientific Sub-Committee (HREC) Dr Katharine Trenholme (Chair) Dr Ian Wilkey (Deputy Chair) Mr Paul Fahey (To 25/03/10) Assoc Professor Gail Garvey Dr Helen Leonard Dr Agnieszka Mitchell
Mr Paul Fennelly (Chair) Mr Chris Coyne Ms Patricia McCormack Mr Rod Wylie
94
The Smart State Medical Research Steering Committee
Mr Alan Stockman Clinical Trial Protocol Committee (CTPC)
Mrs Gwen Eardley
Professor Judith Clements (Chair) Professor Graham Brown
Dr Christopher Schmidt
Assoc Professor David Whiteman (01/02/10 to 30/06/10) Dr Julie-Anne Tarr (To 18/12/09) Ms Nerida Fox – Secretary
Safety Committee
Professor Grant Montgomery
Seminars Committee
Dr Joanna Youngson
Dr Helen Leonard (Chair)
Ms Michelle Neller
Professor Martin Lavin (Chair)
Ms Mandie Quince – Secretary
Dr Glen Boyle (Deputy Chair)
Dr Chris Peatey
IT Committee
Dr Michael Batzloff
Dr Peter Ryan
Professor Michael Good (To 30/06/10)
Dr Anita Burgess (From 20/05/10)
Dr Kevin Spring
Professor Geoff Hill
Mr Ron Buttenshaw
Professor Grant Montgomery
Mr Paul Collins
Dr Katherine Trenholme (To 10/12/09)
Dr Juan Cooper (To 21/01/10)
Dr Patricia Valery
Ms Jann O’Keefe (To 11/12/09)
Ms Gwen Cuthbert
Dr Margie Wright
Mr Macky Edmundson (From 15/04/10)
Ms Nicci Wayte (To 01/05/10)
Ms Deborah Bishop (From 18/01/10)
Dr Geoff Gobert
Dr Andrea Whittaker (From 30/06/10)
Mr Andrew King
Dr Terry Walsh
Professor Emma Whitelaw
Consumer and Community Participation Committee Professor Adèle Green (Chair)
Dr Dale Nyholt (Chair) Mr Harry Beeby Dr Glen Boyle Assoc Professor Scott Burrows Dr Juan Cooper (To 21/01/10) Mr Michael Creevey (From 13/11/09) Mr Mark Feodoroff (To 01/04/10) Ms Michelle Gatton Ms Donna Hancock
Professor Gail Williams (To 01/05/10)
Ms Deborah Bishop
Ms Michelle Richards
Joint Consultative Committee
Mr Ken Dutton-Regester
Dr Christine Rzepczyk
Mr Trevor Greenaway (Chair)
Assoc Professor Gail Garvey
Mr Alan Stockman
Ms Pauline Buratowski (To 30/06/10)
Ms Sara-Jane Georgeson
Assoc Professor Nathan Subramaniam
Ms Melina Georgousakis (To 19/01/10)
Professor Peter Upcroft
Dr Anita Burgess (From 20/05/10)
Dr Julie-Anne Tarr (To 18/12/09)
Mr Paul Collins (To 20/05/10)
Ms Imogen Gillions
Mr Christopher Ward (To 24/12/09)
Ms Donna Hancock (From 14/04/10)
Professor Michael Good (To 30/06/10)
Ms Vivienne Johnson
Ms Jann O’Keefe (To 11/12/09)
Professor Peter Upcroft
Dr David McMillan
Dr Arne Mould
Ms Jo Chow – Secretary (To 12/03/10)
Dr Penny Webb
Dr Amanda Spurdle
Professor Emma Whitelaw
Ms Jann O’Keefe (To 11/12/09)
Ms Jaclyn Hawdon – Secretary (From 11/02/10)
Dr Julie-Anne Tarr (To 18/12/09)
Ms Natasha Stevens
QPSU Representative
Ms Sarah Tennant
QNU Representative
Dr Vicki Whitehall
Dr Agnieszka Mitchell Professor Denis Moss
Dr Joanna Youngson (To 08/03/10)
Equipment Committee Professor Andrew Boyd (Chair) Professor Greg Anderson
Medical Advisory Board
Dr Juan Cooper (To 21/01/10)
Professor Andrew Boyd (Deputy Chair)
Mr Michael Creevey (from 12/11/09)
Dr Paul Bartley
Mr Macky Edmundson (from 21/01/10)
Dr Ian Bunce
Professor James McCarthy Mr Chris Ward (To 24/12/09)
Dr Geoff Beadle
Dr Don Cameron Professor Adèle Green
Ms Simone Cross
Ms Heather Matthews Dr Agnieszka Mitchell Mr Mark Spanevello
Professor Denis Moss
COMMITTEES REPORTING TO SET Strategic Science Committee (To 30/06/10) Professor Martin Lavin (Chair) Professor Greg Anderson Assoc ProfessorGail Garvey
Records and Information Committee ProfessorMartin Lavin (Chair) Dr Suyinn Chong Dr Deepak Darshan Dr Katja Fischer Mr Owen Griffiths Mr Simon Jaremczuk Mr Jason Jeffery (To 15/01/10) Ms Nelly Kremko Dr Rachel Neale Dr Wayne Schroeder Dr Daniel Wallace Dr Michelle Wykes
Professor Michael Good
QIMR TRUST
Professor Adele Green
Ms Jane Seawright (Acting Chair)
Professor Barbara Leggett
Professor Geoff Hill
Higher Degrees Committee
Dr Joseph McCormack
Professor James McCarthy
ProfessorJohn Hay (From 24/09/09)
Assoc Professor Nathan Subramaniam (Chair) (To January 2010)
Dr Paul Sandstrom
Professor Emma Whitelaw
Ms Patricia McCormack
Dr Mark Smithers
Ms Mandie Quince – Secretary
Mr David Stirling
Dr Emma Whitelaw Mrs Joanna Youngson
Professor Michael Good (To 30/06/10)
Dr John Varghese
Dr Penny Webb (Chair from August 2010)
Dr Michael O’Rourke
Dr Glen Boyle (From 10/08/09)
Mentoring Committee
Ms Simone Cross
Assoc Professor David Whiteman (Chair)
Professor Joy Cumming
Professor Georgia Chenevix-Trench
Professor Denise Doolan (From 10/08/09) Professor Michael Good (To 30/06/10)
Assoc Professor Alan Lawson Dr Kelli MacDonald Dr David McMillan (From 10/08/09)
Professor Andrew Boyd (Chair)
Mr Rod Wylie COMMITTEES REPORTING TO TRUST/COUNCIL
Assoc ProfessorGail Garvey Professor Michael Good Professor Adele Green
Investment Committee Mr Rod Wylie (Chair) Mr Bruce Phillips
Professor Nick Hayward
Professor Geoff Hill
Assoc Professor Rajiv Khanna
Dr Corinne Lendon (To 18/01/10)
Professor Emma Whitelaw
Dr Alex Loukas (To 31/12/09)
Marketing Committee
Dr Agnieszka Mitchell
Ms Patricia McCormack
Professor Denis Moss
Ms Jane Seawright
Dr Judith Greer Dr Sergei Kozlov
Clinical and Translational Committee (To 30/06/10)
Scientific Advisory Board Professor Graham Brown (Chair) Professor Dallas English Professor Douglas Hilton
Mr David Stirling
Dr Grant Ramm Dr Chris Schmidt Assoc Professor Nathan Subramaniam
ProfessorJoe Trapani
95
2009-2010 SCIENTIFIC PUBLICATIONS Agrawal A, Lynskey MT, Bucholz KK, Madden PAF, Martin NG, Heath AC. Using twin data to address the relationship between early cannabis use and elevated mood (mania). Behavior Genetics 39(6):632-633. 2009 Agrawal A, Sartor CE, Lynskey MT, Grant JD, Pergadia ML, Grucza R, Bucholz KK, Nelson EC, Madden PAF, Martin NG, Heath AC. Evidence for an Interaction Between Age at First Drink and Genetic Influences on DSM-IV Alcohol Dependence Symptoms. Alcoholism-Clinical and Experimental Research. 33(12):2047 -2056. 2009 Ahlbom A, Feychting M, Green A, Kheifets L, Savitz D, Swerdlow A. Mobile Phone Use and Brain Tumors - A Review of the Epidemiological Evidence. Epidemilogy. 20(6):S241-S241, Suppl. S. 2009 Ainger SA, Wong SS, Roberts DW, Leonard JH, Sturm RA. The role of MC1R in melanogenesis of melanocytic cells in co-culture with keratinocytes. Journal of Investigative Dermatology. 129(12):2920-2920. 2009 Anderson GJ, Vulpe CD. Mammalian iron transport. Cellular and Molecular Life Sciences 66(20):3214-61. 2009 Anderson GJ. Things that go BMP in the liver: bone morphogenetic protein 6 and the control of body iron homeostasis. Hepatology. 50(1):3169. 2009 Anderson S, Panizza B. Are cell salvage and autologous blood transfusion safe in endonasal surgery? Otolaryngology - Head and Neck Surgery. 142(3 Suppl 1):S3-6. Review. 2010 Andrews DM, Estcourt MJ, Andoniou CE, Wikstrom ME, Khong A, Voigt V, Fleming P, Tabarias H, Hill GR, van der Most RG, Scalzo AA, Smyth MJ, Degli-Esposti MA. Innate immunity defines the capacity of antiviral T cells to limit persistent infection. Journal of Experimental Medicine. 207(6):1333-1343. 2010 Andrews KT, Tran T, Bozdech Z, Skinner-Adams T, Lucke A, Boyle G, Fairlie D. Pharmacodynamics of Hydroxamate-based HDAC Inhibitors in Plasmodium Falciparum. American Journal of Tropical Medicine and Hygiene. 81(5):158 Suppl. S. 2009 Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T, Simard J, Spurdle AB, Beesley J, Chen X; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Neuhausen SL, Ding YC, Couch FJ, WangX, Fredericksen Z, Peterlongo P, Peissel B, Bonanni B,
96
QIMR Annual Report 2009/10
Viel A, Bernard L, Radice P, Szabo CI, Foretova L, Zikan M, Claes K, Greene MH, Mai PL, Rennert G, Lejbkowicz F, Andrulis IL, Ozcelik H, Glendon G; OCGN, Gerdes AM, Thomassen M, Sunde L, Caligo MA, Laitman Y, Kontorovich T, Cohen S, Kaufman B, Dagan E, Baruch RG, Friedman E, Harbst K, BarbanyBustinza G, Rantala J, Ehrencrona H, Karlsson P, Domchek SM, Nathanson KL, Osorio A, Blanco I, Lasa A, Benítez J, Hamann U, Hogervorst FB, Rookus MA, Collee JM, Devilee P, Ligtenberg MJ, van der Luijt RB, Aalfs CM, Waisfisz Q, Wijnen J, van Roozendaal CE; HEBON, Peock S, Cook M, Frost D, Oliver C, Platte R, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Chu C, Eccles D, Cole T, Hodgson S; EMBRACE, Godwin AK, Stoppa-Lyonnet D, Buecher B, Léoné M, Bressac-de Paillerets B, Remenieras A, Caron O, Lenoir GM, Sevenet N, Longy M, Ferrer SF, Prieur F; GEMO, Goldgar D, Miron A, John EM, Buys SS, Daly MB, Hopper JL, Terry MB, Yassin Y; Breast Cancer Family Registry, Singer C, Gschwantler-Kaulich D, Staudigl C, Hansen TO, Barkardottir RB, Kirchhoff T, Pal P, Kosarin K, Offit K, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov EN, Allavena A, Schmutzler RK, Versmold B, Engel C, Meindl A, Ditsch N, Arnold N, Niederacher D, Deissler H, Fiebig B, Suttner C, Schönbuchner I, Gadzicki D, Caldes T, de la Hoya M, Pooley KA, Easton DF, Chenevix-Trench G; CIMBA. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genecist. 18(22):4442-56. 2009
Arnold JM, Choong DY, Thompson ER; kConFab, Waddell N, Lindeman GJ, Visvader JE, Campbell IG, Chenevix-Trench G. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors. Breast Cancer Research & Treatment. 119(2):491-6. 2010
Antonsson A, Green AC, Mallitt KA, O'Rourke PK, Pawlita M, Waterboer T, Neale RE. Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. Journal of General Virology. 91 (Pt 7):1849-53. 2010
Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB, Vriends AH; Dutch Lynch Syndrome Study Group, Cartwright NR, Barnetson RA, Farrington SM, Tenesa A, Hampel H, Buchanan D, Arnold S, Young J, Walsh MD, Jass J, Macrae F, Antill Y, Winship IM, Giles GG, Goldblatt J, Parry S, Suthers G, Leggett B, Butz M, Aronson M, Poynter JN, Baron JA, Le Marchand L, Haile R, Gallinger S, Hopper JL, Potter J, de la Chapelle A, Vasen HF, Dunlop MG, Thibodeau SN, Jenkins MA.Risks of Lynch syndrome cancers for MSH6 mutation carriers. Journal National Cancer Institute 102(3):193201. 2010
Apte SH, Groves P, Olver S, Baz A, Doolan DL, Kelso A, Kienzle N. IFN-gamma inhibits IL-4-induced type 2 cytokine expression by CD8 T cells in vivo and modulates the anti-tumor response. Journal of Immunology. 185(2):998-1004. 2010 Arden KE, Faux CE, O'Neill NT, McErlean P, Nitsche A, Lambert SB, Nissen MD, Sloots TP, Mackay IM. Molecular characterization and distinguishing features of a novel human rhinovirus (HRV) C, HRVCQCE, detected in children with fever, cough and wheeze during 2003. Journal of Clinical Virology. 47(3):21923. 2010
Azzato EM, Tyrer J, Fasching PA, Beckmann MW, Ekici AB, Schulz-Wendtland R, Bojesen SE, Nordestgaard BG, Flyger, H; Milne, RL; Arias, JI; Menendez, P; Benitez, J; Chang-Claude, J; Hein, R; Wang-Gohrke, S; Nevanlinna, H; Heikkinen, T; Aittomaki, K; Blomqvist, C; Margolin, S; Mannermaa, A; Kosma, VM; Kataja, V; Beesley, J; Chen, XQ; ChenevixTrench, G; Couch, FJ; Olson, JE; Fredericksen, ZS; Wang, XS; Giles, GG; Severi, G; Baglietto, L; Southey, MC; Devilee, P; Tollenaar, RAEM; Seynaeve, C; GarciaClosas, M; Lissowska, J; Sherman, ME; Bolton, KL; Hall, P; Czene, K; Cox, A; Brock, IW; Elliott, GC; Reed, MWR; Greenberg, D; AntonCulver, H; Ziogas, A; Humphreys, M; Easton, DF; Caporaso, NE; Pharoah, PDP. Kathleen Cuningham Fdn Consortium. Association Between a Germline OCA2 Polymorphism at Chromosome 15q13.1 and Estrogen ReceptorNegative Breast Cancer Survival. Journal of the National Cancer Institute 102(9):650-662. 2010 Baade PD, Youlden DR, Valery PC, Hassall T, Ward L, Green AC, Aitken JF. Trends in incidence of childhood cancer in Australia, 1983-2006. British Journal of Cancer. 102(3): 620-626. 2010.
Batra Jyotsna, Tan Olivia L, O’Mara Tracy, Zammit Rebecca, Nagle Christina M, Clements Judith A, Kedda, Mary-Anne, Spurdle Amanda B. Kallikrein-related peptidase 10 (KLK10) expression and
single nucleotide polymorphisms in ovarian cancer survival. International Journal of Gynecological Cancer. 20(4):529-536. 2010 Bonthuis M, Hughes MC, Ibiebele TI, Green AC, van der Pols JC. Dairy consumption and patterns of mortality of Australian adults. European Journal of Clinical Nutrition. 64(6):569-77. 2010 Becherel OJ, Jakob B, Cherry AL, Gueven N, Fusser M, Kijas AW, Peng C, Katyal S, McKinnon PJ, Chen J, Epe B, Smerdon SJ, Taucher-Scholz G, Lavin MF. CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response. Nucleic Acids Research. 38(5):1489503. 2010. Beckham SA, Boyd SE, Reynolds S, Willis C, Johnstone M, Mika A, Simerská P, Wijeyewickrema LC, Smith AI, Kemp DJ, Pike RN, Fischer K. Characterization of a serine protease homologous to house dust mite group 3 allergens from the scabies mite Sarcoptes scabiei. Journal of Biological Chemistry. 4;284(49):34413-22. 2009 Beesley VL, Janda M, Eakin EG, Auster JF, Chambers SK, Aitken JF, Dunn J, Battistutta D. Gynecological cancer survivors and community support services: referral, awareness, utilization and satisfaction. Psychooncology 19(1):54-61. 2010 Beesley VL, Clavarino AM, Webb PM, Wyld DK, Francesconi AB, Horwood KR, Doecke JD, Loos CA, Green AC. Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients. Support Care Cancer. (Epub ahead of print) 2009 Bellingham M, Fowler PA, Amezaga MR, Whitelaw CM, Rhind SM, Cotinot C, MandonPepin B, Sharpe RM, Evans NP. Foetal Hypothalamic and Pituitary Expression of GonadotrophinReleasing Hormone and Galanin Systems is Disturbed by Exposure to Sewage Sludge Chemicals via Maternal Ingestion. Journal of Neuroendocrinology. 22 (6): 527-533. 2010 Benyamin B, Ferreira MA, Willemsen G, Gordon S, Middelberg RP, McEvoy BP, Hottenga JJ, Henders AK, Campbell MJ, Wallace L, Frazer IH, Heath AC, de Geus EJ, Nyholt DR, Visscher PM, Penninx BW, Boomsma DI, Martin NG, Montgomery GW, Whitfield JB. Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nature Genetics. 41(11):1173-5 2009
2009–2010 SCIENTIFIC PUBLICATIONS CONTINUED Brennan RM, Burrows JM, Bell MJ, Bromham L, Csurhes PA, Lenarczyk A, Sverndal J, Klintenstedt J, Pender MP, Burrows SR. Strains of Epstein-Barr virus infecting multiple sclerosis patients. Multiple Sclerosis. 16(6):643-51. 2010 Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, Corda E, Randerson-Moor J, Aitken JF, Avril MF, Azizi E, Bakker B, Bianchi-Scarra G, Bressac-de Paillerets B, Calista D, CannonAlbright LA, Chin AWT, Debniak T, Galore-Haskel G ,Ghiorzo P, Gut I, Hansson J, Hocevar M, Hoiom V, Hopper JL, Ingvar C, Kanetsky PA, Kefford RF, Landi MT, Lang J, Lubinski J, Mackie R, Malvehy J, Mann GJ, Martin NG, Montgomery GW, van Nieuwpoort FA, Novakovic S, Olsson H, Puig S, Weiss M, van Workum W, Zelenika D, Brown KM, Goldstein AM, Gillanders EM, Boland A, Galan P, Elder DE, Gruis NA, Hayward NK, Lathrop GM, Barrett JH, Bishop JA. Genomewide association study identifies three loci associated with melanoma risk. Nature Genetics 41:920-925. 2009 Birley AJ, James MR, Dickson PA, Montgomery GW, Heath AC, Martin NG, Whitfield JB. ADH single nucleotide polymorphism associations with alcohol metabolism in vivo. Human Molecular Genetics. 18(8):1533-42. 2009 Black M, Trent A, Tirrell M, Olive C. Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists. Expert Review of Vaccines (2): 157173. 2010 Bolderson E, Richard DJ, Zhou BB, Khanna KK. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clinical Cancer Reseach. 15(20):6314-20. 2009 Bolderson E, Tomimatsu N, Richard DJ, Boucher D, Kumar R, Pandita TK, Burma S, Khanna KK. Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks. Nucleic Acids Research. 38(6):1821-31. 2010 Bonthuis M, Hughes MC, Ibiebele TI, Green AC, van der Pols JC. Dairy consumption and patterns of mortality of Australian adults. European Journal of Clinical Nutrition. 64(6):569-77. 2010 Boyle RK, Waters BA, O'Rourke PK. Measures of blood loss and red cell transfusion targets for caesarean delivery complicated by placenta praevia. Australian & New Zealand Journal of Obstetrics & Gynaecology 50(3): 242-245. 2010 Bramhachari PV, Kaul SY, McMillan DJ, Shaila MS, Karmarkar MG, Sriprakash KS. Disease burden due to Streptococcus dysgalactiae subsp equisimilis (group G and C streptococcus) is higher than that due
to Streptococcus pyogenes among Mumbai school children. Journal of Medical Microbiology. 59(2):220-223. 2010 Branstrom R, Chang YM, Kasparian N, Affleck P, Tibben A, Aspinwall LG, Azizi E, Baron-Epel O, Battistuzzi L, Bruno W, Chan M, Cuellar F, Debniak T, Pjanova D, Ertmanski S, Figl A, Gonzalez M, Hayward NK, Hocevar M, Kanetsky PA, Leaf SL, van Nieuwpoort FA, Heisele O, Palmer J, Peric B, Puig S, Ruffin AD, Schadendorf D, Gruis NA, Brandberg Y, Newton-Bishop J. Melanoma risk factors, perceived threat and intentional tanning: an international online survey. European Journal of Cancer Prevention. 19(3):216-226. 2010 Brennan RM, Burrows JM, Bell MJ, Bromham L, Csurhes PA, Lenarczyk A, Sverndal J, Klintenstedt J, Pender MP, Burrows SR. Strains of Epstein-Barr virus infecting multiple sclerosis patients. Multiple Sclerosis. 16(6):643-651. 2010 Brown IS, Whiteman DC, Lauwers GY. Foveolar type dysplasia in Barrett esophagus. Modern Pathology. 23(6):834-843. 2010. Buchanan DD, Sweet K, Drini M, Jenkins MA, Win AK, Gattas M, Walsh MD, Clendenning M, McKeone D, Walters R, Roberts A, Young A, Hampel H, Hopper JL, Goldblatt J, George J, Suthers GK, Phillips K, Young GP, Chow E, Parry S, Woodall S, Tucker K, Muir A, Field M, Greening S, Gallinger S, Green J, Woods MO, Spaetgens R, de la Chapelle A, Macrae F, Walker NI, Jass JR, Young JP. Phenotypic diversity in patients with multiple serrated polyps: a genetics clinic study. International Journal of Colorectal Disease 25 (6): 703-712. 2010 Buchanan DD, Roberts A, Walsh MD, Parry S, Young JP. Lessons from Lynch syndrome: a tumor biology-based approach to familial colorectal cancer. Future Oncology 6 (4): 539-549. 2010 Burke ML, McManus DP, Ramm GA, Duke M, Li Y, Jones MK, Gobert GN. Co-ordinated gene expression in the liver and spleen during Schistosoma japonicum infection regulates cell migration. PLoS Neglected Tropical Diseases. 4(5):e686. 2010 Burke ML, McManus DP, Ramm GA, Duke M, Li Y, Jones MK, Gobert GN. Temporal expression of chemokines dictates the hepatic inflammatory infiltrate in a murine model of schistosomiasis. PLoS Neglected Tropical Diseases. 4(2):e598. 2010 Burger DC, Lawrance IC, Bampton PA, Prosser R, Croft A, Gilshenan K, Radford-Smith GL, Florin TH. Anti-tumour necrosis factor-alpha treatment for perianal Crohn's disease in Australia. Medical Journal of Australia 192(7):375-377. 2010
Burrows SR, Chen Z, Archbold JK, Tynan FE, Beddoe T, KjerNielsen L, Miles JJ, Khanna R, Moss DJ, Liu YC, Gras S, Kostenko L, Brennan RM, Clements CS, Brooks AG, Purcell AW, McCluskey J, Rossjohn J. Hard wiring of T cell receptor specificity for the major histocompatibility complex is underpinned by TCR adaptability. Proceedings of the National Academy of Science USA. 107(23):10608-13 2010 Byrne EM, McRae AF, Duffy DL, Zhao ZZ, Martin NG, Wright MJ, Montgomery GW, Visscher PM. Association study of common mitochondrial variants and cognitive ability. Behaviour Genetics. 39(5):50412. 2009 Byrne EM, McRae AF, Duffy DL, Zhao ZZ, Martin NG, Whitfield JB, Visscher PM, Montgomery GW. Family-based mitochondrial association study of traits related to type 2 diabetes and the metabolic syndrome in adolescents. Diabetologia. 52(11):2359-68. 2009 Chavchich M, Gerena L, Peters J, Chen NH, Cheng Q, Kyle DE. Role of pfmdr1 Amplification and Expression in Induction of Resistance to Artemisinin Derivatives in Plasmodium falciparum. Antimicrobial Agents and Chemotherapy. 54(6):2455-2464. 2010 Chen X, Webb TI, Lynch JW. The M4 transmembrane segment contributes to agonist efficacy differences between alpha1 and alpha3 glycine receptors. Molecular Membrane Biology 26(5):321-32. 2009 Clements ACA, Magalhaes RJS, Tatem AJ, Paterson DL, Riley TV. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infectious Diseases. 10(6):395-404. 2010 Clements ACA, Deville MA, Ndayishimiye O, Brooker S, Fenwick A. Spatial co-distribution of neglected tropical diseases in the East African Great Lakes region: revisiting the justification for integrated control. Tropical Medicine & International Health. 15(2):198-207. 2010 Coventry WL, James MR, Eaves LJ, Gordon SD, Gillespie NA, Ryan L, Heath AC, Montgomery GW, Martin NG, Wray NR. Do 5HTTLPR and stress interact in risk for depression and suicidality? Item response analyses of a large sample. American Journal of Medical Genetics B Neuropsychiatric Genetics. 153B(3):757-65. 2010 Coyne T, Ibiebele TI, Baade PD, McClintock CS, Shaw JE. Metabolic syndrome and serum carotenoids: findings of a cross-sectional study in Queensland, Australia. British Journal of Nutrition. 102(11):1668-77. 2009 Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, Weiss
GE, Molina DM, Burk CR, Waisberg M, Jasinskas A, Tan XL, Doumbo S, Doumtabe D, Kone Y, Narum DL, Liang XW, Doumbo OK, Miller LH, Doolan DL, Baldi P, Felgner PL, Pierce SK. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proceedings of the National Acedemy of Sciences of the United States of America. 107(15):6958-6963. 2010. Cronin-Fenton DP, Murray LJ, Whiteman DC, Cardwell C, Webb PM, Jordan SJ, Corley DA, Sharp L, Lagergren J; Barrett's Esophagus, Adenocarcinoma Consortium (BEACON) Investigators. Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis. European Journal of Cancer. 46(11):2067-76. 2010 Curley C, Kennedy G, Haughton A, Love A, McCarthy C, Boyd, A. Acute myeloid leukemia, the 3q21q26 syndrome and diabetes insipidus: A case presentation. Asia-Pacific Journal of Clinical Oncology 6(2):7779. 2010 Currie BJ, McCarthy JS. Permethrin and Ivermectin for Scabies. New England Journal of Medicine. 362(8):717-725. 2010 Davis RA, Carroll AR, Andrews KT, Boyle GM, Tran TL, Healy PC, Kalaitzis JA, Shivas RG. Pestalactams A-C: novel caprolactams from the endophytic fungus Pestalotiopsis sp. Organic & Biomolecular Chemistry 8(8):17851790. 2010 Doherty JA, Rossing MA, Cushing-Haugen KL, Chen C, Van Den Berg DJ, Wu AH, Pike MC, Ness RB, Moysich K, ChenevixTrench G, Beesley J, Webb PM, Chang-Claude J, Wang-Gohrke S, Goodman MT, Lurie G, Thompson PJ, Carney ME, Hogdall E, Kjaer SK, Hogdall C, Goode EL, Cunningham JM, Fridley BL, Vierkan, RA, Berchuck A, Moorman PG, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Yang HP, Garcia-Closas M, Chanock S, Lissowska J, Song HL, Pharoah PDP, Shah M, Perkins B, McGuire V, Whittemore AS, Di Cioccio, RA Gentry-Maharaj A, Menon U, Gayther SA, Ramus SJ, Ziogas A, Brewster W, Anton-Culver H, Pearce CL, Australian Ovarian Cancer Study Mana, Australian Cancer Study Ovarian Canc. Ovarian Cancer Assoc Consortium. ESR1/SYNE1 Polymorphism and Invasive Epithelial Ovarian Cancer Risk: An Ovarian Cancer Association Consortium Study. Cancer Epidemiology Biomarkers & Prevention. 19(1):245-250. 2010 Dong Y, Tan OL, Loessner D, Stephens C, Walpole C, Boyle GM, Parsons PG, Clements JA. Kallikrein-Related Peptidase 7
97
2009–2010 SCIENTIFIC PUBLICATIONS CONTINUED Promotes Multicellular Aggregation via the alpha(5)beta(1) Integrin Pathway and Paclitaxel Chemoresistance in Serous Epithelial Ovarian Carcinoma. Cancer Research. 70(7):2624-2633. 2010 Doyle AE, Biederman J, Ferreira MAR, Wong P, Smoller JW, Faraone SV. Suggestive Linkage of the Child Behavior Checklist Juvenile Bipolar Disorder Phenotype to 1p21, 6p21, and 8q21. Journal of the American Academy of Child ad Adolescent Psychiatry. 49(4):378-387. 2010 Driguez P, Doolan DL, Loukas A, Felgner PL, McManus DP. Schistosomiasis vaccine discovery using immunomics. Parasites & Vectors. 28;3:4. 2010 Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, Chresta C, McCormack R, Byrne N, Cockerill M, Graham A, Beran G, Cassidy A, Haggerty C, Brown H, Ellison G, Dering J, Taylor BS, Stark M, Bonazzi V, Ravishankar S, Packer L, Xing F, Solit DB, Finn RS, Rosen N, Hayward NK, French T, Smith PD. Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244). Cancer Research. 70(6):2264-2273. 2010. Duffy DL, Iles MM, Glass D, Zhu G, Barrett JH, Höiom V, Zhao ZZ, Sturm RA, Soranzo N, Hammond C, Kvaskoff M, Whiteman DC, Mangino M, Hansson J, NewtonBishop JA; GenoMEL, Bataille V, Hayward NK, Martin NG, Bishop DT, Spector TD, Montgomery GW. IRF4 variants have agespecific effects on nevus count and predispose to melanoma. American Journal Human Genetics. 87(1):6-16. 2010 Duffy DL, Zhao ZZ, Sturm RA, Hayward NK, Martin NG, Montgomery GW. Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. Journal of Investigative Dermatology. 130(2):520-8. 2010 Dunn LA, Burgess AG, Krauer KG, Eckmann L, Vanelle P, Crozet MD, Gillin FD, Upcroft P, Upcroft JA. A new-generation 5-nitroimidazole can induce highly metronidazole-resistant Giardia lamblia in vitro. International Journal of Antimicrobial Agents. 36(1):37-42. 2010 Edo De Bock C, Lin Z, Mekkawy AH, Byrne JA, Wang Y. Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion. International Journal of Oncology. 36(5):1155-63. 2010 Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D,
98
QIMR Annual Report 2009/10
Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dörk T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G; UK Genetic Prostate Cancer Study Collaborators/ British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nature Genetics. 41(10):1116-21. 2009 Falchi M, Bataille V, Hayward NK, Duffy DL, Bishop JA, Pastinen T, Cervino A, Zhao ZZ, Deloukas P, Soranzo N, Elder DE, Barrett JH, Martin NG, Bishop DT, Montgomery GW, Spector TD. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nature Genetics. 41(8):915-9. 2009 Ferreira MA, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, Nyholt DR, Gordon S, Campbell M, McEvoy BP, Henders A, Evans DM, Lanchbury JS, Pereyra F; International HIV Controllers Study, Walker BD, Haas DW, Soranzo N, Spector TD, de Bakker PI, Frazer IH, Montgomery GW, Martin NG. Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. American Journal Human Genetics. 86(1):88-92. 2010 Ferreira MA, Hottenga JJ, Warrington NM, Medland SE, Willemsen G, Lawrence RW, Gordon S, de Geus EJ, Henders AK, Smit JH, Campbell MJ, Wallace L, Evans DM, Wright MJ, Nyholt DR, James AL, Beilby JP, Penninx BW, Palmer LJ, Frazer IH, Montgomery GW, Martin NG, Boomsma DI. Sequence variants in three loci influence monocyte counts and erythrocyte volume. American Journal of Human Genetics. 85(5):745-9. 2009
Ferreira MA, Oates NA, van Vliet J, Zhao ZZ, Ehrich M, Martin NG, Montgomery GW, Whitelaw E, Duffy DL. Characterization of the methylation patterns of MS4A2 in atopic cases and controls. Allergy. 65(3):333-7. 2010 Ferreira MA, Zhao ZZ, Thomsen SF, James M, Evans DM, Postmus PE, Kyvik KO, Backer V, Boomsma DI, Martin NG, Montgomery GW, Duffy DL. Association and interaction analyses of eight genes under asthma linkage peaks. Allergy. 64(11):16238. 2009 Flanagan JM, Cocciardi S, Waddell N, Johnstone CN, Marsh A, Henderson S, Simpson P, da Silva L, Khanna K, Lakhani S, Boshoff C, Chenevix-Trench G, kConFab Investigators. DNA Methylome of Familial Breast Cancer Identifies Distinct Profiles Defined by Mutation Status. American Journal of Human Genetics. 86(3):420-433. 2010 Flesch IEA, Woo WP, Wang Y, Panchanathan V, Wong YC, La Gruta NL, Cukalac T, Tscharke DC. Altered CD8(+) T Cell Immunodominance after Vaccinia Virus Infection and the Naive Repertoire in Inbred and F-1 Mice. Journal of Immunology 184 (1): 4555. 2010 Fischer K, Langendorf CG, Irving JA, Reynolds S, Willis C, Beckham S, Law RH, Yang S, BashtannykPuhalovich TA, McGowan S, Whisstock JC, Pike RN, Kemp DJ, Buckle AM. Structural mechanisms of inactivation in scabies mite serine protease paralogues. Journal of Molecular Biology. 390(4):635-45. 2009 Gamboa D, Ho MF, Bendezu J, Torres K, Chiodini PL, Barnwell JW, Incardona S, Perkins M, Bell D, McCarthy J, Cheng Q. A Large Proportion of P. falciparum Isolates in the Amazon Region of Peru Lack pfhrp2 and pfhrp3: Implications for Malaria Rapid Diagnostic Tests. Plos One 5(1):article -e8091. 2010 Gardiner DL, Skinner-Adams TS, Brown CL, Andrews KT, Stack CM, McCarthy JS, Dalton JP, Trenholme KR. Plasmodium falciparum: new molecular targets with potential for antimalarial drug development. Expert Review of Anti-Infective Therapy 7(9):1087-98. 2009 Garvey G, Rolfe IE, Pearson SA, Treloar C. Indigenous Australian medical students' perceptions of their medical school training. Medical Education. 43(11):1047-55. 2009 Georgousakis MM, Hofmann A, Batzloff MR, McMillan DJ, Sriprakash KS. Structural optimisation of a conformational epitope improves antigenicity when expressed as a recombinant fusion protein. Vaccine. 27(48):6799-806. 2009 Gobert GN, McManus DP, Nawaratna S, Moertel L, Mulvenna
J, Jones MK. Tissue specific profiling of females of Schistosoma japonicum by integrated laser microdissection microscopy and microarray analysis. PLoS Neglected Tropical Diseases. 30;3(6):e469. 2009 Gobert GN, Tran MH, Moertel L, Mulvenna J, Jones MK, McManus DP, Loukas A. Transcriptional changes in Schistosoma mansoni during early schistosomula development and in the presence of erythrocytes. PLoS Neglected Tropical Diseases. 4(2):e600. 2010 Gordon LG, Obermair A. Potential hospital cost-savings attributed to improvements in outcomes for colorectal cancer surgery following self-audit. BMC Surgery. 27;10:4. 2010 Gordon LG, Scuffham PA, van der Pols JC, McBride P, Williams GM, Green AC. Regular sunscreen use is a cost-effective approach to skin cancer prevention in subtropical settings. Journal of Investigative Dermatology. 129(12):2766-71. 2009 Grealy R, Griffiths LR. Current status of pharmacogenomics testing for antitumor drug therapies: approaches to non-melanoma skin cancer. Molecular Diagnosis and Therapy. 13(2):65-72. Review. 2009 Griffiths, LR; Cox, HC; Bellis, C; Nyholt, D; Macgregor, S; Lea, RA; Charlesworth, J; Dyer, T; Blangero, J. A genome-wide linkage analysis of migraine in the descendents of the bounty mutineers implicates the 13q chromosomal region. Cephalalgia 29:83-83, Special Issue Suppl 1. 2009 Hacker E, Hayward NK, Dumenil T, James MR, Whiteman DC. The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. Journal of Investigative Dermatology. 130(1):241-8. 2010 . Hacker E, Muller HK, Hayward N, Fahey P, Walker G. Enhancement of DNA repair using topical T4 endonuclease V does not inhibit melanoma formation in Cdk4(R24C/ R24C)/Tyr-Nras(Q61K) mice following neonatal UVR. Pigment Cell & Melanoma Research. 23(1):121-8. 2010 Hansell NK, Agrawal A, Whitfield JB, Moreley KI, Gordon SD, Lind PA, Pergardia ML, Montgomery GW, Madden PA, Todd RD, Heath AC, Martin NG. Linkage Analysis of Alcohol Dependence Symptoms in the Community. Alcoholism Clinical and Experimental Research. 34(1)158-163(6). 2010 Haque A, Good MF. Malaria vaccine research: lessons from 2008/9. Future Microbiology. 4:649-54. Review. 2009 Haque A, Stanley AC, Amante FH, Rivera FD, Zhou Y, Kuns RD, Yardley V, Sakaguchi S, Hill GR, Engwerda CR. Therapeutic Glucocorticoid-Induced TNF
Receptor-Mediated Amplification of CD4+ T Cell Responses Enhances AntiparasiticImmunity. Journal of Immunology. 184(5):2583-92
Body composition, smoking, and spontaneous dizygotic twinning. Fertility and Sterility. 93(3):885-893. 2010
Harris JL, Jakob B, Taucher-Scholz G, Dianov GL, Becherel OJ, Lavin MF. Aprataxin, poly-ADP ribose polymerase 1 (PARP-1) and apurinic endonuclease 1 (APE1) function together to protect the genome against oxidative damage. Human Molecular Genetics 1;18(21):410217. 2009
Hogg K, Etherington SL, Young JM, McNeilly AS, Duncan WC. Inhibitor of Differentiation (Id) Genes Are Expressed in the Steroidogenic Cells of the Ovine Ovary and Are Differentially Regulated by Members of the Transforming Growth Factor-beta Family. Endocrinology. 151(3):1247-1256. 2010
Harty MW, Muratore CS, Papa EF, Gart MS, Ramm GA, Gregory SH, Tracy TF. Neutrophil Depletion Blocks Early Collagen Degradation in Repairing Cholestatic Rat Livers. American Journal of Patholog.176(3):1271-1281. 2010
Hu WB, Clements A, Williams G, Tong SL. Dengue fever and El Nino/Southern Oscillation in Queensland, Australia: a time series predictive model. Occupational and Environmental Medicine. 67(5):307311. 2010
Healy PC, Loughrey T, Williams ML, Parsons PG. Synthesis, structure and cytotoxicity studies of four-coordinate bis (cis-bis (diphenylphosphino) ethene) gold(I) complexes, [Au(dppey)(2)]X. Journal of Inorganic Biochemistry. 104(6):625-631. 2010
Hugo LE, Cook PE, Johnson PH, Rapley LP, Kay BH, Ryan PA, Ritchie SA, O'Neill SL. Field Validation of a Transcriptional Assay for the Prediction of Age of Uncaged Aedes aegypti Mosquitoes in Northern Australia. PLOS Neglected Tropical Diseases. 4(2):article -e608. 2010
Herath NI, Boyd AW. The role of Eph receptors and ephrin ligands in colorectal cancer. International Journal of Cancer. 126(9):2003-11. Review. 2010 Herath NI, Purdie DM, Kew MC, Smith JL, Young J, Leggett BA, MacDonald GA. Varying etiologies lead to different molecular changes in Australian and South African hepatocellular carcinomas. International Journal of Oncology. 35(5):1081-9. 2009 Herath NI, Doecke J, Spanevelle MD, Leggett BA, Boyd AW. Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival. British Journal of Cancer 100:1095-1102. 2009 Hill GR, Tey SK, Beagley L, Crough T, Morton JA, Clouston AD, Whiting P, Khanna R. Successful immunotherapy of HCMV disease using virus-specific T cells expanded from an allogeneic stem cell transplant recipient. American Journal of Transplantation. 10(1):173-9. 2010 Hinoue T, Weisenberger Daniel J, Pan Fei, Campan Mihaela, Kim Myungjin, Young Joanne, Whitehall Vicki L, Leggett Barbara A, Laird Peter W. Analysis of the Association between CIMP and BRAF in Colorectal Cancer by DNA Methylation Profiling. PLos One 4(12) e8357. 2009 Ho V, Whiteman D, Miller M, Raulli A, Ombiga J, Boyd P. Esophageal cancer in Indigenous Australians in Far North Queensland. Journal of Gastroenterology and Hepatology. 24(10):1683-6. 2009 Hoekstra C, Willemsen G, van Beijsterveldt T, Lambalk CB, Montgomery GW, Boomsma DI.
Hunt NH, Grau GE, Engwerda C, Barnum SR, van der Heyde H, Hansen DS, Schofield L, Golenser J. Murine cerebral malaria: the whole story. Trends in Parasitology. 26(6):272-274. 2010 Hurst TP, Kay BH, Brown MD, Ryan PA. Melanotaenia duboulayi Influence Oviposition Site Selection by Culex annulirostris (Diptera: Culicidae) and Aedes notoscriptus (Diptera: Culicidae) but Not Culex quinquefasciatus (Diptera: Culicidae). Environmental Entomology. 39(2):545-551. 2010 Ibiebele TI, Parekh S, Mallitt KA, Hughes MC, O'Rourke PK, Webb PM; Australian Ovarian Cancer Study Group and the Australian Cancer Study. Reproducibility of food and nutrient intake estimates using a semi-quantitative FFQ in Australian adults. Public Health Nutrition. (12):2359-65. 2009 Ibiebele TI, Van der Pols JC, Hughes MC, Marks GC, Green AC. Dietary fat intake and risk of skin cancer : a prospective study in Australian adults. International Journal of Cancer. 125(7):1678-84. 2009. Idaghdour Y, Czika W, Shianna KV, Lee SH, Visscher PM, Martin HC, Miclaus K, Jadallah SJ, Goldstein DB, Wolfinger RD, Gibson G. Geographical genomics of human leukocyte gene expression variation in southern Morocco. Nature Genetics. 42(1):62-U79. 2010 Jabbar A, Kyngdon CT, Gauci CG, Walduck AK, McCowan C, Jones MK, Beveridge I, Lightowlers MW. Localisation of three host-protective oncospheral antigens of Taenia ovis. International Journal for Parasitology. 40(5):579-589. 2010
Jahanshad N, Lee AD, Barysheva M, McMahon KL, de Zubicaray GI, Martin NG, Wright MJ, Toga AW, Thompson PM. Genetic influences on brain asymmetry: A DTI study of 374 twins and siblings. Neuroimage 52(2):455-469. 2010 Janda M, Baade PD, Youl PH, Aitken JF, Whiteman DC, Gordon L, Neale RE. The skin awareness study: Promoting thorough skin selfexamination for skin cancer among men 50 years or older. Contemporary Clinical Trials. 31(1):119-130. 2010 Jeffery JA, Thi Yen N, Nam VS, Nghia le T, Hoffmann AA, Kay BH, Ryan PA. Characterizing the Aedes aegypti population in a Vietnamese village in preparation for a Wolbachiabased mosquito control strategy to eliminate dengue. PLoS Neglected Tropical Diseases. 3(11):e552. 2009 Jeffery JM, Urquhart AJ, Subramaniam VN, Parton RG, Khanna KK. Centrobin regulates the assembly of functional mitotic spindles. Oncogene. 29(18):2649-58. 2010 Johnatty SE, Couch FJ, Fredericksen Z, Tarrell R, Spurdle AB, Beesley J, Chen X; kConFab Investigators; AOCS Group; Swedish BRCA1 and BRCA2 Study Collaborators, GschwantlerKaulich D, Singer CF, Fuerhauser C, Fink-Retter A, Domchek SM, Nathanson KL, Pankratz VS, Lindor NM, Godwin AK, Caligo MA, Hopper J, Southey MC, Giles GG, Justenhoven C, Brauch H, Hamann U, Ko YD, Heikkinen T, Aaltonen K, Aittomäki K, Blomqvist C, Nevanlinna H, Hall P, Czene K, Liu J, Peock S, Cook M, Platte R, Gareth Evans D, Lalloo F, Eeles R, Pichert G, Eccles D, Davidson R, Cole T, Cook J, Douglas F, Chu C, Hodgson S, Paterson J, Hogervorst FB, Rookus MA, Seynaeve C, Wijnen J, Vreeswijk M, Ligtenberg M, van der Luijt RB, van Os TA, Gille HJ, Blok MJ; HEBON, Issacs C, Humphreys MK, McGuffog L, Healey S, Sinilnikova O, Antoniou AC, Easton DF, Chenevix-Trench G. Breast Cancer Association Consortium and Consortium of Investigators of Modifiers of BRCA1/2. No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Research and Treatment. 117(2):371-9. 2009 Johnatty SE, Beesley J, Chen X, Spurdle AB, Defazio A, Webb PM, Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer), Goode EL, Rider DN, Vierkand RA, AndersonS, Wu AH, Pike M, Van Den Berg D, Moysich K, Ness R, Doherty J, Rossing MA, Pearce CL, ChenevixTrench G. Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium. Twin Research and Human Genetics. 12(3):269-75. 2009
Johnston SE, Beraldi D, McRae AF, Pemberton JM, Slate J. Horn type and horn length genes map to the same chromosomal region in Soay sheep. Heredity. 104(2):196-205. 2010 Jones K, Nourse J, Corbett G, Gandhi MK. Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. International Journal of Laboratory Hematology. 32(1):E169E174,Part 1. 2010 Jordan SJ, Siskind V, C Green A, Whiteman DC, Webb PM. Breastfeeding and risk of epithelial ovarian cancer. Cancer Causes Control. 21(1):109-16. 2010 Joyce P, Kuwahata M, Turner N, Lakshmanan P. Selection system and co-cultivation medium are important determinants of Agrobacterium-mediated transformation of sugarcane. Plant Cell Reports (2):173-183. 2010 Jones K, Nourse J, Corbett G, Gandhi MK. Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. International Journal of Laboratory Hematology. 32(1 Pt 1):e169-74. 2010 Kaminen-Ahola N, Ahola A, Maga M, Mallitt KA, Fahey P, Cox TC, Whitelaw E, Chong S. Maternal ethanol consumption alters the epigenotype and the phenotype of offspring in a mouse model. PLoS Genetics. 6(1):e1000811. 2010 Kay BH, Tuyet Hanh TT, Le NH, Quy TM, Nam VS, Hang PV, Yen NT, Hill PS, Vos T, Ryan PA. Sustainability and cost of a community-based strategy against Aedes aegypti in northern and central Vietnam. American Journal of Tropical Medicine and Hygiene. 82(5):822-30. 2010 Keightley MC, Brown P, Jabbour HN, Sales KJ. F-Prostaglandin receptor regulates endothelial cell function via fibroblast growth factor-2. BMC Cell Biology 11:article 8. 2010 Keller MC, Medland SE, Duncan LE. Are Extended Twin Family Designs Worth the Trouble? A Comparison of the Bias, Precision, and Accuracy of Parameters Estimated in Four Twin Family Models. Behavior Genetics. 40(3):377-393. 2010 Kolahdooz F, van der Pols JC, Bain CJ, Marks GC, Hughes MC, Whiteman DC, Webb PM; Australian Cancer Study (Ovarian Cancer) and the Australian Ovarian Cancer Study Group. Meat, fish, and ovarian cancer risk: Results from 2 Australian case-control studies, a systematic review, and meta-analysis. American Journal of Clinical Nutrition. 91(6):1752-63. 2010.
99
2009–2010 SCIENTIFIC PUBLICATIONS CONTINUED Kominami K, Nagasaka T, Cullings HM, Hoshizima N, Sasamoto H, Young J, Leggett BA, Tanaka N, Matsubara N. Methylation in p14(ARF) is frequently observed in colorectal cancer with low-level microsatellite instability. Journal of International Medical Research. 37: 1038-1045. 2009 Kozlov S, Waters NC, Chavchich M. Leveraging cell cycle analysis in anticancer drug discovery to identify novel plasmodial drug targets. Infectious Disorders Drug Targets. 10(3):165-90. 2010 Krauer KG, Burgess AG, Dunn LA, Upcroft P, Upcroft JA. Sequence map of the 2 Mb Giardia lamblia assemblage A chromosome. Journal of Parasitology. 96(3):660-2. 2010 Kuns RD, Morris ES, Macdonald KP, Markey KA, Morris HM, Raffelt NC, Banovic T, Don AL, Rowe V, Burman AC, Clouston AD, Farah C, Besra GS, Illarionov PA, Smyth MJ, Porcelli SA, Hill GR. Invariant natural killer T cellnatural killer cell interactions dictate transplantation outcome after alphagalactosylceramide administration. Blood. 113(23):5999-6010. 2009 Labadie K, Larcher T, Joubert C, Mannioui A, Delache B, Brochard P, Guigand L, Dubreil L, Lebon P, Verrier B, de Lamballerie X, Suhrbier A, Cherel Y, Le Grand R, Roques P. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. Journal of Cllinical Investigation.120(3):894-906. 2010 Lahmann PH, Wills RA, Coory M. Trends in birth size and macrosomia in Queensland, Australia, from 1988 to 2005. Paediatric & Perinatal Epidemiology. 23(6):533-41. 2009 Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H ,Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P, European Alzheimers Dis Initiative. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics. 41 (10):1094-U68 2009. Laumet G, Petitprez V, Sillaire A, Ayral AM, Hansmannel F, Chapuis J, Hannequin D, Pasquier F, Scarpini E, Galimberti D, Lendon C, Campion D, Amouyel P, Lambert JC. 2010. A study of the
100
QIMR Annual Report 2009/10
association between the ADAM 12 and SH3PXD2A (SH3MD1) genes and Alzheimer's disease. Neuroscience Letters 468 (1):1-2. 2010 Lavin MF, Masci PP. Prothrombinase complexes with different physiological roles. Journal of Thrombosis and Haemotosis. 102(3):421-3. 2009 Leggett Barbara A. Family-based screening for colorectal cancer: The Australian perspective. Journal of Gastroenterology and Hepatology Review 24Suppl3:S29-S32. 2009. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 138(6):2088-100. Review. 2010 Lim YC, Roberts T, Harding A, Day B, Kozlov S, Walker D, Lavin M. Low dose radiation responses and knockdown of ATM kinase activity in glioma stem cells. Acta medica Nagasakiensia. 53(supl.):37043. 2009 Lind PA, Luciano M, Horan MA, Marioni RE, Wright MJ, Bates TC, Rabbitt P, Harris SE, Davidson Y, Deary IJ, Gibbons L, Pickles A, Ollier W, Pendleton N, Price JF, Payton A, Martin NG. No association between Cholinergic Muscarinic Receptor 2 (CHRM2) genetic variation and cognitive abilities in three independent samples. Behavior Genetics. 39(5):513-23. 2009 Lind PA, Luciano M, Wright MJ, Montgomery GW, Martin NG, Bates TC. Dyslexia and DCDC2: normal variation in reading and spelling is associated with DCDC2 polymorphisms in an Australian population sample. European Journal of Human Genetics. 18(6):668-73. 2010 Lind PA, Macgregor S, Vink JM, Pergadia ML, Hansell NK, de Moor MH, Smit AB, Hottenga JJ, Richter MM, Heath AC, Martin NG, Willemsen G, de Geus EJ, Vogelzangs N, Penninx BW, Whitfield JB, Montgomery GW, Boomsma DI, Madden PA. A genomewide association study of nicotine and alcohol dependence in Australian and dutch populations. Twin Research & Human Genetics. 13(1):10-29. 2010 Lindor NM, RabeKG, Petersen GM, Chen H, Bapat B, Hopper J, Young J, Jenkins M, Potter J, Newcomb P, Templeton A, LeMarchand L, Grove J, Burgio MR, Haile R, Green J, Woods MO, Seminara D, Limburg PJ, Thibodeau SN. Parent of origin effects on age at colorectal cancer diagnosis. International Journal of Cancer. 127(2):361-366. 2010 Liu F, Wollstein A, Hysi PG, Ankra-Badu GA, Spector TD, Park D, Zhu G, Larsson M, Duffy DL, Montgomery GW, Mackey DA, Walsh S, Lao O, Hofman A, Rivadeneira F, Vingerling JR, Uitterlinden AG, Martin NG, Hammond CJ, Kayser M. Digital Quantification of Human Eye Color Highlights Genetic Association of Three New Loci. PLOS Genetics
6(5):article e1000934. 2010 Liu JZ, Medland SE, Wright MJ, Henders AK, Heath AC, Madden PA, Duncan A, Montgomery GW, Martin NG, McRae AF. Genomewide association study of height and body mass index in Australian twin families. Twin Research and Human Genetics. 13(2):179-93. 2010 Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, Brown KM; AMFS Investigators, Hayward NK, Montgomery GW, Visscher PM, Martin NG, Macgregor S. A versatile gene-based test for genome-wide association studies. American Journal of Human Genetics. 87(1):139-145. 2010 Loser R, Gut J, Rosenthal PJ, Frizler M, Gutschow M, Andrews KT. Antimalarial activity of azadipeptide nitriles. Bioganic & Medicinal Chemistry letters 20(1):252-255. 2010 Loughrey BT, Williams ML, Carruthers TJ, Parsons PG, Healy PC. Synthesis, Structure, and Selective Cytotoxicity of Organometallic Cp*Ru-II O-AlkylN-phenylcarbamate Sandwich Complexes. Australian Journal of Chemistry 63(2):245-251. 2010 Lu Y, Dimasi DP, Hysi PG, Hewitt AW, Burdon KP, Toh T, Ruddle JB, Li YJ, Mitchell P, Healey PR, Montgomery GW, Hansell N, Spector TD, Martin NG, Young TL, Hammond CJ, Macgregor S, Craig JE, Mackey DA. Common genetic variants near the Brittle Cornea Syndrome locus ZNF469 influence the blinding disease risk factor central corneal thickness. PLoS Genetics. 6(5):e1000947. 2010 Lutzky VP, Corban M, Heslop L, Morrison LE, Crooks P, Hall DF, Coman WB,Thomson SA, Moss DJ. Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine. Journal of Virology. 84(1):407-17. 2010 Lutzky VP, Davis JE, Crooks P, Corban M, Smith MC, Elliott M, Morrison L, Cross S, Tscharke D, Panizza B, Coman W, Bharadwaj M, Moss DJ. Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients. Immunology and Cell Biology. 87(6):481-8. 2009 McCarron JK, Stringer BW, Day BW, Boyd AW. Ephrin expression and function in cancer. Future Oncology. 6(1):165-76. 2010. McCarthy JS, Good MF. Whole parasite blood stage malaria vaccines: A convergence of evidence. Human Vaccine. 6(1):114-23 McCutcheon VV, Heath AC, Nelson EC, Bucholz KK, Madden PAF, Martin NG. Clustering of Trauma and Associations with Single and Co-Occurring Depression and Panic Attack over Twenty Years. Twin Research and Human Genetics. 13(1):57-65. 2010
McDonald CJ, Jones MK, Wallace DF, Summerville L, Nawaratna S, Subramaniam VN. Increased iron stores correlate with worse disease outcomes in a mouse model of schistosomiasis infection. PLoS One 5(3):e9594. 2010 McEvoy BP, Visscher PM. Genetics of human height. Economics & Human Biology. 7(3):294-306. 2009 McEvoy BP, Montgomery GW, McRae AD, Ripatti S, Perola M, Spector TD, Cherkas L, Ahmadi KR, Boomsma D, Willemsen G, Hottenga JJ, Pedersen NL, Magnusson PK, Kyvik KO, Christensen K, Kaprio J, Heikkila K, Palotie A, Widen E, Muilu J, Syvanen AC, Liljedahl U, Hardiman O, Cronin S, Peltonen L, Martin NG, Visscher PM. Geographical structure and differential natural selection among North European populations. Genome Research. 19(5):804-14. 2009 Macgregor S, Bellis C, Lea RA, Cox H, Dyer T, Blangero J, Visscher PM, Griffiths LR. Legacy of mutiny on the Bounty: founder effect and admixture on Norfolk Island. European Journal of Human Genetics. 18(1):67-72. 2010 Macgregor S. Optimal selection of markers from DNA pooling experiments. Behaviour Genetics. 40(1):46-7; discussion 48. 2010 McGowan S, Oellig CA, Birru WA, Caradoc-Davies TT, Stack CM, Lowther J, Skinner-Adams T, Mucha A, Kafarski P, Grembecka J, Trenholme KR, Buckle AM, Gardiner DL, Dalton JP, Whisstock JC. Structure of the Plasmodium falciparum M17 aminopeptidase and significance for the design of drugs targeting the neutral exopeptidases. Proceedings of the National Academy of Sciences of the United States of America. 107(6): 2449-2454. 2010 McManus DP, Gray DJ, Li Y, Feng Z, Williams GM, Stewart D, ReyLadino J, Ross AG. Schistosomiasis in the People's Republic of China: the era of the Three Gorges Dam. Clinical Microbiological Reviews. 23(2):44266. 2010 McManus DP. Reflections on the biochemistry of Echinococcus: past, present and future. Parasitology. 136(12):1643-52. 2009 McMillan DJ, Vu T, Bramhachari PV, Kaul SY, Bouvet A, Shaila MS, Karmarkar MG, Sriprakash KS. Molecular markers for discriminating Streptococcus pyogenes and S. dysgalactiae subspecies equisimilis. European Journal of Clinical Microbiology & Infections Diseases. 29(5):585-9. 2010 Malintan NT, Nguyen TH, Han L, Latham CF, Osborne SL, Wen PJ, Lim SJ, Sugita S, Collins BM, Meunier FA. Abrogating Munc181-SNARE complex interaction has limited impact on exocytosis in PC12 cells. Journal of Biological Chemistry. 284(32):21637-46. 2009
Mallitt KA, O’Rourke P, Bouwes Bavinch JN, Abeni D, de Koning MNC, Feltkamp MCW, Green AC, Quint WGV, Michael KM, Pawlita M, Pfister H, Weissenborn S, Waterboer T, Neale RE and the EPIHPV-UV-CA group. An analysis of clustering of beta papillomavirus DNA and Antibodies. Journal of General Virology. 91(Pt 8):2062-7. 2010 Markey KA, Burman AC, Banovic T, Kuns RD, Raffelt NC, Rowe V, Olver SD, Don AL, Morris ES, Pettit AR, Wilson YA, Robb RJ, Randall LM, Korner H, Engwerda CR, Clouston AD, Macdonald KP, Hill GR. Soluble lymphotoxin is an important effector molecule in GVHD and GVL. Blood. 115(1):122-32. 2010 Mao X, Peng H, Ling J, Friis T, Whittaker AK, Crawford R, Xiao Y. Enhanced human bone marrow stromal cell affinity for modified poly(Llactide) surfaces by the upregulation of adhesion molecular genes. Biomaterials 30(36):6903-11. 2009 Medland SE, Neale MC. An integrated phenomic approach to multivariate allelic association. European Journal of Human Genetics. (2):233-9. 2010 Medland SE, Nyholt DR, Painter JN, McEvoy BP, McRae AF, Zhu G, Gordon SD, Ferreira MA, Wright MJ, Henders AK, Campbell MJ, Duffy DL, Hansell NK, Macgregor S, Slutske WS, Heath AC, Montgomery GW, Martin NG. Common variants in the trichohyalin gene are associated with straight hair in Europeans. American Journal of Human Genetics 85(5):750-5. 2009 Medland SE, Zayats T, Glaser B, Nyholt DR, Gordon SD, Wright MJ, Montgomery GW, Campbell MJ, Henders AK, Timpson NJ, Peltonen L, Wolke D, Ring SM, Deloukas P, Martin NG, Smith GD, Evans DM. A variant in LIN28B is associated with 2D:4D finger-length ratio, a putative retrospective biomarker of prenatal testosterone exposure. American Journal of Human Genetics. 86(4):519-25. 2010 Medland SE, Zhu G, Martin NG. Estimating the heritability of hair curliness in twins of European ancestry. Twin Research and Human Genetics. 12(5):514-8. 2009 Meredith LW, Ducloux C, Isel C, Marquet R, Harrich D. A U5 repressor of reverse transcription is required for optimal HIV-1 infectivity and replication. Retrovirology 6: article O14, Suppl 2009 Meredith LW, Sivakumaran H, Major L, Suhrbier A, Harrich D. Potent inhibition of HIV-1 replication by a Tat mutant. PLoS One. 4(11):e7769. 2009 Merritt MA, Parsons PG, Newton TR, Martyn AC, Webb PM, Green AC, Papadimos DJ, Boyle GM. Expression profiling identifies genes
involved in neoplastic transformation of serous ovarian cancer. BMC Cancer. 23;9:378. 2009 Mika A, Boenisch MJ, Hopff D, Luthje S. Membrane-bound guaiacol peroxidases from maize (Zea mays L.) roots are regulated by methyl jasmonate, salicylic acid, and pathogen elicitors. Journal of Experimental Botany. 61(3):831-841. 2010 Miller SM, Hansell NK, Ngo TT, Liu GB, Pettigrew JD, Martin NG, Wright MJ. Genetic contribution to individual variation in binocular rivalry rate. Proceedings of the National Academy of Sciences of the United States of America. 107(6):2664-2668. 2010 Mitchell D, Olive C. Regulation of Toll-like receptor-induced chemokine production in murine dendritic cells by mitogen-activated protein kinases. Molecular Immunology. 47(11-12):2065-73. 2010 Mitchell, PB, Frankland A, HadziPavlovic D, Roberts G, Wright A, Loo C, Malhi GS, Breakspear M. A comparison of the phenomenology and illness course of major depressive episodes in major depressive disorder and bipolar I and bipolar II disorders. Bipolar Disorders. 12:38-38.Suppl. 1. 2010 Moreira LA, Iturbe-Ormaetxe I, Jeffery JA, Lu GJ, Pyke AT, Hedges LM, Rocha BC, Hall-Mendelin S, Day A, Riegler M, Hugo LE, Johnson KN, Kay BH, McGraw EA, van den Hurk AF, Ryan PA, O'Neill SL. A Wolbachia Symbiont in Aedes aegypti Limits Infection with Dengue, Chikungunya, and Plasmodium. Cell. 139(7):1268-1278. 2010 Morrow BJ, Keddie DJ, Gueven N, Lavin MF, Bottle SE. A novel profluorescent nitroxide as a sensitive probe for the cellular redox environment. Free Radical Biology and Medicine. 49(1):67-76. 2010 Mosing MA, Gordon SD, Medland SE, Statham DJ, Nelson EC, Heath AC, Martin NG, Wray NR. Genetic and Environmental Influences on the Co-morbidity between depression, panic disorder, agoraphobia and social phobia: A Twin Study. Depression and Anxiety. 26(11):10041011. 2009 Mosing MA, Zietsch BP, Shekar SN, Wright MJ, Martin NG. Genetic and environmental influences on optimism and its relationship to mental and selfrated health: a study of aging twins. Behavioral Genetics. 39(6):597-604. 2009 Mounsey KE, Holt DC, McCarthy JS, Currie BJ, Walton SF. Longitudinal Evidence of Increasing In Vitro Tolerance of Scabies Mites to Ivermectin in ScabiesEndemic Communities. Archives of Dermatology. 145(7):840-841. 2009.
Mounsey KE, Pasay CJ, Arlian LG, Morgan MS, Holt DC, Currie BJ, Walton SF, McCarthy JS. Increased transcription of Glutathione S-transferases in acaricide exposed scabies mites. Parasites & Vectors. 3:43. 2010 Mujaj S, Manton K, Upton Z, Richards S. Serum-Free Primary Human Fibroblast and Keratinocyte Coculture. Tissue Engineering Part A.16(4):1407-1420. 2010 Mulvenna J, Moertel L, Jones MK, Nawaratna S, Lovas EM, Gobert GN, Colgrave M, Jones A, Loukas A, McManus DP. Exposed proteins of the Schistosoma japonicum tegument. International Journal of Parasitology. 40(5):543-454. 2010 Mulvenna J, Sripa B, Brindley PJ, Gorman J, Jones MK, Colgrave ML, Jones A, Nawaratna S, Laha T, Suttiprapa S, Smout MJ, Loukas A. The secreted and surface proteomes of the adult stage of the carcinogenic human liver fluke Opisthorchis viverrini. Proteomics. 10(5):1063-78. 2010 Nagamine Y, Pong-Wong R, Visscher PM, Haley CS. Detection of multiple quantitative trait loci and their pleiotropic effects in outbred pig populations. Genetics Selection Evolution. 41: article - 44. 2009
Tey SK, Kennedy G, Gandhi MK. Fulminant infectious mononucleosis and recurrent Epstein-Barr virus reactivation in an adolescent. Clinical Infectious Diseases. 50(6):e34-7. 2010 Nyholt DR. Letter to the Editor: Further evidence is required to confirm association between CACNA1C gene variants and bipolar affective disorder. Psychological Medicine. 40(4):702; author reply 703-4. 2010 O'Leary CA, Duffy D, Biros I, Corley S. Linkage confirms canine pkd1 orthologue as a candidate for bull terrier polycystic kidney disease. Animal Genetics. 40(4):543-546. 2009 O'Mara TA, Clements JA, Spurdle AB. The Use of Predictive or Prognostic Genetic Biomarkers in Endometrial and Other HormoneRelated Cancers: Justification for Extensive Candidate Gene Single Nucleotide Polymorphism Studies of the Matrix Metalloproteinase Family and their Inhibitors. Cancer Epidemiology Biomarkers & Prevention.18 (9): 2352-2365. 2009 Olsen CM, Carroll HJ, Whiteman DC. Familial melanoma: a meta-analysis and estimates of attributable fraction. Cancer Epidemiology Biomarkers and Prevention. 19(1):65-73. 2010
Naidu D, Scott J, Ong D, Ho CTC. Validity, reliability and reproducibility of three methods used to measure tooth widths for Bolton analyses. Australian Orthodontic Journal. 25(2):97-103. 2009
Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for Cancer : A meta-analysis of nevi and melanoma. Cancer Prevention Research (Phila Pa). 3(2):233-45. 2010
Neale RE, Hamilton AR, Janda M, Gies P, Green AC. Seasonal variation in measured solar ultraviolet radiation exposure of adults in subtropical Australia. Photochemistry & Photobiology. 86(2):445-8. 2010
Osborne NJ, Gurrin LC, Allen KJ, Constantine CC, Delatycki MB, McLaren CE, Gertig DM, Anderson GJ, Southey MC, Olynyk JK, Powell LW, Hopper JL, Giles GG, English DR. HFE C282Y Homozygotes Are at Increased Risk of Breast and Colorectal Cancer. Hepatology. 51(4):1311-1318. 2010
Nelson EC, Agrawal A, Pergadia ML, Wang JC, Whitfield JB, Saccone FS, Kern J, Grant JD, Schrage AJ, Rice JP, Montgomery GW, Heath AC, Goate AM, Martin NG, Madden PAF. H2 haplotype at chromosome 17q21.31 protects against childhood sexual abuse-associated risk for alcohol consumption and dependence. Addiction Biology. 15(1):1-11. 2010 Netzel-Arnett S, Bugge TH, Hess RA, Carnes K, Stringer BW, Scarman AL, Hooper JD, Tonks ID, Kay GF, Antalis TM. The GlycosylphosphatidylinositolAnchored Serine Protease PRSS21 (Testisin) Imparts Murine Epididymal Sperm Cell Maturation and Fertilizing Ability. Biology of Reproduction. 81(5):921-932. 2009 Nourse JP, Crooks P, Van DN, Jones K, Ross N, Gandhi MK. EBV MicroRNA Expression in Virus Driven B-Cell Differentiation and Lymphomagenesis. Blood. 114(22):43-4. 2009 Nourse JP, Jones K, Dua U, Runnegar N, Looke D, Schmidt C,
Osorio A, Milne RL, Pita G, Peterlongo P, Heikkinen T, Simard J, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Healey S, Neuhausen SL, Ding YC, Couch FJ, Wang X, Lindor N, Manoukian S, Barile M, Viel A, Tizzoni L, Szabo CI, Foretova L, Zikan M, Claes K, Greene MH, Mai P, Rennert G, Lejbkowicz F, BarnettGriness O, Andrulis IL, Ozcelik H, Weerasooriya N, Gerdes AM, Thomassen M, Cruger DG, Caligo MA, Friedman E, Kaufman B, Laitman Y, Cohen S, Kontorovich T, Gershoni-Baruch R, Dagan E, Jernstrom H, Askmalm MS, Arver B, Malmer B, Domchek SM, Nathanson KL, Brunet J, Cajal TRY, Yannoukakos D, Hamann U, Hogervorst FBL, Verhoef S, Garcia EBG, Wijnen JT, van den Ouweland A, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Luccarini C, Evans DG, Lalloo F, Eeles R, Pichert G, Cook J, Hodgson S, Morrison PJ, Douglas F, Godwin AK, Sinilnikova OM, Barjhoux L,
101
2009–2010 SCIENTIFIC PUBLICATIONS CONTINUED Stoppa-Lyonnet D, Moncoutier V, Giraud S, Cassini C, Olivier-Faivre L, Revillion F, Peyrat JP, Muller D, Fricker JP, Lynch HT, John EM, Buys S, Daly M, Hopper JL, Terry MB, Miron A, Yassin Y, Goldgar D, Singer CF, Gschwantler-Kaulich D, Pfeiler G, Spiess AC, Hansen TV, Johannsson OT, Kirchhoff T, Offit K, Kosarin K, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov EN, Allavena A, Schmutzler RK, Versmold B, Engel C, Meindl A, Ditsch N, Arnold N, Niederacher D, Deissler H, Fiebig B, Varon-Mateeva R, Schaefer D, Froster UG, Caldes T, de la Hoya M, McGuffog L, Antoniou AC, Nevanlinna H, Radice P, Benitez J. KConFab, OCGN, SWE-BRCA, HEBON, EMBRACE, GEMO, Breast Cancer Family Registry, CIMBA. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/ BRCA2 (CIMBA). British Journal of Cancer. 101(12): 2048-2054. 2009 Painter JN Willemsen G Nyholt D Hoekstra C Duffy DL Henders AK Wallace L Healey S CannonAlbright LA Skolnick M Martin NG Boomsma DI Montgomery GW. A genome wide linkage scan for dizygotic twinning in 525 families of mothers of dizygotic twins. Human Reproduction. 25(6):1569-80. 2010 Palath V, Vekhande R, Lee A, Williams J, Zhang L, List AF, Boyd A, Lackmann M, Scott AM, Cilloni D, Yarranton GT, Bebbington C. A Recombinant Human Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Shows Selective Cytotoxicity against Myeloid Leukemia Cells and CD123-Positive Leukemic Stem Cells. Blood. 114(22):688-688. 2009 Pampillo M, Camuso N, Taylor JE, Szereszewski JM, Ahow MR, Zajac M, Millar RP, Bhattacharya M, Babwah AV. Regulation of GPR54 Signaling by GRK2 and betaArrestin. Molecular Endocrinology. 23(12):2060-2074. 2009 Pandian JD, Dalton K, Scott J, Read SJ, Henderson RD. Cardiovascular autonomic function tests to provide normative data from a healthy older population. Journal of Clinical Neuroscience. 17(6):731-735. 2010 Pandeya N, Williams GM, Green AC, Webb PM, Whiteman DC. Do low control response rates always affect the findings? Assessments of smoking and obesity in two Australian case-control studies of cancer. Australia New Zealand Journal of Public Health. 33(4):312-9. 2009
102
QIMR Annual Report 2009/10
Pandeya N, Webb PM, Sadeghi S, Green AC, Whiteman DC, Australian Cancer Study. Gastrooesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking NSAIDs or acid suppressants? Gut. 59(1):318. 2010 Pandey M Batzloff MR Good MF. Mechanism of protection induced by group A Streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection. PLoS One. 4(4):e5147. 2009 Pandey M Sekuloski S Batzloff MR. Novel strategies for controlling Streptococcus pyogenes infection and associated diseases: from potential peptide vaccines to antibody immunotherapy. Immunology and Cell Biology, 87(5):391-9. 2009 Papp LV Holmgren A Khanna KK. Selenium and Selenoproteins in Health and Disease. Antioxidants & Redox Signaling. 12(7):793-795. 2010 Papp LV Lu J Bolderson E Boucher D Singh R Holmgren A Khanna KK. SECIS-binding protein 2 promotes cell survival by protecting against oxidative stress. Antioxidants and Redox Signalling. 12(7):797-808. 2010 Parriott SK, Suttiprapa S, Laha T, Sripa B, Loukas A, Brindley PJ. Recombinant Expression and Purification of Caspase 9 of Opisthorchis Viverrini. American Journal of Tropical Medicine and Hygiene. 81(5):1130, Suppl. S. 2009 Pasay C, Mounsey K, Arlian L, Morgan M, Holt D, Currie B, Walton S, McCarthy J. Role of elevated transcription of Glutathione S-transferases (GSTS) in Pyrethroid Resistant Scabies Mites. American Journal of Tropical Medicine and Hygiene. 81(5):8, Suppl. S. 2009 Pearson MS Bethony JM Pickering DA de Oliveira LM Jariwala A Santiago H Miles AP Zhan B Jiang D Ranjit N Mulvenna J Tribolet L Plieskatt J Smith T Bottazzi ME Jones K Keegan B Hotez PJ Loukas A. An enzymatically inactivated hemoglobinase from Necator americanus induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection. Federation of American Societies for Experimental Biology Journal (FASEB J) 23(9):300719. 2009 Pearson MS Pickering DA Tribolet L Cooper L Mulvenna J Oliveira LM Bethony JM Hotez PJ Loukas A. Neutralizing antibodies to the hookworm hemoglobinase Na-APR-1: implications for a multivalent vaccine against hookworm infection and schistosomiasis. Journal of Infectious Diseases. 201(10):1561-9. 2010
Peatey CL Skinner-Adams TS Dixon MW McCarthy JS Gardiner DL Trenholme KR. Effect of antimalarial drugs on Plasmodium falciparum gametocytes. Journal of Infectious Diseases. 200(10):151821. 2009
Goodman MT, Schildkraut JM, Chenevix-Trench G, Berchuck A, Sellers TA. Australian Canc Study Ovarian Canc, Australian Ovarian Canc Study Grp. Polymorphism in the GALNT1 Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women: The Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention. 19(2):600-604. 2010
Peatey CL Andrews KT Eickel N MacDonald T Butterworth AS Trenholme KR Gardiner DL McCarthy JS Skinner-Adams TS. Antimalarial asexual stage-specific and gametocytocidal activities of HIV protease inhibitors. Antimicrobial Agents and Chemotherapy. 54(3):1334-7. 2010
Phillipps KSM, Wykes MN, Liu XQ, Brown M, Blanchfield J, Toth I. A novel synthetic adjuvant enhances dendritic cell function. Immunology 128(1):e582-e588, Part 2. 2009
Pereria TN, Walsh M, Rowsell D, Shepherd R, Lewindon PJ, Ramm GR. The role of monocyte chemotaxis protein-1 and the ductular reaction in initiating fibrogenesis in paediatric cholestatic liver disease. Journal of Gastroenterology and Hepatology. 24:A304-A304 Suppl. 2. 2009
Plasmeijer EI, Neale RE, de Koning MNC, Quint WGV, McBride P, Feltkamp MCW, Green AC. Persistence of Betapapillomavirus Infections as a Risk Factor for Actinic Keratoses Precursor to Cutaneous Squamous Cell Carcinoma. Cander Research 69 (23): 8926-8931. 2009
Pergadia ML, Agrawal A, Loukola A, Montgomery GW, Broms U, Saccone SF, Wang JC, Todorov AA, Heikkila K, Statham DJ, Henders AK, Campbell MJ, Rice JP, Todd RD, Heath AC, Goate AM, Peltonen L, Kaprio J, Martin NG, Madden PAF. Genetic Linkage Findings for DSM-IV Nicotine Withdrawal in Two Populations. American Journal of Medical Genetics Part B – Neurophychiatric Genetics. 150B(7):950-959. 2009
Plasmeijer EI Green AC de Koning MNC O'Rourke P Quint GV Feltkamp MCW Neale RE. Transmission of betapapillomaviruses between domestic partners in an Australian community. Journal of Clinical Virology 47 (3): 216-218. 2010.
Perttila J, Merikanto K, Naukkarinen J, Surakka I, Martin NW, Tanhuanpaa K, Grimard V, Taskinen MR, Thiele C, Salomaa V, Jula A, Perola M, Virtanen I, Peltonen L, Olkkonen VM. OSBPL10, a novel candidate gene for high triglyceride trait in dyslipidemic Finnish subjects, regulates cellular lipid metabolism. Journal of Molecular Medicine. 87(8):825-835. 2009 Pettigrew CA, French JD, Saunus JM, Edwards SL, Sauer AV, Smart CE, Lundstrom T, Wiesner C, Spurdle AB, Rothnagel JA, Brown MA. Identification and functional analysis of novel BRCA1 transcripts, including mouse Brca1-Iris and human pseudo-BRCA1. Breast Cancer Research and Treatment. 119 (1): 239-247. 2010 Phelan CM, Tsai YY, Goode EL, Vierkant RA, Fridley BL, Beesley J, Chen XQ, Webb PM, Chanock S, Cramer DW, Moysich K, Edwards RP, Chang-Claude J, Garcia-Closas M, Yang H, Wang-Gohrke S, Hein R, Green AC, Lissowska J, Carney ME, Lurie G, Wilkens LR, Ness RB, Pearce CL, Wu AH, Van Den Berg DJ, Stram DO, Terry KL, Whiteman DC, Whittemore AS, DiCioccio RA, McGuire V, Doherty JA, Rossing MA, Anton-Culver H, Ziogas A, Hogdall C, Hogdall E, Kjaer SK, Blaakaer J, Quaye L, Ramus SJ, Jacobs I, Song HL, Pharoah PDP, Iversen ES, Marks JR, Pike MC, Gayther SA, Cunningham JM,
Posthuma D, de Koning DJ, Dolan C, Goddard ME, Visscher PM. A Note on Permutation Tests for Genetic Association Analysis of Quantitative Traits When Variances Are Heterogeneous. Genetic Epidemiology. 33(8):710-716. 2009 Powell LW Overview: Liver disease and transplantation. Journal of Gastroenterology and Hepatology. Suppl 3:S97-S104. 2009 Poynter JN, Haile RW, Siegmund KD, Campbell PT, Figueiredo JC, Limburg P, Young J, Le Marchand L, Potter JD, Cotterchio M, Casey G, Hopper JL, Jenkins MA, Thibodeau SN, Newcomb PA, Baronlo JA. Colon Canc Family Registry. Associations between Smoking, Alcohol Consumption, and Colorectal Cancer, Overall and by Tumor Microsatellite Instability Status. Cancer Epidemiology Biomarkers & Prevention. 18(10):2745-2750. 2009 Price MA, Zachariae R, Butow PN, Defazio A, Chauhan D, Espie CA, Friedlander M, Webb PM, Australian Ovarian Canc Study Grp, Australian Ovarian Cancer Study Qual. Prevalence and predictors of insomnia in women with invasive ovarian cancer: Anxiety a major factor. European Journal of Cancer. 45(18):3262-3270. 2009 Pritchard AL Ratcliffe L Sorour E Haque S Holder R Bentham P Lendon CL. Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer's disease. International Journal of Geriatric Psychiatry. 24(9):1020-5. 2009
Prodoehl MJ, Hatzirodos N, IrvingRodgers HF, Zhao ZZ, Painter JN, Hickey TE, Gibson MA, Rainey WE, Carr BR, Mason HD, Norman RJ, Montgomery GW, Rodgers RJ. Genetic and gene expression analyses of the polycystic ovary syndrome candidate gene fibrillin-3 and other fibrillin family members in human ovaries. Molecular Human Reproduction. 15 (12): 829-841. 2009 Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, Sklar P, Ruderfer DM, McQuillin A, Morris DW, O'Dushlaine CT, Corvin A, Holmans PA, Macgregor S, Gurling H, Blackwood DHR, Corvin A, Craddock NJ, Gill M, Hultman CM, Kirov GK, Lichtenstein P, Muir WJ, Owen MJ, Pato CN, Scolnick EM, St Clair D, Craddock NJ, Holmans PA, Williams NM, Georgieva L, Nikolov I, Norton N, Williams H, Toncheva D, Milanova V, Hultman CM, Lichtenstein P, Thelander EF, Sullivan P, Kenny E, Quinn EM, Gill M, Corvin A, Choudhury K, Datta S, Pimm J, Thirumalai S, Puri V, Krasucki R, Lawrence J, Quested D, Bass N, Crombie C, Fraser G, Kuan SL, Walker N, Blackwood DHR, Muir WJ, McGhee KA, Pickard B, Malloy P, Maclean AW, Van Beck M, Wray NR, Macgregor S, Visscher PM, Pato MT, Medeiros H, Middleton F, Carvalho C, Morley C, Fanous A, Conti D, Knowles JA, Ferreira CP, Macedo A, Azevedo MH, Kirby AN, Ferreira MAR, Daly MJ, Chambert K, Kuruvilla F, Gabriel SB, Ardlie K, Moran JL, Daly MJ, Scolnick EM.. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 460(7256):748-752. 2009 Radford-Smith G, Croft A, Doecke J, Walsh A. Outcomes of salvage therapy for acute severe ulcerative colitis Cyclosporin versus Infliximab. Inflammatory Bowel Diseases. 15(12): S43-S44, Suppl. S. 2009 Ramm GA. Chemokine (C-C motif) receptors in fibrogenesis and hepatic regeneration following acute and chronic liver disease. Hepatology. 50(5):1664-1668. 2009 Ramm GA Ruddell RG Subramaniam VN. Identification of ferritin receptors: their role in iron homeostasis hepatic injury and inflammation. Gastroenterology. 137(5):1849-51. 2009 Randall LM Kenangalem E Lampah DA Tjitra E Mwaikambo ED Handojo T Piera KA Zhao ZZ de Labastida Rivera F Zhou Y McSweeney KM Le L Amante FH Haque A Stanley AC Woodberry T Salwati E Granger DL Hobbs MR Price RN Weinberg JB Montgomery GW Anstey NM Engwerda CR. Age-Related Susceptibility to Severe Malaria Associated with Galectin-2 in Highland Papuans. Journal of Infectious Diseases. 202(1):117-124. 2010
Rebbeck TR Mitra N Domchek SM Wan F Chuai S Friebel TM Panossian S Spurdle A ChenevixTrench G, kConFab Singer CF Pfeiler G Neuhausen SL Lynch HT Garber JE Weitzel JN Isaacs C Couch F Narod SA Rubinstein WS Tomlinson GE Ganz PA Olopade OI Tung N Blum JL Greenberg R Nathanson KL Daly MB. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Research. 69(14):5801-10. 2009 Reid DW, Anderson GJ, Lamont IL. Role of lung iron in determining the bacterial and host struggle in cystic fibrosis. American Journal of Physiology – Lung Cellular and Molecular Physiology. 297(5):L795-L802. 2009 Reid H, Vallely A, Taleo G, Tatem AJ, Kelly G, Riley I, Harris I, Henri I, Iamaher S, Clements ACA. Baseline spatial distribution of malaria prior to an elimination programme in Vanuatu. Malaria Journal. 9: article 150. 2010 Richards AA Colgrave ML Jialiang Z Webster J Simpson F Preston E Wilks D Hoehn KL Stephenson M Macdonald GA Prins JB Cooney GJ Xu A Whitehead JP. Sialic Acid Modification of Adiponectin Is Not Required for Multimerization or Secretion but Determines Half-Life in Circulation. Molecular Endocrinology. 24(1):229-39. 2009 Rist M Smith C Bell MC Burrows SR Khanna R. Cross-recognition of HLA DR4 alloantigen by virus-specific CD8+T cells: a new paradigm for self-/nonself-recognition. Blood. 114(11):2244-53. 2009 Rizzi SC Upton Z Bott K Dargaville TR. Recent advances in dermal wound healing: biomedical device approaches. Expert Review of Medical Devices. 7(1):143-54. 2010 Roddam AW, Appleby P, Neale R, Dowsett M, Folkerd E, Tipper S, Allen NE, Key TJ. Association between endogenous plasma hormone concentrations and fracture risk in men and women: the EPIC-Oxford prospective cohort study. Journal of Bone and Mineral Metabolism. 27(4):485-493. 2009 Rogers C, Kvaskoff M, DiSipio T, Youlden D, Whiteman D, Eakin E, Youl PH, Aitken J, Fritschi L. Prevalence and determinants of sunburn in Queensland.Health Promotion Journal of Australia. 20(2):102-6. 2009 Rolfe MI, Mengersen K, Beadle G, Vearncombe K, Andrew B, Johnson HL, Walsh C. Latent class piecewise linear trajectory modelling for short-term cognition responses after chemotherapy for breast cancer patients. Journal of Applied Statistics. 37(5):725-738. 2010
Roque JB, O'Leary CA, KyawTanner M, Latter M, Mason K, Shipstone M, Vogelnest L, Duffy DL. Haplotype sharing excludes canine orthologous Filaggrin locus in atopy in West Highland White Terriers. Animal Genetics. 40(5):793-794. 2009 Ross AG, Hou XY, Chen SX, McManus DP, Li YS. A 36-YearOld Chinese Man with High Fever, Abdominal Pain, Watery Diarrhea, and Myalgia. Clinical Infectious Diseases. 50(9): 1256-+. 2010 Rulli NE, Guglielmotti A, Mangano G, Rolph MS, Apicella C, Zaid A, Suhrbier A, Mahalingam S. Amelioration of Alphavirus-Induced Arthritis and Myositis in a Mouse Model by Treatment With Bindarit, an Inhibitor of Monocyte Chemotactic Proteins. Arthritis and Rheumatism. 60(8):2513-2523. 2009 Ruyssers NE, De Winter BY, De Man JG, Ruyssers ND, Van Gils AJ, Loukas A, Pearson MS, Weinstock JV, Pelckmans PA, Moreels TG. Schistosoma mansoni proteins attenuate gastrointestinal motility disturbances during experimental colitis in mice. World Journal of Gastroenterology.16(6): 03-712. 2010 Sachdev PS, Lammel A, Trollor JN, Lee T, Wright MJ, Ames D, Wen W, Martin NG, Brodaty H, Schofield PR, OATS Res Team. A Comprehensive Neuropsychiatric Study of Elderly Twins: The Older Australian Twins Study. Twin Research and Human Genetics. 12 (6): 573582. 2009 Samaratunga H, Duffy D, Yaxley J, Delahunt B. Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension. Human Pathology. 41 (2): 281-285. 2010 Sandbacka M, Painter J, Puhakka M, Halttunen M, Laivuori H, Aittomaki K. Does the Y chromosome have a role in Mullerian aplasia?. Fertility and Sterility. 94(1):120-125. 2010 Sartor CE Grant JD Bucholz KK Madden PA Heath AC Agrawal A Whitfield JB Statham DJ Martin NG Lynskey MT. Common genetic contributions to alcohol and cannabis use and dependence symptomatology. Alcoholism: Clinical and Experimental Research. 1,34(3):545-54. 2010 Schira MM, Tyler CW, Spehar B, Breakspear M. Modeling Magnification and Anisotropy in the Primate Foveal Confluence. PLOS Computational Biology. 6(1):article -e1000651. 2010 Schira MM, Tyler CW, Breakspear M, Spehar B. The Foveal Confluence in Human Visual Cortex. Journal of Neuroscience. 29(28):9050-9058. 2009 Schroder WA Le TT Major L Street S Gardner J Lambley E Markey K MacDonald KP Fish RJ Thomas R
Suhrbier A. A physiological function of inflammation-associated SerpinB2 is regulation of adaptive immunity. Journal of Immunology 184(5):266370. 2010 Sedegah M, Kim Y, McGrath S, Ganeshan H, Lejano J, Abot S, Banania G, Belmonte M, Sayo R, Farooq F, Doolan DL, Peters B, Bruder J, King CR, Soissons L, Diggs C, Ockenhouse CF, Hollingdale M, Sette A, Richie TL. Identification of HLA restricted CD8+T-cell epitopes on the Plasmodium Falciparum AMA1 protein. American Journal of Tropical Medicine and Hygiene. 81(5):743, Suppl. S. 2009 Selonen V, Hanski IK, Painter JN. Gene flow and natal dispersal in the Siberian flying squirrel based on direct and indirect data. Conservation Genetics. 11 (4): 1257-1264. 2010 Serewko-Auret MM Mould Arne W Loffler KA Duncan R Kay GF Hayward NK. Alternations in Gene Expression in MEN1-Associated Insulinoma Development. Pancreas 00. 2010 Schistosoma japonicum Genome Sequencing and Functional Analysis Consortium, Liu F, Zhou Y, Wang ZQ, Lu G, Zheng H, Brindley PJ, McManus DP, Blair D, Zhang QH, Zhong Y, Wang S, Han ZG, Chen Z. The Schistosoma japonicum genome reveals unique features of host-parasite interplay. Nature 460:345-352 (featured on front cover) Shah SP, Kobel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao YJ, Zeng T, Glover JNM, Vanderhyden B, Zhao CQ, Parkinson CA, Jimenez-Linan M, Bowtell DDL, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG. Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary. New England Journal of Medicine. 360(26):27192729. 2009 Shanks GD, MacKenzie A, Mclaughlin R, Waller M, Dennis P, Lee SE, Brundage JF. Mortality Risk Factors During the 1918-1919 Influenza Pandemic in the Australian Army. Journal of Infectious Diseases. 201(12):1880-1889. 2010 Sheel M Pandey M Good MF Batzloff MR. Correlation between bioluminescence and bacterial burden in passively protected mice challenged with a recombinant bioluminescent M49 group A streptococcus strain. Clinical and Vaccine Immunology 17(1):127-33 2010 Shekar SN Duffy DL Youl P Baxter AJ Kvaskoff M Whiteman DC Green AC Hughes MC Hayward NK Coates M Martin NG. A
103
2009–2010 SCIENTIFIC PUBLICATIONS CONTINUED population-based study of Australian twins with melanoma suggests a strong genetic contribution to liability. Journal of Investigative Dermatology. 129(9):2211-9. 2009 Shi JX, Levinson DF, Duan JB, Sanders AR, Zheng YL, Pe'er I, Dudbridge F, Holmans PA, Whittemore AS, Mowry BJ, Olincy A, Amin F, Cloninger CR, Silverman JM, Buccola NG, Byerley WF, Black DW, Crowe RR, Oksenberg JR, Mirel DB, Kendler KS, Freedman R, Gejman PV. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature. 460(7256):753-757. 2009 Simerska P McGeary RP AbdelAal AB Moyle PM Olive C Good M.F Toth I. Vaccine delivery utilizing liposaccharides. Advances in Experimental Medicine and Biology 611:345-346. 2009 Singh, S, van Hauten, P, Jones, K, Grimmett, K, Mills, AK, Gandhi, MK. Selective accumulation of virusspecific CD8(+) T cells within the peripheral blood stem cell compartment. Blood. 114 (9): 20012003. 2009 Sinilnikova OM, Antoniou AC, Simard J Healey, S Léoné M, Sinnett D, Spurdle AB, Beesley J Chen X, kConFab, Greene MH, Loud JT, Lejbkowicz F, Rennert G, Dishon S, Andrulis IL, OCGN, Domchek SM, Nathanson KL, Manoukian S, Radice P, Konstantopoulou I, Blanco I, Laborde AL, Durán M, Osorio A, Benitez J, Hamann U, Hogervorst FB, van Os TA, Gille HJ, HEBON, Peock S, Cook M, Luccarini C, Evans DG, Lalloo F, Eeles R, Pichert G, Davidson R, Cole T, Cook J, Paterson J, Brewer C, EMBRACE,Hughes DJ, Coupier I, Giraud S, Coulet F, Colas C, Soubrier F, Rouleau E, Bièche I, Lidereau R, Demange L, Nogues C, Lynch HT, GEMO, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Sutter C, Deissler H, Schaefer D, Froster UG, GCHBOC, Aittomäki K, Nevanlinna H, McGuffog L, Easton DF, ChenevixTrench G, Stoppa-Lyonnet D, Consortium of Investigators of Modifiers of BRCA1/2. The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer. 101(8):1456-60. 2009 Sivakumaran H, van der Horst A, Fulcher AJ, Apolloni A, Lin MH, Jans DA, Harrich D. 2009. Arginine Methylation Increases the Stability of Human Immunodeficiency Virus Type 1 Tat. Journal of Virology 83 (22): 11694-11703. 2009 Smith KJ, O'Brien SM, Green AC, Webb PM, Whiteman DC; Study of Digestive Health. Current and past smoking significantly increase
104
QIMR Annual Report 2009/10
risk for Barrett's esophagus. Clinical Gastroenterology & Hepatology. 7(8):840-8. 2009
Neck Journal for the Sciences and Specialties of the Head and Neck. (6):802-806. 2009
Smout MJ, Laha T, Mulvenna J, Sripa B, Suttiprapa S, Jones A, Brindley PJ, Loukas A. A granulinlike growth factor secreted by the carcinogenic liver fluke Opisthorchis viverrini promotes proliferation of host cells. PLoS Pathogens. 5(10):e1000611. 2009
Song HL, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, Dork T, Goode EL, Goodman MT, Schildkraut JM, Sellers T, Baglietto L, Beckmann MW, Beesley J, Blaakaer J, Carney ME, Chanock S, Chen ZH, Cunningham JM, Dicks E, Doherty JA, Durst M, Ekici AB, Fenstermacher D, Fridley BL, Giles G, Gore ME, De Vivo I, Hillemanns
Skaar JR, Richard DJ, Saraf A, Toschi A, Bolderson E, Florens L, Washburn MP, Khanna KK, Pagano M. INTS3 controls the hSSB1mediated DNA damage response. Journal of Cell Biology. 187(1):25-32. 2009 Skinner-Adams TS, Andrews KT, Gardiner DL, McCarthy JS. Understanding the Antimalarial Action of the HIV Protease Inhibitors. American Journal of Tropical Medicine and Hygiene. 81(5):299,Suppl. S. 2009 Skinner-Adams TS, Stack CM, Trenholme KR, Brown CL, Grembecka J, Lowther J ,Mucha A, Drag M, Kafarski P, McGowan S, Whisstock JC, Gardiner DL, Dalton JP. Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials. Trends in Biochemical Science. 35(1):53-61. 2010 Slutske WS, Zhu G, Meier MH, Martin NG. Genetic and Environmental Influences on Disordered Gambling in Men and Women. Archives of General Psychiatry. 67(6):624-630. 2010 Slutske WS, Blaszczynski A, Martin NG. Sex Differences in the Rates of Recovery, Treatment-Seeking, and Natural Recovery in Pathological Gambling: Results From an Australian Community-Based Twin Survey. Twin Research and Human Genetics. 12(5):425-432. 2009 Smeesters PR, McMillan DJ, Sriprakash KS, Georgousakis MM. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines? Expert Review of Vaccines. 2009 Smeesters PR, McMillan DJ, Sriprakash KS. The streptococcal M protein: a highly versatile molecule. Trends in Microbiology. 18(6):275282. 2010. Smith KJ, O’Brien SM, Green AC, Webb PM, Whiteman DC, Study of Digestive Health. Current and past smoking significantly increase risk for Barrett’s esophagus. Clinical Gastroenterology and Hepatology. 7(8):840-8. 2009 Solares CA, Brown I, Boyle GM, Parsons PG, Panizza B. Neural cell adhesion molecule expression: no correlation with perineural invation in cutaneious squamous cell carcinoma of the head and neck. Head and
P, Hogdall C, Hogdall E, Iversen ES, Jacobs IJ, Jakubowska A, Li D, Lissowska J, Lubinski J, Lurie G, McGuire V, McLaughlin J, Medrek K, Moorman PG, Moysich K, Narod S, Phelan C, Pye C, Risch H, Runnebaum IB, Severi G, Southey M, Stram DO, Thiel FC, Terry KL, Tsai YY, Tworoger SS, Van Den Berg DJ, Vierkant RA, WangGohrke S, Webb PM, Wilkens LR, Wu AH, Yang HN, Brewster W, Ziogas A, Houlston R, Tomlinson I, Whittemore AS, Rossing MA, Ponder BAJ, Pearce CL, Ness RB, Menon U, Kjaer SK, Gronwald J, Garcia-Closas M, Fasching PA, Easton DF, Chenevix-Trench G, Berchuck A, Pharoah PDP, Gayther SA. Australian Canc Ovarian Study; Australian Ovarian Canc Study Grp; Ovarian Canc Assoc Consortium. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics. 4 (9) 996-U60. 2009 Spurdle AB. Clinical relevance of rare germline sequence variants in cancer genes: evolution and application of classification models. Current Opinion in Genetics & Development. 20(3):315-23. 2010 Spurdle AB, Lakhani SR, Da Silva LM, Balleine RL, kConFab Investigators Goldgar DE. Bayes analysis provides evidence of pathogenicity for the BRCA1 c.1351G>T (IVS3-1) and BRCA2 c.79771G>C (IVS17-1) variants displaying in vitro splicing results of equivocal clinical significance. Human Mutation. 31(2):E1141-5. 2010 Spurdle AB, Fahey P, Chen X, McGuffog L, kConFab, Easton D, Peock S, Cook M, EMBRACE Simard J, INHERIT Rebbeck TR, MAGIC Antoniou AC, ChenevixTrench G. Pooled analysis indicates that the GSTT1 deletion GSTM1 deletion and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. 122(1):2815. 2010 Sripa B, Mairiang E, Thinkhamrop B, Laha T, Kaewkes S, Sithithaworn P, Tessana S, Loukas A, Brindley PJ, Bethony JM. Advanced Periductal Fibrosis from Infection with the
Carcinogenic Human Liver Fluke Opisthorchis viverrini Correlates with Elevated Levels of Interleukin-6. Hepatology. 50(4):1273-1281. 2009 Stark MS, Tyagi S, Nancarrow DJ, Boyle GM, Cook AL, Whiteman DC, Parsons PG, Schmidt C, Sturm RA, Hayward NK. Characterization of the Melanoma miRNAome by Deep Sequencing. PLoS One. 5(3):e9685. 2010 Steer AC, Batzloff MR, Mulholland K, Carapetis JR. Group A streptococcal vaccines: facts versus fantasy. Current Opinion in Infectious Diseases. 22(6):544-552. 2009 Steer AC, Magor G, Jenney AWJ, Kado J, Good MF, McMillan D, Batzloff M, Carapetis JR. emm and C-Repeat Region Molecular Typing of Beta-Hemolytic Streptococci in a Tropical Country: Implications for Vaccine Development. Journal of Clinical Microbiology. 47 (8): 25022509. 2009 Stringer BW, Day BW, Spanevello MD, Reynolds BA, Carter JC, Cox JM, Ellis VJ, Brown CL, Walker DG, Lickliter JD, Boyd AW. ELK4 Neutralisation sensitises highgrade Glioma to apoptosis through downregulation of the antiapoptotic protein MCL-1. Neuro-oncology. 11 (6): 959-960. 2009 Sturm RA, Larsson M. Genetics of human iris colour and patterns. Pigment Cell & Melanoma Research. 22(5):544-562. 2009 Subramaniam VN. Regulation of Iron Homeostasis: Is it All in the HBD? Gastroenterology. 136(4):1449-51. 2009 Suhrbier A, Mahalingam S. The immunobiology of viral arthritides. Pharmacology and Therapeutics 2009 Summers KM, Bokil NJ, Lu FT, Low JT, Baisden JM, Duffy D, Radford DJ. Mutations at KCNQ1 and an Unknown Locus Cause Long QT Syndrome in a Large Australian Family: Implications for Genetic Testing. American Journal of Medical Genetics. Part A.152A(3):613-621. 2010 Sun C, Zhu G, Wong TY, Hewitt AW, Ruddle JB, Hodgson L, Montgomery GW, Young TL, Hammond CJ, Craig JE, Martin NG, He M, Mackey DA. Quantitative genetic analysis of the retinal vascular caliber: the Australian Twins Eye Study. Hypertension. 54(4):788-95. 2009 Sun XP, Barlow EA, Ma SD, Hagemeier SR, Duellman SJ, Burgess RR, Tellam J, Khanna R, Kenney SC. Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism. Proceedings of the National Academy of Sciences of the United States of America.107(7):3146-3151. 2010
Suraweera A, Lim Y, Woods R, Birrell GW, Nasim T, Becherel, OJ Lavin MF. Functional role for senataxin defective in ataxia oculomotor apraxia type 2 in transcriptional regulation. Human Molecular Genetics. 18(18):3384-96. 2009 Tabakoff B, Saba L, Printz M, Flodman P, Hodgkinson C, Goldman D, Koob G, Richardson HN, Kechris K, Bell RL, Hubner N, Heinig M, Pravenec M, Mangion J, Legault L, Dongier M, Conigrave KM, Whitfield JB, Saunders J, Grant B, Hoffman PL. WHO ISBRA Study State Trait Marker. Genetical genomic determinants of alcohol consumption in rats and humans. BMC Biology 7: article 70. 2009 Tallis C, Boyd P, Ombiga J, Terry S, O'Rourke P, Chin B. Blinded randomised trial of efficacy, acceptance and adherence of standard bowel preparation of "glycoprep" and "fleet" versus "colocap balance (TM)" in bowel preparation for colonoscopy. Journal of Gastroenterology and Hepatology. 24: A254-A254, Suppl. 2. 2009 Tang J, Harper SJ, Wei T, Clover GRG. Characterization of hydrangea chlorotic mottle virus, a new member of the genus Carlavirus. Archives of Virology. 155(1) 7-12. 2010 Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F, Lesueur F, Byrnes GB, Chuang SC, Forey N, Feuchtinger C, Gioia L, Hall J, Hashibe M, Herte B, McKayChopin S, Thomas A, Vallee MP, Voegele C, Webb PM, Whiteman DC, Sangrajrang S, Hopper JL, Southey MC, Andrulis IL, John EM, Chenevix-Trench G. Australian Canc Study, BCFR, Kathleen Cuningham Fdn Consortium. Rare, Evolutionarily Unlikely Missense Substitutions in ATM Confer Increased Risk of Breast Cancer. American Journal of Human Genetics. 85(4):427-446. 2009 Taylor BV, Lucas RM, Dear K, Kilpatrick TJ, Pender MP, van der Mei IAF, Chapman C, Coulthard A, Dwyer T, McMichael AJ, Valery PC, Williams D, Ponsonby AL. Latitudinal variation in incidence and type of first central nervous system demyelinating events. Multiple Sclerosis. 16(4):398-405. 2010 Teng L, Buck M, Scells B, Clarke RA, Samaratunga MLTH, Yaxley J, Gianduzzo T, Coughlin G, Lavin MF, Gardiner RA. Molecular & metabonomic profiling of ejaculate fluid in prostate cancer detection. British Journal of Urology International. 105:004 Suppl 1. 2010 Teng MWL, Andrews DM, McLaughlin N, von Scheidt B, Ngiow SF, Moller A, Hill GR, Iwakura Y, Oft M, Smyth MJ. IL-23 suppresses innate immune response
independently of IL-17A during carcinogenesis and metastasis. Procedings of the National Academy of Sciences of the United States of America. 107(18):8328-8333. 2010 Teng RW, McManus D, Aylward J, Ogbourne S, Armstrong D, Mau SL, Johns J, Bacic A. Biotransformation of ingenol-3-angelate in four plant cell suspension cultures. Biocatalysis and Biotransformation. 27 (3): 186-194. 2009 Thara R, Srinivasan T, John S, Nancarrow D, Chant D, Holliday E, Mowry B. Design and clinical characteristics of a homogeneous schizophrenia pedigree sample from Tamil Nadu, India. Australian and New Journal of Psychiatry. 43 (6): 561570. 2009 Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, Sulem P, Rafnar T, Esko T, Walter S, Gieger C, Rawal R, Mangino M, Prokopenko I, Magi R, Keskitalo K, Gudjonsdottir IH, Gretarsdottir S, Stefansson H, Thompson JR, Aulchenko YS, Nelis M, Aben KK, den Heijer M, Dirksen A, Ashraf H, Soranzo N, Valdes AM, Steves C, Uitterlinden AG, Hofman A, Tonjes A, Kovacs P, Hottenga JJ, Willemsen G, Vogelzangs N, Doring A, Dahmen N, Nitz B, Pergadia ML, Saez B, De Diego V, Lezcano V, Garcia-Prats MD, Ripatti S, Perola M, Kettunen J, Hartikainen AL, Pouta A, Laitinen J, Isohanni M, Huei-Yi S, Allen M, Krestyaninova M, Hall AS, Jones GT, van Rij AM, Mueller T, Dieplinger B, Haltmayer M, Jonsson S, Matthiasson SE, Oskarsson H, Tyrfingsson T, Kiemeney LA, Mayordomo JI, Lindholt JS, Pedersen JH, Franklin WA, Wolf H, Montgomery GW, Heath AC, Martin NG, Madden PAF, Giegling I, Rujescu D, Jarvelin MR, Salomaa V, Stumvoll M, Spector TD, Wichmann HE, Metspalu A, Samani NJ, Penninx BW, Oostra BA, Boomsma DI, Tiemeier H, van Duijn CM, Kaprio J, Gulcher JR, McCarthy MI, Peltonen L, Thorsteinsdottir U, Stefansson K. ENGAGE Consortium. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nature Genetics. (5): 448-U135. 2010 Thurber E, Sturm EC, Douglas G, Leonard JH, Sturm RA. Induction of spheroid cultures from adherent melanoma cell lines to study the heterogenous nature of melanoma tumours. Journal of Investigative Dermatology. 129 (12): 2920-2920. 2009 Tong ENC, Clements ACA, Haynes MA, Jones MA, Morton AP, Whitby M. Improved hospital-level risk adjustment for surveillance of healthcare-associated bloodstream infections: a retrospective cohort study. BMC Infectious Diseases. 9:article 145. 2009
Tonks ID, Mould AW, Schroder WA, Cotterill A, Hayward NK, Walker GJ, Kay GF. Dual loss of rb1 and Trp53 in the adrenal medulla leads to spontaneous pheochromocytoma. Neoplasia. 12(3):235-43. 2010 Tonks ID, Mould AW, Schroder WA, Hacker E, Bosenberg M, Hayward NK, Walker GJ, Kay GF. Melancyte homeostasis in vivo tolerates rb1 loss in a developmentally independent fashion. Pigment Cell & Melanoma Research. Short Communication 2010 Toth I, Moyle PM, Simerska P, Fujita Y, Olive C, Good M.F. Vaccine delivery: synthesis and investigation of a highly pure multi-epitopic lipopeptide vaccine candidate. Advances in Experimental Medicine and Biology 611: 347-349 2009. Tran MH, Freitas TC, Cooper L, Gaze S, Gatton ML,Jones MK, Lovas E, Pearce EJ ,Loukas A. Suppression of mRNAs encoding tegument tetraspanins from Schistosoma mansoni results in impaired tegument turnover. PLoS Pathogens. 6(4):e1000840. 2010 Treloar SA, Bell TA, Nagle CM, Purdie DM, Green AC. Early menstrual characteristics associated with subsequent diagnosis of endometriosis. American Journal or Obstetrics and Gynecology. 202(6):534. 2010 Trenholme KR, Brown CL, SkinnerAdams TS, Stack C, Lowther J, To J, Robinson MW, Donnelly SM, Dalton JP, Gardiner DL. Aminopeptidases of malaria parasites: new targets for chemotherapy. Infectious Disorders Drug Targets. 10(3):217-25. 2010 Turner MS, Andersson P, Bell JM, Turnidge JD, Harris T, Giffard PM. Plasmid-borne blaSHV genes in Klebsiella pneumoniae are associated with strong promoters. Journal of Antimicrobial Chemotherapy 64(5):960-4. 2009 Umapathy A, Whitehall V, Tran K, Grieu F, Hewitt C, Evans TJ, Ismail T, Li W, Collins P, Ravetto P, Fox S, Salto-Tellez M, Soong R, Scott R, Leggett B, Dobrovic A, Iacopetta B. A multicentre study to evaluate k-ras mutation testing methodologies in the clinical setting. Journal of Gastroenterology and Hepatology. 24:A240-A240. Suppl 2. 2009 Ungerer JPJ, Pretorius CJ, Dimeski G, O'Rourke PK, Tyack SA. Falsely elevated troponin I results due to outliers indicate a lack of analytical robustness. Annals of Clinical Biochemistry. 47: 242-247 Part 3. 2010 Upcroft JA, Krauer KG, Burgess AG, Dunn LA, Chen N, Upcroft P. Sequence map of the 3-Mb Giardia duodenalis assemblage A chromosome. Chromosome Research. 17(8):1001-14. 2009
Upcroft JA Dunn LA Wal T Tabrizi S Delgadillo-Correa MG Johnson PJ Garland S Siba P Upcroft P. Metronidazole resistance in Trichomonas vaginalis from highland women in Papua New Guinea. Sexual Health. 6(4):334-8. 2009 Upcroft JA. History of Parasitology at QIMR. In: “The History of Parasitology in Australia” Ed. Beveridge I. and O’Donoghue P.J. Australian Society for Parasitology publication. Raw Publishing Blackburn Victoria Australia 2009. Utzinger J, Raso G, Brooker S, de Savigny D, Tanner M, Ornbjerg N, Singer BH, N'Goran EK. Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. Parasitology. 136(13):18591874. 2009 Valdez CA, Tripp JC, Miyamoto Y, Kalisiak J, Hruz P, Andersen YS, Brown SE, Kangas K, Arzu LV, Davids BJ, Gillin FD, Upcroft JA, Upcroft P, Fokin VV, Smith DK, Sharpless KB, Eckmann L. Synthesis and Electrochemistry of 2-Ethenyl and 2-Ethanyl Derivatives of 5-Nitroimidazole and Antimicrobial Activity against Giardia lamblia. Journal of Medicinal Chemistry. 52(13):4038-4053. 2009 Valery PC Masters IB Taylor B Laifoo Y O'Rourke PK Chang AB. An education intervention for childhood asthma by Aboriginal and Torres Strait Islander health workers: a randomised controlled trial. Medical Journal of Australia. 192(10):574-9. 2010 Van de Horst A Khanna KK. The peptidyl-prolyl isomerise Pin1 regulates cytokinesis through Cep55. Cancer Research. 69(16):6651-9. 2009 Van der Horst A Simmons J Khanna KK. Cep55 stabilization is required for normal execution of cytokinesis. Cell Cycle. 8(22):3742-9. 2009 Van der Pols JC Gunnell D Williams GM Holly JM Bain C Martin RM. Childhood dairy and calcium intake and cardiovascular mortality in adulthood: 65-year follow-up of the Boyd Orr cohort. Heart. 95(19):16006. 2009 Vearncombe KJ, Rolfe M, Wright M, Pachana NA, Andrew B, Beadle G. Predictors of Cognitive Decline After Chemotherapy in Breast Cancer Patients. Journal of the International Neuropsychological Society. 15(6):951-962. 2009 Verderio P Pizzamiglio S Southey MC Spurdle AB Hopper JL Chen X Beesley J, Australian Ovarian Cancer Study Group KConFab Schmutzler RK Engel C Burwinkel B Bugert P Ficarazzi F Manoukian S Barile M Wappenschmidt B Chenevix-Trench G Radice P
105
2009–2010 SCIENTIFIC PUBLICATIONS CONTINUED Peterlongo P. A BRCA1 promoter variant (rs11655505) and breast cancer risk. Journal of Medical Genetics. 47(4):268-70. 2010 Verweij KJH, Zietsch BP, Bailey JM, Martin NG. Shared etiology of risky sexual behaviour and adolescent misconduct: Genetic and environmental influences. Behavior Genetics. 39(6): 687-687. 2009 Verweij KJ, Zietsch BP, Lynskey MT, Medland SE, Neale MC, Martin NG, Boomsma DI, Vink JM. Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies. Addiction. 105(3):41730. 2010 Visscher PM, Montgomery GW. Genome-wide Association Studies and Human Disease: From Trickle to Flood. Journal of the American Medical Association. 302(18):2028-9. 2009 Visscher PM, Hill WG. The limits of individual identification from sample allele frequencies: theory and statistical analysis. PLoS Genetics 5(10) e1000628. 2009 Visscher PM, Goddard ME. Systems genetics: the added value of gene expression. HFSP Journal. 4(1):6-10. 2010 Vounatsou P, Raso G, Tanner M, N'Goran EK, Utzinger J. Bayesian geostatistical modelling for mapping schistosomiasis transmission. Parasitology. 136(13):1695-1705. 2009. Vu LH, van der Pols JC, Whiteman DC, Kimlin MG, Neale RE. Knowledge and Attitudes about Vitamin D and Impact on Sun Protection Practices among Urban Office Workers in Brisbane Australia. Cancer Epidemiology Biomarkers & Prevention. 19(7):1784-9. 2010 Wainwright CE, France MW, O'Rourke P, Anuj S, Kidd TJ, Nissen MD, Sloots TP, Coulter C, Ristovski Z, Hargreaves M, Rose BR, Harbour C, Bell SC, Fennelly KP. Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis. Thorax. 64(11):926-931. 2009. Waldron M, Heath AC, Martin NG. Alcohol dependence predicts delayed marriage in men: Findings in Australian twins. Behavior Genetics. 39(6):688-689. 2009 Waldron M, Martin NG, Heath AC. Parental Alcoholism and Offspring Behavior Problems: Findings in Australian Children of Twins. Twin Research and Human Genetics. 12(5):433-440. 2009 Walker G, Gabrielli B, Box N, Takahiro K, Muller HK. Kit signalling in melanoma and the melanocyte proliferative response to UVR. Journal of Investigative Dermatology. 29(12):2922-2922. 2009.
106
QIMR Annual Report 2009/10
Walker LC, Thompson BA, Waddell N, kConFab Investigators, Grimmond SM, Spurdle AB. Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients. PLoS Genetics. 6(2):e1000850. 2010 Walker LC, Whiley PJ, Couch FJ, Farrugia DJ, Healey S, Eccles DM, Lin F, Butler SA, Goff SA, Thompson BA, Lakhani SR, Da Silva LM, kConFab Investigators Tavtigian SV Goldgar DE Brown MA Spurdle AB. Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. Human Mutation. 31(6):E1484-505. 2010 Wallace AE, Sales KJ, Catalano RD, Anderson RA, Williams ARW, Wilson MR, Schwarze J, Wang HW, Rossi AG, Jabbour HN. Prostaglandin F-2 alpha-F-Prostanoid Receptor Signaling Promotes Neutrophil Chemotaxis via Chemokine (C-X-C Motif) Ligand 1 in Endometrial Adenocarcinoma. Cancer Research. 6 (14) 5726-5733. 2009 Wallace DF, Harris JM, Subramaniam VN. Functional analysis and theoretical modeling of ferroportin reveals clustering of mutations according to phenotype. American Journal of Physiology Cell Physiology. 298(1):C75-84. 2010 Wallace DF, Summerville L, Crampton EM, Frazer DM, Anderson GJ, Subramaniam VN. Combined deletion of Hfe and transferrin receptor 2 in mice leads to marked dysregulation of hepcidin and iron overload. Hepatology. Dec,50(6):1992-2000. 2009 Wallace DF Trinder D Subramaniam VN. Hepcidin regulation by HFE and TFR2: is it enough to give a hepatocyte a complex? Gastroenterology. 137(3):1173-5,discussion 1175. 2009 Wallace GL, Lee NR, PromWormley EC, Medland SE, Lenroot RK, Clasen LS, Schmitt JE, Neale MC, Giedd JN. A Bivariate Twin Study of Regional Brain Volumes and Verbal and Nonverbal Intellectual Skills During Childhood and Adolescence. Behavior Genetics. 40(2): 125-134, Sp. Iss. SI. 2010. Walsh MD, Buchanan DD, Cummings MC, Pearson SA, Arnold ST, Clendenning M, Walters R, McKeone DM, Spurdle AB, Hopper JL, Jenkins MA, Phillips KD, Suthers GK, George J, Goldblatt J, Muir A, Tucker K, Pelzer E, Gattas MR, Woodall S, Parry S, Macrae FA, Haile RW, Baron JA, Potter JD, Le Marchand L, Bapat B, Thibodeau SN, Lindor NM, McGuckin M,A Young JP. Lynch syndrome-associated breast cancers: clinicopathologic characteristics of
a case series from the colon cancer family registry. Clinical Cancer Research. 16(7):2214-24. 2010 Walsh MD, Buchanan DD, Walters R, Roberts A, Arnold S, McKeone D, Clendenning M, Ruszkiewicz AR, Jenkins MA, Hopper JL, Goldblatt J, George J, Suthers GK, Phillips K, Young GP, Macrae F, Drini M, Woods MO, Parry S, Jass JR, Young JP. Analysis of families with Lynch syndrome complicated by advanced serrated neoplasia: the importance of pathology review and pedigree analysis. Familial Cancer. 8(4):313-323. 2009 Walsh MJ, Lewindon PJ, Shepherd RW, Greer RM, Williamson R, Pereira TN, Frawley K, Bell S, Smith JL, Ramm GA. Detection and followup of hepatic fibrosis in cystic fibrosis: a role for diagnostic liver biopsy and serum markers in evaluating outcomes of cystic fibrosis liver disease. Journal of Gastroenterology and Hepatology. 24:A225-A225, Suppl. 2. 2009 Wang X Pankratz VS Fredericksen Z Tarrell R Karaus M McGuffog L Pharaoh PD Ponder BA Dunning AM Peock S Cook M Oliver C Frost D, EMBRACE Sinilnikova OM Stoppa-Lyonnet D Mazoyer S Houdayer C, GEMO Hogervorst FB Hooning MJ Ligtenberg MJ, HEBON Spurdle A ChenevixTrench G, kConFab Schmutzler RK Wappenschmidt B Engel C Meindl A Domchek SM Nathanson KL Rebbeck TR Singer CF Gschwantler-Kaulich D Dressler C Fink A Szabo CI Zikan M Foretova L Claes K Thomas G Hoover RN Hunter DJ Chanock SJ Easton DF Antoniou AC Couch FJ. Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics. 19(14):2886-97. 2010 Warrilow D Tachedjian G Harrich D. Maturation of the HIV reverse transcription complex: putting the jigsaw together. Reviews in Medical Virology. 19(6):324-37 2009. Waterboer T, Neale R, Michael KM, Sehr P, de Koning MNC, Weissenborn SJ, Sampogna F, Abeni D, Green AC, Bavinck JNB, Pawlita M. EPI HPV UV CA Grp. Antibody responses to 26 skin human papillomavirus types in the Netherlands, Italy and Australia. Journal of General Virology. 90:19861998, Part 8. 2009 Webbink D, Martin NG, Visscher PM. Does education reduce the probability of being overweight?. Journal of Health Economics. 29(1):29-38. 2010 Weissenborn SJ, Neale R, de Koning MNC, Waterboer T, Abeni D, Bavinck JNB, Wieland U, Pfister HJ. EPI-HPV-UV-CA Grp. Prevalence and multiplicity of cutaneous beta
papilloma viruses in plucked hairs depend on cellular DNA input. Journal of Virological Methods. 161(2):280283. 2009 Whiley PJ Pettigrew CA Brewster BL Walker LC, kConFab Investigators Spurdle AB Brown MA. Effect of BRCA2 sequence variants predicted to disrupt exonic splice enhancers on BRCA2 transcripts. BMC Medical Genetics. 11:80. 2010 Whisstock JC, McGowan S, Trenholme KR, Gardiner DL, Dalton JP. Reply to Klemba: Intracellular processing of the membrane-bound PfA-M1 neutral aminopeptidase, a target for new antimalarials. Proceedings of the National Academy of Sciences of the United States of America. 106(22):E56-E56. 2009 Whitehall V, Tran K, Umapathy A, Grieu F, Hewitt C, Evans TJ, Ismail T, Li WQ, Collins P, Ravetto P, Leggett B, Salto-Tellez M, Soong R, Fox S, Scott RJ, Dobrovic A, Iacopetta B. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. Journal Molecular Diagnostics. 11(6):543-52. 2009 Whiteman DC. Testing the divergent pathway hypothesis for melanoma: recent findings and future challenges. Expert Review of Anticancer Therapy. 10(5):615-8. 2010 Whiteman DC, Parmar P, Fahey P, Moore SP, Stark M, Zhao ZZ, Montgomery GW, Green AC, Hayward NK, Webb PM for the Australian Cancer Study. Helicobacter pylori infection and esophageal cancer: exploring potential environmental and genetic modifiers of the effect. Gastroenterology. 139(1):73-83. 2010 Whitfield JB, Dy V, McQuilty R, Zhu G, Heath AC, Montgomery GW, Martin NG. Genetic effects on toxic and essential elements in humans: arsenic cadmium copper lead mercury selenium and zinc in erythrocytes. Environmental Health Perspectives. 118(6):776-82. 2010 Whitfield, JB. Molecular biology and genetics in clinical chemistry and laboratory medicine. Clinical Chemistry and Laboratory Medicine. 48(4):431-434. 2010 Wieser T, Dresler K, Evers S, Gaul C, Konig D, Holzl D, Berger K, Nyholt D, Deufel T. No Influence of 5-HTTLPR Gene Polymorphism on Migraine Symptomatology, Comorbid Depression, and Chronification. Headache. 50(3):420-430. 2010 Williams A, O'Rourke P, Keogh S. Making choices: why parents present to the emergency department for non-urgent care. Archives of Disease in Childhood. 94(10):817-820. 2009
Wilson R, Diseberg AF, Gordon L, Zivkovic S, Tatarczuch L, Mackie EJ, Gorman JJ, Bateman JF. Comprehensive Profiling of Cartilage Extracellular Matrix Formation and Maturation Using Sequential Extraction and Label-free Quantitative Proteomics. Molecular & Cellular Proteomics. 9(6):1296-1313. 2010 Wood MJ, Skoien R, Powell LW. The global burden of iron overload. Hepatology International. 3(3):434444. 2009 Wooldridge L, Clement M, Lissina A, Edwards ESJ, Ladell K, Ekeruche J, Hewitt RE, Laugel B, Gostick E, Cole DK, Debets R, Berrevoets C, Miles JJ, Burrows SR, Price DA, Sewell AK. MHC Class I Molecules with Superenhanced CD8 Binding Properties Bypass the Requirement for Cognate TCR Recognition and Nonspecifically Activate CTLs. Journal of Immunology. 184(7):3357-3366. 2010 Worthley DL, Johnson DF, Eisen DP, Dean MM, Heatley SL, Tung JP, Scott J, Padbury RT, Harley HA, Bardy PG, Angus PW, Mullighan CG. Donor mannose-binding lectin deficiency increases the likelihood of clinically significant infection after liver transplantation. Clinical Infectious Diseases. 48(4):410-7. 2009 Worthley DL, Leleu R, Whitehall V, Conlon M, Christophersen C, Belobrajdic D, Mallitt K, Ogino S, Irahara N, Leggett B, Young G. A human, double-blind, placebocontrolled, cross-over trial of prebiotic, probiotic and synbiotic supplementation: effects on luminal, inflammatory, epigenetic and epithelial biomarkers of colorectal cancer. Journal of Gastroenterology and Hepatology. 24:A239-A239, Suppl. 2. 2009 Worthley DL, Whitehall VL, Bampton P, Prosser R, Simms L, Ogino S, Irahara N, RadfordSmith G, Legget BA. Chronic colitis is associatied with significant hypomethylation of LINE-1 within the colorectal mucosa. Journal of Gastroenterology and Hepatology. 24: A242-A242, Suppl. 2. 2009 Worthley DL ,Whitehall VL, Buttenshaw RL, Irahara N, Greco SA, Ramsnes I, Mallitt KA, Le Leu RK, Winter J, Hu Y, Ogino S, Young GP, Leggett BA. DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer. Oncogene. 29(11):1653-62. 2010 Worthley Daniel L, Leggett Barbara A. Colorectal Cancer : Molecular Features and Clinical Opportunities. Clinical Biochemists Reviews. 31 2010
Worthley DL, Hewett DG, Spring K, Whitehall VL, Leggett BA. Proximal serrated polyps: inconspicuous but not inconsequential. Re: Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. Journal of the National Cancer Institute in press (letter) 2010 Wray NR, Visscher PM. Narrowing the boundaries of the genetic architecture of schizophrenia. Schizophrenia Bulletin 36(1):14-23. 2010 Wray NR, Goddard ME. Multi-locus models of genetic risk of disease. Genome Medicine. 2(2):10. 2010 Wray NR, Yang J, Goddard ME, Visscher PM. The genetic interpretation of area under the ROC curve in genomic profiling. PLoS Genetics. 6(2):e1000864. 2010 Wray NR, James MR, Gordon SD, Dumenil T, Ryan L, Coventry WL, Statham DJ, Pergadia ML, Madden PA, Heath AC, Montgomery GW, Martin NG. Accurate Large-Scale Genotyping of 5HTTLPR and Flanking Single Nucleotide Polymorphisms in an Association Study of Depression Anxiety and Personality Measures. Biological Psychiatry. 2009 66(55):468-76 Wright JM Webb RI O'Donoghue P Upcroft P Upcroft JA. Hydrogenosomes of LaboratoryInduced Metronidazole-Resistant Trichomonas vaginalis Lines are Down Sized While Those from Clinically Metronidazole-Resistant Isolates Are Not. Journal Of Eukaryotic Microbiology. 57 2: 171-176. 2009 Wykes MN Good MF. What have we learnt from mouse models for the study of malaria? European Journal of Immunology. 39(8):2004-7. 2009 Wynn KK Crough T Campbell S McNeil K Galbraith A Moss DJ Silins SL Bell S Khanna R. Narrowing of T-cell receptor beta variable repertoire during symptomatic herpesvirus infection in transplant patients. Immunology and Cell Biology. 88(2):125-35. 2010 Yang J Benyamin B McEvoy BP Gordon S Henders AK Nyholt DR Madden PA Heath AC Martin NG Montgomery GW Goddard ME Visscher PM. Common SNPs explain a large proportion of the heritability for human height. Nature Genetics. 42(7):565-9. 2010 Yang YR Gray DJ Ellis MK Yang SK Craig PS McManus DP. Human cases of simultaneous echinococcosis and tuberculosis - significance and extent in China. Parasites & Vectors. 2(1):53. 2009 Yang YR, Craig PS, Ito A, Giraudoux P, Zhang JZ, McManus DP. A rodent species (spermophilus dauricus) infected with Echinococcus Granulosus in Ningxia China: A potentially new mode of hydatid transmission. American Journal of Tropical Medicine and Hygiene. 81(5):55, Suppl S. 2009
Yang YR, Liu TX, Bai XL, Boufana B, Craig PS, Nakao M, Ito A, Zhang JZ, Giraudoux P, McManus DP. Natural Infection of the Ground Squirrel (Spermophilus spp.) with Echinococcus granulosus in China. PLOS Neglected Tropical Diseases. 3(9):article e518. 2009 Yang J, Wray NR, Visscher PM. Comparing apples and oranges: equating the power of case-control and quantitative trait association studies. Genetic Epidemiology. 34(3):257-7. 2010 Yang JZ, Zhao ZY, Li YS, Krewski D, Wen SW. A multi-level analysis of risk factors for Schistosoma japonicum infection in China. International Journal of Infectious Diseases. 13 (6):E407-E412. 2009 You H, Zhang W, Jones MK, Gobert GN, Mulvenna J, Rees G, Spanevello M, Blair D ,Duke M, Brehm K, McManus DP. Cloning and characterisation of Schistosoma japonicum insulin receptors. PLoS One. 5(3):e9868. 2010 You H, Zhang WB, Moertel L, McManus DP, Gobert GN. Transcriptional profiles of adult male and female Schistosoma japonicum in response to insulin reveal increased expression of genes involved in growth and development. International Journal for Parasitology. 39(14): 1551-1559. 2009 Zaman M, Abdel-Aal AM, Phillipps KSM, Fujita Y, Good MF, Toth I. Structure-activity relationship of lipopeptide Group A streptococcus (GAS) vaccine candidates on toll-like receptor 2. Vaccine. 28(10):22432248. 2010 Zhan B, Perally S, Brophy PM, Xue J, Goud G, Liu S, Deumic V, de Oliveira LM, Bethony J, Bottazzi ME, Jiang D, Gillespie P, Xiao SH, Gupta R, Loukas A, Ranjit N, Lustigman S, Oksov Y, Hotez P. Molecular cloning biochemical characterization and partial protective immunity of the heme-binding glutathione S-transferases from the human hookworm Necator americanus. Infection & Immunity. 78(4):1552-63. 2010 Zhan L, Leow AD, Jahanshad N, Chiang MC, Barysheva M, Lee AD, Toga AW, McMahon KL, de Zubicaray GI, Wright MJ, Thompson PM. How does angular resolution affect diffusion imaging measures?. Neuroimage. 49(2):13571371. 2010
Zhang WB, Zhang ZZ, Yimit T, Shi BX, Aili H, Tulson G, You H, Li J, Gray DJ, McManus DP, Wang JC. A Pilot Study for Control of Hyperendemic Cystic Hydatid Disease in China. PLOS Neglected Tropical Diseases. (10):article e534. 2009 Zhong J, Khanna R. Ad-gBCMVpoly: A novel chimeric vaccine strategy for human cytomegalovirus-associated diseases. Journal of Clinical Virology. 46 Suppl 4:S68-72. 2009 Zhong W, Skwarczynski M, Fujita Y, Simerska P, Good MF, Toth I. Design and Synthesis of LipopeptideCarbohydrate Assembled Multivalent Vaccine Candidates Using Native Chemical Ligation. Australian Journal of Chemistry. 62(9):993-999. 2009 Zhou Y, Zheng HJ, Chen YY, Zhang L, Wang K, Guo J, Huang Z, Zhang B, Huang W, Jin K, Dou TH, Hasegawa M, Wang L, Zhang Y, Zhou J, Tao L, Cao ZW, Li YX, Vinar T, Brejova B, Brown D, Li M, Miller DJ, Blair D, Zhong Y, Chen Z, Hu W, Wang ZQ, Zhang QH, Song HD, Chen SJ, Xu XN, Xu B, Ju C, Huang YC, Brindley PJ, McManus DP, Feng Z, Han ZG, Lu G, Ren SX, Wang YZ, Gu WY, Kang H, Chen J, Chen XY, Chen ST, Wang LJ, Yan J, Wang BY, Lv XY, Jin L, Wang BF, Pu SY, Zhang XL, Zhang W, Hu QP, Zhu GF, Wang J, Yu J, Wang J, Yang HM, Ning ZM, Beriman M, Wei CL, Ruan YJ, Zhao GP, Wang SY, Liu F, Wang ZQ, Zheng HJ, Zhang QH, Wang SY, Han ZG. Schistosoma Japonicum Genome Seque. The Schistosoma japonicum genome reveals features of host-parasite interplay. Nature. 460(7253):345-U56. 2009 Zietsch BP, Verweij KJ, Bailey JM, Wright MJ, Martin NG. Genetic and environmental influences on risky sexual behaviour and its relationship with personality. Behavioral Genetics. 40(1):12-21. 2010 Zou YY, Su ZX, Yang J, Zeng YW, Gu X. 2009. Uncovering Genetic Regulatory Network Divergence Between Duplicate Genes Using Yeast eQTL Landscape. Journal of Experimental Zoology Part B – Molecular and Developmental Evolution. 312B(7):722-733. 2009
Zhang N, Fu ZX, Linke S, Chicher J, Gorman JJ, Visk D, Haddad GG, Poellinger L, Peet DJ, Powell F, Johnson RS. The Asparaginyl Hydroxylase Factor Inhibiting HIF-1 alpha Is an Essential Regulator of Metabolism. Cell Metabolism. 11(5):364-378. 2009
107
INVITED LECTURES AND PRESENTATIONS 2009-2010 PROFESSOR GREG ANDERSON Mechanisms of iron homeostasis in the perinatal period
Department of Biochemistry, University of Otago, Dunedin, New Zealand, December 2009
Body iron absorption and trafficking
Laboratory for Nonoscience and Technology, Chinese Academy of Sciences, Beijing, China, April 2010
Body iron absorption and trafficking
Institute of Molecular Neurobiology and Neuropharmacology, Hebei Normal University, Shijiazhuong, China, April 2010
Adaptations in iron homeostasis in early post natal life
Veterans Affairs Longbeach Healthcare System, Long Beach, CA, USA, April 2010
The molecular basis of intestinal iron absorption and its regulation
FASEB - Experimental Biology 2010, Anaheim, CA, USA, April 2010
New aspects of the absorption of iron - an essential trace element
CAS Institute for Nutritional Sciences, Shanghai, China, June 2010
The molecular basis of body iron trafficking
School of Chemical and Molecular Biosciences, University of Queensland, Brisbane, March 2010
DR KATHY ANDREWS Targeting histone deacetylases for malaria therapy
Department Seminar, University of Florida, USA, November 2009
Malaria drug discovery: from trees to targets
Queensland Institutes of Health Forum, Townsville, November 2009
Negotiating the Global Research Environment
Women in Research Leadership program, Brisbane, June 2010
DR SIMON APTE Analyzing CD8+ T cell function with flow cytometry
Australasian Flow Cytometry Group conference, Brisbane, November 2009
IFNg and IL-4 as master regulators of CD8 T cell function and phenotype
University of Melbourne, Melbourne, VIC, February 2010
DR JULIE BALEN Global public health: what a human security framework can bring to the discourse
Infectious Diseases, Security and Ethics, University of Sydney, February 2010
DR BEBEN BENYAMIN For genes affecting iron status in general populations: a GWAS approach
Australian Medical Bioinformatics Resources (AMBeR) Scientific Meeting, Brisbane, August 2009
Genetics of iron status
The Centers for Disease Control and Prevention (CDC), Division of Blood Disorder’s 2009 Iron Overload Conference, USA, September 2009
Panel member
The Centers for Disease Control and Prevention (CDC), Division of Blood Disorder’s 2009 Iron Overload Conference, USA, September 2009
MS GABRIELLA BLOKLAND Quantifying the heritability of task-related brain activation and performance during the N-back working memory task: A twin fMRI study.
UQ Psychiatry Research Seminar, Brisbane, November 2009
PROFESSOR ANDREW BOYD Eph receptors in cancer and development.
Cell Signalling in Cancer and Development, Adelaide, November 2009
Novel approaches to glioma therapy
QBI Retreat, Noosa Heads, October 2009
EphA3 as a target for leukaemia therapy
New Directions in Leukaemia Research, Twin Waters, March 2010
Eph receptors in cancer
Curie Institute, Paris, December 2009
The role of EphA4 in spinal cord development
Frontiers in Spinal Cord Research, Brisbane, September 2009
PROFESSOR MICHAEL BREAKSPEAR Multistability of Brain Rhythms
Brain Connectivity Workshop, Berlin, Germany, June 2010
The Nonlinear Brain
Opening Symposium of the Laboratory for Social and Neural Systems Research, Zurich, Switzerland, June 2010
Nonlinear Brain Dynamics
Human Brain Mapping, Barcelona, Spain,June 2010
Multistable and Hierarchical Cortical Dynamics
Computational Neurosciences meeting, Max Planck Institute for Complex Systems, Dresden, Germany, November 2009
Modelling Nonlinear Brain Dynamics
Brain Modes Meeting, Bristol, UK, December 2009
Multistable and Hierarchical Cortical Dynamics
Computational Medicine Meeting, Chinese Academy of Sciences, Beijing, November 2009
Computational Models of the Brain
Winter School in Computational Biology, Brisbane, July 2009
Brain Network Perturbation in Schizophrenia
Royal Brisbane and Women's Hospital Health Care Symposium, Brisbane, October 2009
On Criticality and Perception in the Human Brain
Australian Society for Cognitive Sciences, Sydney, September, 2009
MS REBEKAH BRENNAN Sequence polymorphism in the human TCR loci and its influence on herpes virus infection
108
QIMR Annual Report 2009/10
Frontiers in Immunology Research Network, Kona, Hawaii, July 2009
INVITED LECTURES AND PRESENTATIONS 2009-2010 CONTINUED ASSOCIATE PROFESSOR SCOTT BURROWS Allelic polymorphism in the T-cell receptor loci and its impact on antiviral immunity
Australasian Society for Immunology, Gold Coast, December 2009
The Specificity/Degeneracy of T Cell Recognition
“Eijkman Lecture”, Infection & Immunity Center, Utrecht, The Netherlands, May 2010
Allelic polymorphism in the T-cell receptor loci and its functional and structural impact on antiviral immunity
7th International Congress on Autoimmunity, Ljubljana, Slovenia, May 2010
Allelic polymorphism in the T-cell receptor loci and its functional and structural impact on antiviral immunity
4th MASIR Conference (Measuring Antigen-Specific Immune Responses), Mykonos, Greece, June 2010
PROFESSOR GEORGIA CHENEVIX-TRENCH Chemoresponse in ovarian cancer
AACR, USA, April 2010
DR QIN CHENG Update on HRP2 antigen polymorphism, including gene deletions, and its effect on RDT performance and product testing/lot testing of malaria RDTs
WHO Technical Consultation on Parasitological Confirmation of Malaria Diagnosis, Geneva, Switzerland, October 2009
Parasite densities and fever in malaria infections in Temotu, Solomon Islands
WHO Technical Consultation on Parasitological Confirmation of Malaria Diagnosis, Geneva, Switzerland, October 2009
P. falciparum pyrogenic threshold in naive individuals
WHO Technical Consultation on Parasitological Confirmation of Malaria Diagnosis, Geneva, Switzerland, October 2009
Selection of malaria RDTs in South America
58th ASTMH annual meeting, Washington DC, USA, November 2009
DR SUYINN CHONG Maternal ethanol consumption alters the epigenotype and phenotype of offspring in a mouse model
Griffith Medical Research College Retreat, Brisbane, June 2009
Epigenetics and the determination of phenotype
Epigenetics 2009 Australian Scientific Conference, Melbourne, January 2009
Maternal ethanol consumption alters the epigenotype and the phenotype of offspring in a mouse model
Queensland Brain Institute Symposium: Epigenomics, Behaviour & Disease, Brisbane, March 2010
PROFESSOR DENISE DOOLAN Genome Credentialing and Malaria Vaccine Development
“Malaria Vaccine – Fact or Fantasy?” Symposium. 2009 Joint Meeting of the Australian Society for Parasitology and the ARC/NHMRC Research Network for Parasitology. Sydney, July 2009
qRT-PCR evaluation of malaria immunity in infants.
AgeMal Consortium, Barcelona, Spain, September 2009
Immunomics & Malaria Vaccine Development
University of Melbourne, Melbourne, October 2009
The Search for the Holy Grail – a universal cross-species malaria vaccine.
Pfizer Australia, Melbourne, October 2009
Attenuated whole organism sporozoite vaccines for malaria symposium: Plasmodium immunomics.
58th American Society of Tropical Medicine and Hygiene Meeting. Washington, DC, USA., November 2009
Immunomics & Malaria Vaccine Development
La Jolla Institute of Allergy and Immunology., November 2009
Protein arrays for malaria vaccine development.
Australian Society of Immunology Conference. Gold Coast, December 2009
MR PATRICK DRIGUEZ Development and Immunoscreening of an Immunomics Protein Microarray to Investigate Asian Schistosomiasis
Hunan Institute of Parasitic Diseases, Yueyang, Jiangxi Provincial Institute of Parasitic Diseases, Nanchang, Nanjing Medical University, Nanjing and National Institute of Parasitic Diseases, Shanghai, China, May 2010
ASSOCIATE PROFESSOR CHRISTIAN ENGWERDA Changes in malaria-specific CD4+ T cell responses following vaccination and co-infection
ARC/NHMRC Research Network for Parasitology Conference, Sydney July 2009
T cells mediate parasite tissue sequestration during experimental cerebral malaria
Australian Society for Immunology, Gold Coast, December 2009
The pathogenesis of experimental cerebral malaria: The role of the host immune response
Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, UK, November 2009
DR MANUEL FERRIERA Association Mapping
WEHI - Postgraduate Teaching Course - seminar series, Melbourne May 2010
DR KATJA FISCHER Detecting Complement Deficiencies
Workshop at the 12th European Meeting on Complement in Human Disease, Visegrad, Hungary, September 2009
Scabies mite inactivated serine protease paralogs inhibit the human complement system
Sixth General International Meeting of the International Proteolysis Society, Surfers Paradise, October 2009
109
INVITED LECTURES AND PRESENTATIONS 2009-2010 CONTINUED ASSOCIATE PROFESSOR MAHER GANDHI The B and T of EBV
Mater Medical Research Institute, Brisbane, November 2009
EBV as a model of immunity
Pathology Dept, Royal Brisbane Hospital, Brisbane, July 2009
Chronic Myeloid Leukaemia
Human Immunology Society, Brisbane May 2010
EBV-positive Lymphomas
British Society of Immunology, Wales, June 2010
DR MICHELLE GATTON An overview of Round 2 Malaria RDT product testing results
WHO Specimen Bank Steering Committee, Bangkok, Thailand, February 2010
Analyzing the bench performance of malaria RDTs
58th ASTMH annual meeting, Washington DC, USA, November 2009
An overview of the VEDS System for mosquito-borne disease surveillance
Communicable Diseases Unit, Queensland Health, Brisbane, Australia, June 2010
ASSOCIATE PROFESSOR DON GARDINER Aminopeptidase inhibitors
Scripps Research Centre, Jupiter, USA, November 2009
ASSOCIATE PROFESSOR GAIL GARVEY Closing the divide: Understanding the reasons for poorer cancer outcomes in Indigenous Queenslanders.
National Maori Cancer Forum 2009 – Revolution of cancer care for Maori and Whanau, NZ, August 2009
Improving the health of Aboriginal and Torres Strait Islander children through research
Queensland Health, Brisbane, May 2010
DR GEOFF GOBERT Microarray Studies of the Schistosoma japonicum lifecycle
Veterinary Research Institute, Xinjiang Academy of Animal Science, Urumqi and College of Veterinary Medicine, South China Agricultural University, Guangzhou, China, July 2010
PROFESSOR MICHAEL GOOD
110
The Future of Infectious Diseases
50th Australian Medical Student’s Association (AMSA) National Convention, Brisbane, July 2009
Malaria Vaccine: Fact or Fantasy?
2009 Australian Parasitology Conference, Sydney, July 2009
Prevention and early intervention approaches to tackle chronic diseases
Social Development Committee Inquiry into Chronic Diseases, Parliament House, Brisbane, August 2009
Vaccines for the developing world – status of rheumatic fever
Barbara Ell Seminar Series, Victor Chang Cardiac Research Institute, Sydney, August 2009
Recent developments in QIMR Research
Kowloon Rotary Club, Hong Kong, October 2009
Progress on the NPC Immunotherapy Study
Dynasty Club, Hong Kong, October 2009
Developing vaccines for the world’s poorest. Do hidden molecules hold the key?
The Nancy Millis Lecture, La Trobe University, Melbourne, October 2009
QIMR and the Leukaemia Foundation
Leukaemia Foundation of Queensland Annual State Conference, Brisbane, October 2009
Developing vaccines for the world’s poorest
Warren Jones Oration, Fremantle Hospital Medical Research Foundation, Perth, October 2009
The challenges of developing vaccines for the world’s poorest
School of Biomolecular and Physical Sciences, Griffith University, Nathan Campus, Brisbane, November 2009
Enduring lessons from a student’s life
QUT IHBI Postgraduate Student Conference, Brisbane, November 2009
The immunological challenges of developing vaccines for variant organisms. Do hidden molecules hold the key?
School of Chemistry and Molecular Biosciences 5th Annual Research Students Symposium, University of Queensland, Brisbane, November 2009
The importance of clinical leadership in improving health care
NHMRC NICS Implementation Fellows Graduation, Brisbane, November 2009
Suppressed immune responses and hidden epitopes: the keys to unlocking the challenges to the next generation of vaccines
10th FIMSA Immunology Training Course, Tangalooma, December 2009
From a mug punter to directing medical research – has anything changed?
ASI 2009, Gold Coast, December 2009
The importance of science education
The importance of science education, Brisbane, February 2010
The Inaugural Eureka Moments Address
Australian Museum, Sydney, March 2010
Our progress towards making a malaria vaccine
Rotary District 9600 Conference, Caloundra, March 2010
Address to Graduands
The University of South Australia Graduation Ceremony, Adelaide, March 2010
Malaria vaccines: Lessons from immune escape instruct new strategies
Keystone Symposium (Malaria: New Approaches to Understanding Host-Parasite Interactions), Colorado, USA, April 2010
Graduation Address
University of Sydney Faculty of Medicine, Sydney, May 2010
QIMR Annual Report 2009/10
PROFESSOR JEFFREY GORMAN Proteomic dissection of RSV-host cell interactions
Laboratory of Infectious Diseases Seminar at the National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD US, April 2010
Human respiratory syncytial virus proteins suppress host cell innate antiviral responses via interferon-dependent and -independent pathways
Lorne Protein Structure and Function Conference, Lorn, Australi, Feb 2010
Human respiratory syncytial virus proteins suppress host cell innate antiviral responses via interferon-dependent and -independent pathways
ComBio2009, Christchurch, New Zealand, 2009
Human respiratory syncytial virus proteins suppress host cell innate antiviral responses
Australian Peptide Conference, Couran Cove, Australi, 2009
PROFESSOR ADÈLE GREEN Insights from epidemiological studies
European Society of Photobiology, Wroclaw, Poland, September 2009
Causes and preventability of skin cancer
Children's Cancer Institute, Sydney, NSW, August 2009
Causes & preventability of skin cancer
ARC Epidemiology Unit, University of Manchester, Manchester, UK, March 2010
Current evidence on skin cancers and their prevention
Division of Genetics and Molecular Medicine, King's College, London, UK, May 2010
Prevention of skin cancer: Insights from 'Down Under'
AACR: Cancer Prevention Research Annual Conference, Houston, USA, December 2009
The Epidemiology of Melanoma in Young People
6th International Conference on Teenage And Young Adult Cancer Medicine, London, UK, June 2010
DR ASHRAFUL HAQUE Parasite load & T cells: inter-dependent factors causing Experimental Cerebral Malaria
Australian Society for Immunology,Gold Coast 2009
Designing the perfect adjuvant for a malaria vaccine
Australian Vaccine and Immunotherapeutics Development Meeting, Melbourne, May 2010
What molecule from which cell-type?
Federation of the Immunological Societies of Asia-Oceania (FIMSA) Advanced Immunology training course, Moreton Island, December 2009
Year 12 Explore, Dream, Discover Careers Dinner
All Saints School, Gold Coast, July 2009
In vivo modelling of multi-organ, parasite-driven pathology in severe malaria
Sanger Research Institute, Cambridge, UK, April 2010
An inter-dependent relationship between CD8+ T cells and antigen loaddrives cerebral immune path
Woods Hole Immunoparasitology Meeting, Woods Hole, MA, USA, April 2010
DR DAVID HARRICH A U5 repressor of reverse transcription is required for optimal HIV-1 infectivity and replication
Retrovirology Meeting, Montpelier, France, September 2009
PROFESSOR NICHOLAS HAYWARD Low penetrance melanoma predisposition genes in relation to skin phenotypes and sunlight exposure
Society of Melanoma Research Congress, Boston, USA, November 2009
Identifying low penetrance melanoma predisposition genes: is it all about skin phenotypes?
Clinical Oncological Society of Australia Conference, Gold Coast, November 2009
What's next for finding high penetrance genes in melanoma families?
International Melanoma Genetics Consortium Meeting, Leeds, UK, June 2010
PROFESSOR GEOFF HILL Ian McKenzie Lecture
Transplantation Society of Australia and NZ annual meeting, Canberra, June 2010
IL-17 and antigen presentation in transplantation
Australasian vaccines and immunotherapeutics annual meeting, Melbourne, May 2010
NKT cells in transplantation
Australian Society of Immunology annual meeting, plenary lecture annual meeting plenary lecture, Gold Coast, December 2009
NKT cells in transplantation
Haematology Society of Australia and NZ annual meeting, plenary lecture, Adelaide, October 2009
New roles for the stem cell donor
Australian Bone Marrow Donor Registry meeting, Sydney, August 2009
ASSOCIATE PROFESSOR MALCOLM JONES Laser Microdissection and tissue-specific transcriptomes of schistosomes
Schistosomiasis Molecular Toolbox Workshop, San Francisco, USA, September 2009
Aspects of the host-parasite interface of schistosomes
Department of Parasitology, Veterinary School, South China , Agricultural University, Guangzhou, China, July 2009
Aspects of the host-parasite interface of schistosomes
Xinjiang Veterinary Institute, Urumchi, Xinjiang Province China, July 2009
Aspects of the host-parasite interface of schistosomes
Xinjiang Medical College, Urumchi, Xinjiang Province China, July 2009
111
INVITED LECTURES AND PRESENTATIONS 2009-2010 CONTINUED PROFESSOR BRIAN KAY Surveillance and control of dengue vectors
Second Dengue Program Managers Meeting, WHO, Hanoi, Vietnam, December 2009
Community-based Mesocyclops and Popcorn Wolbachia
41st Asia-Pacific Academic Consortium on Public Health conference, Taipei, Taiwan, December 2009
Exciting progress in dengue vector control
Emerging Infectious Diseases: The Global Perspective, Canberra, November 2009
PROFESSOR KUM KUM KHANNA DNA damage as a cause and cure for cancer
Peter MacCallum Cancer Institute Seminar, Melbourne, July 2009
Defective cellular responses to DNA damage and its link with cancer
Seminar at Mater Medical Research Institute, Brisbane, July 2009
Checkpoint responses to DNA damage. International Cell Cycle
Symposium in the Institute of Molecular and Cellular Biology, Singapore, September 2009
Characterization of novel players involved in Genome Maintenance
Indo-US Bilateral workshop on Epigenetics and Genome Stability, Hyderabad, India, December 2009
Centrobin as a regulator of microtubule and centrosome integrity
Hunter Valley Cell Biology Conference, NSW, Australia, March 2010
Overview of research in Signal Transduction laboratory
Seminar at Eskitis Institute for Cell and Molecular Therapies, Griffith University, April 2010
Pathways relevant to development of targeted therapies for Breast cancer
Seminar at Pfizer Biopharmaceuticals, Pine River, New York, USA, April 2010
Coping with DNA damage to maintain genomic stability; functional characterization of novel repair proteins
Seminar at University of Texas Southwestern Medical Centre, Dallas, USA, April 2010
PROFESSOR MARTIN LAVIN Rare Autosomal Recessive Ataxias: Cancer Predisposition and Neurodegeneration
University of Qld Centre for Clinical Research, July 2009
Upregulation of PCA3 and BMMC1 in prostate cancer
URS 2009, August 2009
Role of Rad50 in the DNA Damage Response
NUI Galway, Ireland, September 2009
DNA Damage Signalling through the MRN Complex
Telomere Biology and DNA Repair, Australia, October 2009
Snake Venom Proteins with potential as Therapeutic Agents
Venomics Program UQ, Brisbane, October 2009
Senataxin, defective in ataxia oculomotor apraxia type 2, is involved in transcription and the defense against oxidative DNA damage
ASMR AGM, Australia, November 2009
Workshop on “Irradiation of Living Cells with High Resolution X-Ray Microbeam”
Monash Centre for Synchrotron Science (MCSS), Australia, December 2009
Fara (A) Friedrich Ataxia National Research Review Meeting
University of Melbourne, December 2009
Venomics: Pre-clinical evaluation of snake venom with Therapeutic Potential
University of Queensland, Brisbane February 2010
Senataxin, defective in AOA2, protects against oxidative stress and transcription dysregulation
Ataxia Investigators Meeting, USA, March 2010
Ataxia oculomotor apraxia and other autosomal recessive ataxias
53rd Ataxia National Foundation Annual Membership Meeting, USA, March 2010
A varied phenotype with Rad50 deficiency
Memorial Sloan Kettering Meeting, USA, March 2010
Faculty Retreat
UQ CCR Retreat, Australia, May 2010
PROFESSOR BARBARA LEGGETT Molecular Pathogenesis of Colorectal polyps
Mater Medical Research Institute, Brisbane, July 2009
Serrated Neoplasia
CaSS/Pathology Queensland GIT Pathology Course, Brisbane, October 2009
Family based screening for colorectal cancer
Australian Gastroenterology Week, Sydney, October 2009
Serrated Neoplasia
GE Society of Queensland, Brisbane, March 2010
DR CORINNE LENDON Dementia Research In SEQ
Queensland Dementia Clinical Network Forum, 2009
ASSOCIATE PROFESSOR J. ALEJANDRO LÓPEZ
112
Células Madres Cancerígenas en Cáncer del Seno
Invited Speaker, Chile, September 2009
Breast Cancer Stem Cells for Immunotherapy
ASI Annual Meeting, Gold Coast December 2009
Clickers on Academic Performance in Bio-medical Sciences. Have We Got The Picture?
Griffith University Seminar, Brisbane, July 2010
QIMR Annual Report 2009/10
DR KELLI MACDONALD G-CSF promotes type-17 differentiation and scleroderma
European Society of Bone Marrow Transplantation, Vienna, Austria, March 2010
PROFESSOR NICHOLAS MARTIN Genetics of brain structure and function
International Congress of Psychiatric Genetics (ISPG), San Diego, USA, November 2009
Progress in the genetics of moliness and melanoma
GenoMel consortium meeting, Leiden, The Netherlands, December 2009
Genetics of visible traits
VisiGen consortium meeting, Rotterdam, The Netherlands, December 2009
Genetics of moliness and melanoma
Melanoma Research Alliance, Las Vegas, USA, February 2010
Twin studies and the GWAS revolution in mental health research
Central Institute of Mental Health Research, Mannheim, Germany, March 2010
Global CNV burden and IQ
Behavior Genetics Association, Seoul, Korea, June 2010
The role of twin studies in elucidating disease etiology
INVITED PLENARY: International Congress of Twin Studies, Seoul, Korea, June 2010
DR BRIAN MCEVOY Will redheads be extinct in 100 years?
QIMR High School lecture Series, September 2009
PROFESSOR DON MCMANUS Pathways to improved, sustainable morbidity control and prevention of schistosomiasis in the Peoples’s Republic of China
NHMRC: Global Health - addressing the health needs of the Asia/Pacific region, workshop, Canberra, May 2010
Schistosomiasis work in China and developing a transmission blocking vaccine for use in water buffaloes
Pan Pacific Veterinary Conference 2010, Brisbane, April 2010
Echinococcosis and Schistosomiasis
Disease Reference Group Conference on Zoonoses and Marginalized Infectious Diseases of Poverty, UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Cairo,Egypt, April 2010
Transmission blocking vaccine for schistosomiasis japonica in China
2nd World Congress of Vaccine, Beijing, China, March 2010
Dog vaccination for echinococcosis
World Congress of the International Association of Hydatidology, Colonia del Sacramento, Uruguay, December 2009
Transmission Blocking Veterinary Vaccines for Zoonotic S. japonicum
American Society for Tropical Medicine and Hygiene 58th Annual Meeting, Washington, USA, November 2009
Schistosomiasis Control
The Ninth Regional Network Meeting for Asian Schistosomiasis and Other Helminth Zoonoses (RNAS+), Vientiane, Lao, PDR, October 2009
Asian Schistosomiasis
WHO/TDR Regional Consultation Conference on Infectious Diseases of Poverty in Western Pacific Countries Vientiane, Lao, PDR, October 2009
Echinococcosis and Zoonotic Schistosomiasis
Disease Reference Group Conference on Zoonoses and Marginalized Infectious Diseases of Poverty, UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Liverpool, UK, November 2009
Schistosome vaccines
Joint Meeting of the Australian Society for Parasitology and the ARC/NHMRC Research Network for Parasitology, Sydney,July 2009
DR DAVID MCMILLAN Genetic variation in group G Streptococci
School of Veterinary and Microbiological Sciences, James Cook University, July 2009
DR ALLAN MCRAE Using sequence data to unravel the genetic architecture of complex traits
Australasian Conference on Statistical Methods for Genomic Data Analysis, Brisbane, October 2009
Gene mapping with sequence data
Winter School in Mathematical and Computational Biology, Brisbane, July 2009
DR SARAH MEDLAND Common variants in the Trichohyalin gene are associated with straight hair in Europeans
6th World Congress of Hair Research, Townsville, June 2010
DR ANGELA MIKA Scabies mite proteases and serpins inhibit human complement and promote streptococcal growth
Clinical Research Centre, Lund University, University Hospital, Malmö, Sweden, September 2009
PROFESSOR GRANT MONTGOMERY Genomics and genetic architecture in common complex disease
COMBIO, New Zealand, December 2009
Genome-wide association studies and beyond
Otago Genomics 2010, New Zealand, February 2010
Genome wide associations studies for disease traits
International Symposium on Genomics for Animal Health, France, June 2010
113
INVITED LECTURES AND PRESENTATIONS 2009-2010 CONTINUED MR BRIAN MORRISON Breast Cancer Stem Cells and Therapy: Characteristics of Mammospheres Generated From Cell Lines
Griffith Gold Coast Health and Medical Research Conference, Gold Coast, December 2009
PROFESSOR DENIS MOSS A case for the ascent of non-furry immunology
AVID conference, Melbourne, June 2010
DR DEREK NANCARROW Whole genome approach to biomarker discovery for Barrett’s oesophagus and adenocarcinoma
Frontiers in Barrett’s Oesophagus and Oesophageal Cancer, Sydney, November 2009
MS MICHELLE NELLER Ex vivo analysis of effective T cell responses against advanced melanoma.
Australasian Flow Cytometry Group 32nd Annual Meeting,Brisbane, November 2009
ASSOCIATE PROFESSOR COLLEEN OLIVE Targeting dendritic cells with Toll-like receptor agonists to enhance and modulate immune responses - implications for peptide vaccines
Seventh World Congress on Vaccines, Immunisation and Immunotherapy, Berlin, Germany, May 2010
DR CATHERINE OLSEN Divergent causal pathways to melanoma
Skin Cancer College of Australia and New Zealand Skin Cancer Conference 2010, Gold Coast, April 2010
DR JODIE PAINTER Genome-wide linkage scan for dizygotic twinning
13th International Congress on Twin Studies, Korea, June 2010
Application of GWA data to address issues of genetic loading in complex human diseases.
57th annual conference of the Genetics Society of Australasia, Canberra, July 2010
DR CHRIS PEATEY The effect of antimalarial drugs on P. falciparum gametocytes
American Society of Tropical Medicine, Washington, November 2009
PROFESSOR LAWRIE POWELL Iron and non-alcoholic fatty liver disease
APASL, Beijing, China, March 2010
ASSOCIATE PROFESSOR GRANT RAMM Mechanisms Underlying Liver Fibrosis: Role of the Chemokine C-C Motif System
50th Anniversary of Australian Gastroenterology Week, Sydney, October 2009
DR PETER RYAN Emerging threats and opportunities in dengue vector control in Queensland
Queensland Institutes of Health Meeting, Cairns 2009
DR CHRISTOPHER SCHMIDT Characteristics of immunotherapeutic dendritic cells
Tumour Immunology Workshop at the Annual Meeting of the Australasian Society for Immunology, Gold Coast, December 2009
T cells kill cancer
Volunteers of the Cancer Council Queensland, Brisbane, November 2009
Characteristics of immunotherapeutic dendritic cells
Ludwig Cancer Research Institute Translational Oncology Conference, Melbourne, November 2009
Immunological Monitoring of Immunotherapy Trials
3rd Australasian Vaccines & Immunotherapeutics Development Meeting, Melbourne, May 2010
DR TINA SKINNER-ADAMS Examining the Antimalarial activity of the HIV Protease Inhibitors
University of Florida, Gainsville, November 2009
DR AMANDA SPURDLE
114
Update on the moderate-risk study, assessing risk associated with the BRCA1 R1699Q va
ENIGMA (Evidence-based Network for the Interpretation of Germline, London, UK, May 2010
Inclusion of MSI in a multifactorial model for mismatch repair gene variants
InSIGHT, Paris, France, May 2010
SNPs in irradiation-responsive genes and modification of breast cancer risk in BRCA1/2 mutation carriers.
Consortium for Investigators of Modifiers of BRCA1 and BRCA2 Biannual meeting, Cambridge, UK, April 2010
Candidate breast cancer predisposition SNPs and modification of breast cancer risk in BRCA1/2 mutation carriers: results from phase 7 B-list.
Consortium for Investigators of Modifiers of BRCA1 and BRCA2 Biannual meeting, New York City, USA, November 2009
QIMR Annual Report 2009/10
Assessing risk associated with the BRCA1 R1699Q variant.
ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) Consortium Meeting, New York City USA, November 2009
Translational research capabilities of ANECS
Australian & New Zealand Gynaecological Oncology Group Annual Meeting, Noosa, Qld, February 2010
DR BRETT STRINGER EphA3 regulates high-grade glioma stem/progenitor cell proliferation and differentiation.
2nd Eph/Ephrins and Cancer Meeting, Winston-Salem, North Carolina, June 2010
ASSOCIATE PROFESSOR NATHAN SUBRAMANIAM Non-HFE Haemochromatosis
USA Centers for Disease Control Iron Overload Conference, Atlanta, USA, September 2009
Identification of novel genes in iron metabolism: implications for iron deficiency and overload
5th Indo-Australian Biotech Conference, Hyderabad, India, September 2009
DR ANGELA TRIEU Protein arrays for malaria vaccine development
Australian Society of Immunology Conference. Gold Coast, December 2009
DR PATRICIA VALERY Adapting an existing Supportive Care Needs tool to be used with Indigenous cancer patients
Cancer Care Coordination Conference, Clinical Oncological Society of Australia, Gold Coast, March 2010
Closing the divide: Understanding the reasons for poorer cancer outcomes in Indigenous Queenslanders.
National Maori Cancer Forum 2009 – Revolution of cancer care for Maori and Whanau, NZ, August 2009
DR ANNA VINKHUYZEN Reconsidering the Heritability of General Intelligence in Adults, Taking into Account Assortative Mating and Cultural Transmission
Behavior Genetics Association Conference, Korea, June 2010
PROFESSOR PETER VISSCHER Risk prediction for complex disease
Seminar, University of Central Otago, New Zealand, March 2010
The genetic basis of complex traits
Seminar at the University of Queensland, Brisbane, August 2010
Genome wide association studies and the problem of missing heritability
Seminar at the WEHI, Melbourne, May 2010
Genetic of schizophrenia
2nd Schizophrenia International Research Society Conference, Italy, 2010
Prediction of individual risk to disease from genetic data
Australian Pharmacogenomics Summit, Sydney, July 2009
The missing heritability problem
Australasian Conference on Statistical Methods for Genomic Data Analysis, Brisbane, October 2009
Quantitative genetics of human height
German Biotechnology Consortium, Germany, October 2009
Genetics of human height
Seminar at Washington University, USA, November 2009
The Queensland Statistical Genetics laboratory
Diamantina Institute retreat, Brisbane, December 2009
The genetic basis of quantitative trait variation
Australian Academy of Science New Fellows lecture, May 2010
Quantitative genetics of human height
Invited talk, statistical genetics symposium, Auckland, New Zealand, May 2010
Genome-wide association studies and the missing heritability
Invited speaker, European Society of Human Genetics conference, Gothenburg, Sweden, June 2010
Genome-wide association studies and the missing heritability
Seminar, Cardiff University, UK, June 2010
Human quantitative genetics
Invited lecturer, Statistical Genetics Summer School, Seattle, USA, June 2010
inexpensive whole genome association using pooled whole blood
Invited Oral Presentation: Australasian Conference on Statistical Methods for Genomic Data Analysis. Brisbane, October 2009
Legacy of Mutiny on the Bounty: Founder Effect and Admixture on Norfolk Island
Oral presentation, International Genetic Epidemiology Society conference, USA, November 2009
DR GRAEME WALKER Kit signaling drives melanocyte proliferation in response to DNA damage and the development of some forms of melanoma”.
University of Colorado, Denver, CO, USA, September 2009
DR DANIEL WALLACE Hepcidin, the iron regulator, will this eliminate venesections?
AGM of the Haemochromatosis Society of Australia Inc, Brisbane August 2009
DR PENNY WEBB Confounding
QUT Public health students, Brisbane. August 2009
PROFESSOR EMMA WHITELAW Intangible Variation
Gordon Conference on Epigenetics, New Hampshire, USA, August 2009
A screen for modifiers of epigenetic reprogramming
University College, London, London UK
The role of epigenetic modifiers in intangible variation in
Peterhouse College,Cambridge, UK, September 2009
115
INVITED LECTURES AND PRESENTATIONS 2009-2010 CONTINUED The role of epigenetics in the determination of phenotype
Mental Health Research Institute, Melbourne, November 2009
A screen for epigenetic modifiers
International Human Epigenome Consortium, Paris, France, January 2010
An ENU screen for epigenetic modifiers in the mouse
Review of Australian Phenomics Network, Canberra, March 2010
A new model of fetal alcohol spectrum disorder in the mouse
Symposium on Epigenetics of Brain Development, Montreal, Canada, March 2010
A random mutagenesis screen for epigenetic modifiers
Division Seminar, WEHI, Melbourne, April 2010
Epigenetics and Transgenerational Effects
Keystone Symposium on Epigenetics, Singapore, April 2010
Environmental Influences on the Epigenome
Lund University, Lund, Sweden, May 2010
Transgenerational epigenetic inheritance
Stockholm University, Stockholm, Sweden, May 2010
Epigenetics 101
James Cook University, Townsville, May 2010
ASSOCIATE PROFESSOR DAVID WHITEMAN Plenary lecture: Blue Sky Epidemiology
Public Health Association of Australia Annual Conference, Canberra, September 2009
Obesity and Cancer
Royal Brisbane and Women's Hospital Annual Conference, Brisbane, October 2009
Lifestyle factors and oesophageal cancer
Australian Gastroenterology Week, Sydney, October 2009
Cancer registration
UICC Cancer Epidemiology Course, Port Moresby, Papua New Guinea, November 2009
Research and clinical frontiers in oesophageal cancer
Cancer Council NSW Oesophageal Cancer Workshop, Sydney, November 2009
Towards the control of melanoma
American Association for Cancer Research Frontiers in Cancer Prevention Research, Houston, USA, December 2009
Genes, sunlight and the origins of cutaneous melanoma
6th Annual Congress of the European Association for Dermatologic Oncology, Athens, Greece, June 2010
Screening for melanoma: The Australian Perspective
6th Annual Congress of the European Association for Dermatologic Oncology, Athens, Greece, June 2010
Blue Sky Epidemiology
Murdoch Children’s Research Institute, Melbourne, February 2010
DR JOHN WHITFIELD Markers of Alcohol Sensitivity
AACB Annual Scientific Meeting, Brisbane, September 2009
DR MICHELLE WYKES Malaria impedes short and long term immunity via dendritic cells
ASP & ARC/NHMRC Research Network for Parasitology Annual Conference, Sydney July 2009
Malaria impedes short and long term immunity via Dendritic cells
Brisbane Immunology Group Meeting, Gold Coast, August 2009
B cell assays
10th FIMSA Immunology Training Course, Tangalooma, December 2009
Chair, “Humoral Immunity” session
Australian Society of Immunology Conference, Gold Coast, December 2009
Malaria impedes short and long term immunity via dendritic cells
Australian Society of Immunology Conference, Gold Coast, December 2009
DR JOANNE YOUNG Molecular Pathology of Colorectal Cancers
COSA Meeting, Gold Coast, November 2009
A Tribute to Jeremy Jass
Collaborative Group of the Americas, Honolulu, October 2009
Familial Serrated Neoplasia
Gut Club of NZ, Auckland, NZ, March 2010
Serrated Neoplasia in the Family Cancer Clinic
University of WA, Perth, February 2010
Serrated Polyposis: an Update
Ohio State University, Columbus, May 2010
DR LI YUESHENG Human immunity and schistosomiasis
Howard Hughes Medical Institute Annual Meeting for Research Washington DC, USA, September 2009
DR WENBAO ZHANG Dog vaccine against Echinococcus granulosus
116
QIMR Annual Report 2009 2009/10
World Congress of the International Association of Hydatidology, Colonia del Sacramento, USA, December 2009
QIMR STAFF 2009-2010 DIRECTOR M F Good (to Jun 10)
AO BSc(Med) MBBS(Hons) PhD MD DSc FASM FAFPHM FRACP(Hon) FAIM
DEPUTY DIRECTOR A Green
MBBS MSc PhD AC
GENERAL MANAGER BComm MBA MAICD
J Tarr (to Dec 09)
BA LLM PhD JD
ASSISTANT DIRECTORS A Boyd (UQ)
BMedSc(Hons) MBBS PhD FRACP
M Lavin (UQ)
BSc(Hons) PhD
EXECUTIVE SECRETARY TO THE DIRECTOR J Black ADMINISTRATIVE SUPPORT TO THE DIRECTOR T Checkley CANCER AND CELL BIOLOGY DIVISION Division Chair: G Anderson DRUG DISCOVERY GROUP
BAppSc(Hons) PhD
S Stein (to Feb 10)
BAppSc
B Stringer
BMedSc MBBS PhD
T Yeadon
BSc(Hons) PhD
V Subramaniam
BSc MSc PhD
P Lusby
BAppSc(Hons) GradDipComm
C McDonald
BSc (Hons) PhD
L Ostini
BSc GradDipCBioChem
D Wallace
BSc(Hons) MSc PhD
CCQ TRANSGENICS G Kay
BSc(Hons) PhD
D Carrie
BSc
A Mould
BSc(Hons) PhD
Z Pang
BBiotech MBiotech
I Tonks
BSc(Hons) PhD
RADIATION BIOLOGY AND ONCOLOGY
P Parsons
BSc(Hons) PhD
G Boyle
BSc(Hons) PhD
J Johns
BSc(Hons)
L Maslovskaya
PhD
J Pedley
BSc
C Pierce
BBioMedSc(Hons)
HEPATIC FIBROSIS BSc(Hons) PhD
M Bertrand-Philippe (to Dec 09) MSc PhD D Hoang-Le
BSc(Hons)
T Pereira
BSc(Hons) PhD
L Ramm
BSc
D Rowsell
BSc(Hons)
R Ruddell
BSc(Hons) PhD
R Shepherd
MBBS MD
M Walsh (to Mar 10)
BSc(Hons) PhD
IRON METABOLISM
M Lavin
BSc PhD
O Becherel
BSc MSc PhD
M Buck
DipMedTech
P Chen
BSc MSc PhD
J Cullen
BSc(Hons) PhD
S Earl (to Aug 09)
BBiotech(Hons) PhD
A Farrell
NCEA CAppSc
M Gatei
BSc PhD
U Ho
BSc(Hons)
A Kijas
BBiotech(Hons) PhD
S Kozlov
MSc PhD
J Luff
CertVetNurs
T Roberts
BSc(Hons) PhD
S Stirling
BSc(Hons) PhD
A Suraweera (to Jul 09)
PhD BSc(Hons)
M Trabi (to Dec 09)
BSc(Hons) PhD
RBWH GASTROENTEROLOGY
G Anderson
BSc(Hons) MSc PhD
K Boorman
BVsc
D Darshan
MBBS MAppSc PhD
J Dixon
BA(Hons) RN MPh
D Frazer
BAppSc(Hons) PhD
J Ghazali
BNurs
N Houston
BSc MEnvSt CT (ASC)
L Rawlings D Reid
BAppSc
M Spanevello
MEMBRANE TRANSPORT
D Hancock (Acting)
G Ramm
F Smith
BMedSc MBChB MRCP FRACP
V Shaw T Steele
BSc(Hons)
S Wilkins
BSc(Hons)
LEUKAEMIA FOUNDATION
B Leggett
BSc(Hons) PhD
K Banducci (to Sep 09)
BAppSc(Hons)
T Dumenil
BAppSc MAppSc
P Faleiro
BSc
W Fernando (to Jan 10)
BTech
S Greco
BSc
S Nayler
BAppSc(Hons)
D Mckeone
AssocDipLabTech
C Rickman (to Jan 10)
BSc(Hons)
J Robinson (to Nov 09)
BSc(Hons) PhD
K Spring
BSc PhD
SIGNAL TRANSDUCTION K Khanna
A Boyd
BMedSc(Hons) MBBS PhD FRACP
S Charmsaz (to Mar 10)
MBiotech BBiotech
B Day
BAppSc BSc(Hons) PhD
C De Bock (to Dec 09)
BSc MSc PhD
K Ensbey
BSc BBehavSc
N Herath
BSc(Hons) PhD
P Jamieson
BA BSc(Hons)
E Lau (to Aug 09)
BSc PostGradDipSc
K Miller
BSc
BSc MSc PhD
F Al-Ejeh
BBio(Hons) PhD
A Bain
BSc BSc(Hons)
E Bolderson
BSc(Hons) PhD
D Boucher
DipHlth MRadBiol PhD
J Jeffery
BSc(Hons) PhD
S Miles
AssocDipAppBiol
M Miranda
BSc
J Pagan
BSc(Hons) PhD
L Papp
BSc(Hons) PhD
117
QIMR STAFF 2009-2010 CONTINUED M Parish
N Pandeya
BSc GradDipAppSc MMedSc PhD
D Richard
BSc(Hons) PhD
S Perry
BAppSc BEnvironHlth MEnvirCommHlth
W Shi
BMed MSc PhD
V Siskind
BSc PhD
A Urquhart
BSc(Hons) PhD
CANCER GENETICS
A Wiegmans
BSc(Hons) GradDipBiotech GradDipIPL
G Trench
BSc PhD
A Van Der Horst (to Jul 09)
PhD BBioMedSc
S Andrews (to Mar 10)
BSc
SKIN CANCER CARCINOGENESIS
J Beesley
BSc(Hons) PhD
G Walker
BSc GradDipCBioChem MSc PhD
X Chen
BMed
B Ferguson
BSc
S Healey
BAppSc BSc DipEd
H Handoko
BSc MSc PhD
H Holland
BA BHlthSc(Hons)
GENETICS AND POPULATION HEALTH
S Johnatty
MSc PhD
Division Head: E Whitelaw
S Kugler
BSc(Hons)
BIOINFORMATICS L Krause
MBioinf PhD
MSc PhD
H Mariasegaram
BSc(Hons) PhD
CANCER AND POPULATION STUDIES
A Marsh
BSc(Hons)
A Green
MBBS MSc PhD AC
N Waddell (to Sep 09)
BSc(Hons) PhD
L Braatvedt
BSc MSpeechPath
EPIGENETICS
R Cicero
BA
E Whitelaw
BSc(Hons) PhD
T Corish
CertGenNurs
A Ahola (to Mar 10)
MSc
P Fahey (to Apr 10)
BSc DipMedStats MMedStats
A Chapman (to May 10)
BSc(Hons) MSc PhD
L Gordon
BEcon MPH PhD
S Chong
BAppSc(Hons) PhD
R Grealy
BBiomedSc(Hons)
A Combes
BSc (Hons) PhD
L Green
RN
T Epp
BSc(Hons) MSc PhD
N Hirst
BEcon BCom
S Harten
BAppSc(Hons) PhD
M Hughes
BSc MMedSc
N Kaminen-Ahola (to Dec 09)
MSc PhD
C Jaremczuk
BA GradDipProfPsych
E Lambley
BSc(Hons)
J Jetann (to Aug 09)
BNurs
D Morgan (to Aug 09)
BSc(Hons)
T Luong
AssocDipArtsPho
H Oey
BSc (Hons) PhD
K Mallitt (to Apr 10)
BSc(Hons)
J Sutton
Cert2ComAnimal
L Marquart
BSc BEcon
N Whitelaw (to Jun 10)
BSc(Hons) PhD
P McBride
BMedSc MBBS
S Young (to Jan 10)
BAppSc(Hons)
A McMurtrie
BNurs
N Youngson
BSc(Hons) PhD
F Millar
BNurs
FAMILIAL CANCER
E Minehan
RN
J Young
GradDipBiotech MAppSc PhD
R Neale
BVSc PhD
D Buchanan
BSc(Hons)
P O'Rourke
BA(Hons) BSc(Hons) GradCertEd PhD
M Clendenning
BSc(Hons) PhD
N Richmond
BAppSc(Hons)
B Nagler
DipAssSci BSc
M Russell
BSc DipNutr MMedStats
E Pavluk
BSc DipEd GradDipZoo
D Simmonds (to Dec 09)
BNurs MPH
S Pearson
AssDipBioLabTec
J Van Der Pols
BSc MSc PhD
A Roberts
BSc(Hons)
T Vu
BSc
M Walsh
BSc
A Ward
RN
R Walters
BAppSc
B Waters (to Oct 09)
BAppSc MPh
L Young
CANCER CONTROL GROUP
GENETIC EPIDEMIOLOGY
D Whiteman
BMedSc MBBS(Hons) PhD
N Martin
BSc PhD FASSA FAA
I Antonsson
MBBS(Hons) PhD
H Beeby
BSc(Hons)
C Baxter
BA
M Caffrey
H Carroll (to Feb 10)
DipObsGynae AdvDipNat MBBS MPH
J Cochrane (to Feb 10)
BBus
M Davis
MD MPH
M De Nooyer
BBehavSc BPsych(Hons)
K Harrap
BInfoTech
A Dormer
AssocDipArts
C Hill
BNurs
D Duffy
MBBS PhD
L Jackman
DipBusAdmin
G Dwyer
BHlthSc
P Lahmann
DipOecTroph PhD
A Eldridge
RN
J Evans
AssDipBus
D Lancini
118
I Makunin
A McMurtrie
BNurs
M Ferguson
S O'Brien
BNurs MPH
M Ferreira
PhD
C Olsen
BSc(Hons) PhD
S Fox
BSc
QIMR Annual Report 2009/10
N Garden
BBehavSc(Hons)
B Alexander
BNurs RN
S Gordon
BEng(Hons) PhD
V Beesley
BHlthSc(Hons) PhD
M Grace
RN CoronCareCert
S Brown
BA RN
L Grey
BSc
J Griffith
S Hancock
BHlthSc BA BBusMgt
T Ibiebele
BSc MPh PhD
K Hanigan
BSc
F Kolahdooz (to Jul 09)
MSc BSc
N Hansell
BA(Hons) PhD
T Lawton
D Hickey
AssocDipArts
M Malt
BBus EN
N Huang
DipHortSc BAgSc MAppSc
K Martin
BHealthAdmin RN
L Hume (to Oct 09)
BA MA PhD
M Mosey
BSc (Nursing)
M James
BSc(Hons) MSc PhD
C Nagle
PhD BAppSc MPH
K Johnson
BPsychSc(Hons)
B Ranieri
M Ikonomopoulou (to Jan 10)
BSc MSc PhD
D Roffe
K Krishnaprasad
BEng
H Steane
C Laizans A Lin
BMedSc
E Mallon (to Feb 10) K McAloney
RN
K Van Dooran
BSc
J White
RN
INDIGENOUS HEALTH BComm
G Garvey
BEd MEd
V Clements (to Oct 09)
MAppEpi
DipHort BBus
V Harrhy (to Sep 09)
RN
S Medland
BA(Hons) PhD
C Jacka
R Middelberg (to May 10)
PhD
V Logan
E Miller (to Jul 09)
BBehavSc(Hons)
S Moore
BHlthSc MPH CertNurs
N Moghbelpour
BSc GradDipPsych MInterPubHlth
T O'Brien
BJournalism
J Moir
BA BSc
P Valery
BMed MPH PhD
L Whop
BAppSc
S McCoombe (to Jun 10) J Medhurst
J Morrissey L Nunn
DipTeach
S Woolford
H Park
MHumServs GradDipRehab GradCertDisStud
MOLECULAR CANCER EPIDEMIOLOGY
D Park
BAppSc
R Parker
BPsych(Hons)
C Pink
S Shekar
AssDipComWel DipSocWelfare BSocSc MArts BSc(Hons) BLaws PhD
L Simms
BSc(Hons)
C Singer
BA MInfMgtSys BEng(Hons)
A Somerville
BA
D Statham (to Feb 10)
BA(Hons)
L Sullivan
BA
H Taylor A Toivanen
BPsych(Hons)
A Vanderstaay
BSc
K Watson K White (to Dec 09) J Whitfield
AdvCertArts BSc(Hons) MSc PhD FRACB FRCPath
L Winkler J Wood M Wright O Zheng
BSc(Hons) PhD DipInfoTech
G Zhu
BMedSc MPH PhD
B Zietsch (to Dec 09)
BPsychSc(Hons) PhD
GYNAECOLOGICAL CANCER P Webb
K Ferguson BSc(Hons) PhD
M O'Brien (to Dec 09)
P Shertock
D Smyth
BSc MSc PhD
H Baxter
F Lose
C Pretsel (to Apr 10) S Rodda
A Spurdle
MA PhD
M Parsons
BBioTechInv
C Paterson (to May 10)
BSc
S Rounsevell
BSc (IT) Grad Cert Bus
B Thompson
BForSc BSc(Hons)
L Walker
BSc MSc PhD
S Webb (to Mar 10)
BNurs
P Whiley
BAppSc BBus BSc(Hons)
MOLECULAR EPIDEMIOLOGY G Montgomery
BAgSc(Hons) PhD
L Bowdler
BAppSc
N Campbell (to Dec 09)
MSc BSc
M Campbell (to May 10)
BAppSc
A Caracella
BSc
J Chaplin (to Jan 10)
BMath BSc
B Chapman
BAppSc
S Crooks
BSc GradDipCMicrBio
A Henders
BSc(Hons)
M Lin (to Jan 10)
BMed MSc
P Lind
BSc(Hons) PhD
J McAloney J Painter
BSc(Hons) PhD
K Patel (to Mar 10)
BSc(Hons) PostGradCertImm
M Richter
BAppSc
S Smith
BBioSc(Hons)
119
QIMR STAFF 2009-2010 CONTINUED S Thomas (to Feb 10)
BSc
M Bell
BSc(Hons)
L Wallace
BBioMedSc GradDipGenCouns
R Brennan
BSc(Hons)
R Zhang (to Jan 10)
BSc(Hons)
J Burrows
BSc GradDipTeach
Z Zhao
MDentalSc PhD
J Miles
BSc(Hons) PhD
M Neller
BAppSc(Hons) BSc(Hons) PhD
MOLECULAR PSYCHIATRY C Lendon (to Jan 10)
BSc(Hons) PhD
S Silins (to Dec 09)
A Pritchard (to Sep 09)
BMedSc(Hons)
CLINICAL IMMUNOHAEMATOLOGY
NEUROGENETICS D Nyholt
BSc(Hons) PhD
ONCOGENOMICS
MBChB PhD FRACP FRCP FRCPath
P Crooks
BSc(Hons)
E Han
BMed MMed
N Hayward
BSc MSc PhD
K Jones (to Jul 09)
BSc
L Aoude
BA BEng
J Nourse
BSc DipSc MSc EMP Research Officer PhD
M Auret
BSc(Hons) PhD
N Ross
BSc (Hons)
V Bonazzi
PhD
F Vari
BSc(Hons) PhD
M Gartside
BAppSc
DENDRITIC CELLS AND CANCER
K Loffler
BSc(Hons) PhD
A Lopez
MD
D Nancarrow
BSc MSc PhD
B Morrison
BA MSc
L Packer
BSc(Hons)
EBV BIOLOGY
J Palmer
RN
D Moss
BSc(Hons) PhD
A Poh
BSc(Hons)
V Lutzky
MSc PhD
M Stark
BAppSc(Hons)
M Martinez
DipAppSc
J Symmons
BBus
L Morrison
CertBioLabTech
S Tyagi
MSc PhD
N Stevens
BSc GradDipMedSc
S Woods
BSc(Hons) PhD
IMMUNOLOGY & INFECTION
QLD STATISTICAL GENETICS
C Engwerda
BAgSc(Hons) PhD
P Visscher
BSc MSc PhD FAA
F Amante
BSc(Hons) PhD
B Benyamin
BAgSc(Hons) MAg PhD
S Best
BSc (Hons)
S Lee
BAg MAg PhD
P Bunn
J Liu
BEcon BSc(Hons)
J De Labastida Rivera
BSc GradDipBiotech MBiotech
S MacGregor
BSc MSc PhD
K Evans (to Jul 09)
BMedChem PhD
B McEvoy
BA(Hons) PhD
A Haque
BA(Hons) PhD
A McRae
BSc(Hons) PhD
M Sheel
BSc(Biotech) PhD
J Powell
BSc MSc
IMMUNOVIROLOGY
A Vinkhuyzen
MSc
A Suhrbier
BA(MA)(Hons) PhD
J Yang
BSc PhD
I Anraku
BSc(Hons) PhD
IMMUNOLOGY DIVISION
S Cozzi-Boyle
BAppSc(Hons) PhD
Division Chair: G Hill
J Gardner
BAppSc
ANTIGEN PRESENTATION AND IMMUNOREGULATION
C James
BBiotech MA
K MacDonald
T Le
BAppSc GradDipBiotech
BONE MARROW TRANSPLANTATION
L Major
BAppSc(Hons) PhD
G Hill
MBChB MD BHB FRCPA FRACP
W Schroder
BSc(Hons) PhD
T Banovic (to Jul 09)
MMedSc MD
MOLECULAR IMMUNOLOGY
BSc(Hons) MSc PhD
A Don
BSc(Hons)
M Koyama
MD PhD
R Kuns
BSc(Hons) BSc(Vet)
S Olver
BSc(Hons)
N Raffelt A Varelias Y Wilson
BSc(Hons) BAppSc PhD BAppSc(Hons)
CANCER IMMUNOTHERAPY C Schmidt
BSc(Hons) PhD
X Huang
BMed PhD
C Lanagan
BBioSc
L O'Connor
AssocDegAppSc
CELLULAR IMMUNOLOGY
120
M Gandhi
S Burrows
BSc PhD
J Arnold
BSc(Hons) PhD
QIMR Annual Report 2009/10
M F Good (to Jun 10)
AO BSc(Med) MBBS(Hons) PhD MD DSc FASM FAFPHM FRACP(Hon) FAIM
P Anderson (to Dec 09) V Kienzle
BSc(Hons)
X Liu
BMed MMedSc
V McPhun
BSc MSc
D Mitchell (to Feb 10)
BSc(Hons)
A Pinzon-Charry
MD&S PhD
M Wykes
BSc(Hons) PhD
MOLECULAR VACCINOLOGY D Doolan
BSc(Hons) MPh PhD
S Apte
BSc(Hons) PhD
K Buttigieg (to Jul 09)
BBioTech
F Caldas Cardoso
BSc MSc PhD
P Day (to Feb 10)
B Douradinha Mateus
MSc Biotech PhD
HELMINTH BIOLOGY
P Groves
BAppSc
A Loukas (to Dec 09)
J Roddick
BSc(Hons)
A Aziz (to Dec 09)
A Trieu
BBiotech(Hons) PhD
L Cooper (to Nov 09)
BAppSc AssocDipCLT
S Gaze (to Dec 09)
BSc MSc PhD MSc PhD
TUMOUR IMMUNOLOGY
BSc(Hons) PhD
R Khanna
BSc MSc PhD
H McSorley (to Dec 09)
L Beagley
BSc
M Meuleman (to Dec 09)
T Crough
BSc(Hons)
J Mulvenna (to Dec 09)
BComm BSc(Hons) PhD
D Elhassen
BSc MSc PhD
M Pearson (to Dec 09)
BSc MSc PhD
L Heslop
BBiomedSc(Hons)
M Smout (to Dec 09)
BSc(Hons)
D Hoang-Le
BSc(Hons)
L St Pierre (to Dec 09)
BSc(Hons) PhD
M Tran (to Jan 10)
BSc GradDipCBioChem PhD BAppSc PostGradDipBio
L Jones J Peet
BAppSc(Hons)
L Tribolet (to Dec 09)
C Smith
BSc(Hons) PhD
HIV MOLECULAR VIROLOGY
J Tellam
BSc(Hons) MSc PhD
D Harrich
N Tellam
BSc
A Apolloni
BSc PhD
J Zhong
BSc PhD
D Sivakumaran
BSc(Hons) PhD
INFECTIOUS DISEASES DIVISION
D Warrilow
BSc(Hons) PhD
Division Chair: J McCarthy
T Wei
BAgSc MAgSc PhD
AMI MALARIA DRUG RESISTANCE
IMMUNITY AND VACCINOLOGY
Q Cheng
MBBS MMed PhD
C Olive
L Bain
BSc
J Raju
BBio MSc
M Gatton
BSc(Hons) PhD
N Willemsen (to Jun 10)
BAppSc (Hons) PhD
K Gresty
BSc(Hons)
MALARIA BIOLOGY
D Kerlin
BSc(Hons) MInfTech PhD
D Gardiner
BAppSc PhD
A Pelecanos
BSc(Hons) BBioinformatics
K Anderson
CBLT
W Sharrock
BSc(Hons)
R McGeorge
BForensicSc BCCJ
F Teuscher
BPharm PhD
E Saig (to Apr 10)
BMedSc MMolBio
N Walpole
Cert3AnimalServ Cert3BusAdmin
T Skinner-Adams
BSc(Hons) PhD
K Trenholme
BSc MSc PhD
BACTERIAL PATHOGENESIS K Sriprakash
BSc PhD
BSc(Hons) PhD
MPharm PhD
MOLECULAR GENETICS
M Bauer
BBio BAppSc(Hons)
P Upcroft
BSc(Hons) PhD
M Georgousakis (to Jan 10)
BSc(Hons) PhD
A Burgess
BSc MSc PhD
D McMillan
BSc(Hons) PhD
L Dunn
BSc(Hons) PhD
J Shera
BSc(Hons)
K Krauer
BSc PhD
T Vu
BAppSc(Hons) BAppSc
J Upcroft
BSc(Hons) PhD
D Smyth
BSc(Hons) PhD
MOLECULAR PARASITOLOGY
BACTERIAL VACCINES
D McManus
BSc(Hons) DSc PhD
M Batzloff
BSc(Hons) PhD
B Anthony
BSc(Hons) MSc PhD
J Hartas
BAppSc
M Burke
BBiomedSc PhD
G Magor (to Jun 10)
BSc(Hons)
M Duke
AssocDipFarmMgt
J Malcolm
BSc(Hons)
M Ellis
BSc(Hons) MSc PhD
M Pandey
BSc MSc PhD
G Gobert
BSc(Hons) PhD
S Sekuloski
BSc(Hons) PhD
D Gray (to Sep 09)
BSc MSc GradCertPublicHlth PhD
CLINICAL TROPICAL MEDICINE
Y Li
MD PhD
J McCarthy
MBBS MD FRACP
J Li
BPharm PhD
A Butterworth
BSc(Hons)
L McGarvey
BSc(Hons)
W Chung (to Feb 10)
BSc (Hons) PhD
L Moertel (to Dec 09)
BBiomedSc(Hons) PhD
L Hannon (to Feb 10)
BSc (Hons)
H You
BSc MSc PhD
M Ho
BSc(Hons)
W Zhang
BSc PhD
D Jones
BAppSc DipAppSc RN
MOSQUITO CONTROL
M Kuwahata (to Apr 10)
BA BAppSc MSc
P Ryan
BSc(Hons) MAppSc PhD
K Mounsey
BSc (Hons) PhD
J Darbro
BA MSc PhD
M Pasay
BSc MSc PhD
P Fraley
A Robertson (to Jan 10)
BSc(Hons)
R Hugo
BSc(Hons) PhD
Y Wang
BBioSc
T Hurst
BSc(Hons) PhD
121
QIMR STAFF 2009-2010 CONTINUED J Jeffery (to Jan 10)
BA BSc(Hons) PhD
C Groennou
B Kay
BSc(Hons) PhD FAA
D Gunn
A Kho
BSc(Hons)
S Hunting
W Lee (to May 10)
BMultimedia BA
T Laing
G Lu
BAgSc MAgSc MVetSc PhD
D Meaclem
K Marshall
M Randle
J Monkman
BSc(Hons)
G Sriprakash
B Trewin
BSc(Hons)
BUILDING SERVICES
PARASITE CELL BIOLOGY
Cert 3Admin&Fin DipBasicOps DipBasicMgt
A Stockman
HigherCertEng HigherNatDipEng NatEngCert
M Jones
BSc(Hons) PhD
M Bugden
Trade Cert
A GlanямБeld
BSc(Hons) PhD
K Eaton (to Jan 10)
E Lovas (to Dec 09)
BAppSc(Hons)
J Fahrner
M Perumalpillai-McGarry
BSc
G Madders
Electrical Mech
L Schulte
BSc(Hons)
A McKee
AdvDipElect&Eng
PROTEIN DISCOVERY CENTRE
D Patrick
AdvDipEng AssocDipElecEng
J Gorman
BSc PhD
R Tyrrell
Fitter
J Chicher
BSc MSc
REGULATORY AFFAIRS
K Dave
BSc(Hons) MSc PhD
A Mitchell
BSc(Hons) PhD
A Diseberg
BSc(Hons)
S Chow
BA BSc MPh
M Hastie
BAppSc(Hons) PhD
R Lacey (to Jun 10)
M Headlam
BSc PhD
H Phillips (to Apr 10)
B Jayakody Arachchige
BSc
SAFETY
H Jiang (to Oct 09)
BSc MSc PhD
J Leonard
M Plan
BAgSc PostGradDipAgSt PhD
J Hawdon
BSc(Hons)
E Redhead
BSc(Hons)
L Richards
BSc PosGradDipSc
C Wright
BSc(Hons)
EXTERNAL RELATIONS GROUP
SCABIES
V Johnson
Cert3Kennel&Cat
BSc(Hons) MSc
BSc MSc PhD AdvDipOHS
BA MBus GradCertMktg
K Fischer
PhD
V Torres
Cert3BusAdmin
D Kemp
BSc(Hons) PhD FAA
A Van Der Beek (to Dec 09)
BBus
M Johnstone
BSc(Hons) PhD
FUNDRAISING
A Mika
BSc MSc PhD
T Scanlan
D Pickering
BAppSc(Hons)
H Astbury
Y Zhou
BMed DipAppSc
A Dignan
TROPICAL PARASITOLOGY
A Hall
K Andrews
BSc(Hons) GradCertEd PhD
A McGaw
L Melville (to Dec 09)
BA BSc
M O'Hara
T Tran
BSc(Hons)
J Stockman
MENTAL HEALTH DIVISION
BA(Hons) MBBS(Hons) PhD
N Quirk (to Dec 09) J Roberts
Bsc(Hons)
PSYCHIATRIC GENETICS N Wray
BSc(Hons) MSc PhD
E Byrne
BA(Hons)
CORPORATE DIVISION
BSc(Hons) GradDipScComm GradDipSecEd MEnvSc&Law
D Bishop
BA BCrA Cert4Train&Assess
S Cross
BSc(Hons) MSc DipEd
J Tarr (to Dec 09)
BComm MBA MAICD BA LLM PhD JD
BComm
S Matthews
BSc
J O'Keefe (to Apr 10)
BSc DipBusComm
M Quince
DipBus
H Matthews
BA(Hons) GradCertPhtgrphy
M Kersting
BFA
SCIENTIFIC SERVICES GROUP
N Fox EXECUTIVE SECRETARY TO THE GENERAL MANAGER
J Cooper (to Jan 10)
BSc MSc PhD GradCertMgt
ANALYTICAL FACILITY
B Wanrooy ADMINISTRATION B Wanrooy
QIMR Annual Report 2009/10
BBehSc
J Gill (to Mar 10)
G Melissari (to Oct 09)
ASSISTANT SECRETARY
C Green
S Georgeson
GRAPHIC SUPPORT
GENERAL MANAGER D Hancock (Acting)
BBus
S Tennant
MENTAL HEALTH M Breakspear
GradCertBus
SCIENCE COMMUNICATION
Division Chair: M Breakspear
122
BA
Cert3BusAdmin
H Edmundson
BSc MAppSc
P Collins
BSc(Hons)
ANIMAL FACILITY S Cassidy
BUSINESS DEVELOPMENT Cert4TrainAsses CertAnimalCare
G Haaima
BSc(Hons) PhD MBA
C Alexander
J Fox
BSc PhD
A Allester (to Nov 09)
R Parlett
BBiotech(Hons) PhD
L Billing
FINANCE
J Bonnily S Buckland
Cert3AnimalTec Cert3ComAnimal Cert3ChildStud
C Cross Cert3ComAnimal
C Dickfos
CertLabCare AssocDipAppSc
A Dorrington (to Dec 09)
BCom CPA
J Lin
BLit GradDipMan MComm
K Moran M Stromberg A Valentine
N Felder
GRANTS
B Fewster
D Evans
L Gunn A Hale D Mcneilly
Cert3LabAnmlTec
A O'Regan
Cert3ComAnimal
T Scown
CertAnimTech
I Shiels
BVSc PhD MACVSc
CULTURE MEDIA SERVICES CertAnimTech
FLOW CYTOMETRY G Chojnowski
BAppSc
G Chapman
BSc MSc PhD DipTexChem
P Hall
BSc
D Sivakumaran
BSc(Hons) PhD
GLASSWARE SERVICES G Cuthbert
BBus
T Booth
C McNally
A Cross
S Gregg
G Cunningham
L Casey
BSc GradDipTh
K Dry
DipMgt
B Dunphy
BBus
J Whybird
BBus GradDipAdVocEd
HUMAN RESOURCES AND PAYROLL T Greenaway
BComm GradDipPsych
M Anderson
Cert2BusAdmin
P Buratowski S Field
Cert1WorkplaceT BA GradDipBus
E Horsfield (to Jan 10)
Cert3Bus DipBus
L Lane S Pekhu M Weaver
AdvDipBus
INFORMATION TECHNOLOGY Cert3HlthServ BNurs C Ward (to Dec 09)
MACS GradDipCommComp AssocDipAppBiol
L Thompson
M Creevey
BEng
L Thompson (to Jan 10)
A De Guzman
BBus MInfTech
S Watkins
M Feodoroff (to Apr 10)
BInfo
V Mathews
HISTOTECHNOLOGY
D James
C Winterford
AssDipAppBiol
S Jaremczuk
R Collins
CertBioLabTech
D Johnstone
DipInfoTech
D Harbrow
BSc MSc
P Kaim (to Jun 10)
BAppSc
S Park
DipClinPath
X Lin
BEng MEng PhD GradDipIT
G Rees
CertDiagCytlgy AssDipCLT DipOHS
V Mar
COBC CCSA HP-UX
S McDonagh
BSc
Q-GEN
BBioSc MInfoSys MBA MCITP AAIM MACS
J Youngson
BSc PhD
X Nguyen
K Miller
DipLabTech CertLabTech
A Nutley-Govaerts
M Peters
BAppSc
A Stevens
P Toh (to Jan 10)
BSc
T Tomlin
BEng
J Uksanovic-Barnjak
DipLabTech DipVetFoodSc
L Ward
BInfoTech
STORES
PURCHASING
A Kent A Girle
Cert3IT CertTrsWareDist
M Mcdade A Reeves
DipVisArts
S Wood
CertTrsWareDist
M Eaton
CertTrsWareDist
A Hough
DipBus
RECORDS AND INFORMATION SERVICES
CORPORATE SERVICES GROUP
N Kremko
CHIEF COMMERCIAL MANAGER
A Crace (to Dec 09)
D Hancock
O Griffiths
BComm MBA
BUSINESS ANALYST P Verso
BAppSc
BA
L O'Mahoney BBus DipConsLandMgt
123
RESEARCH STUDENTS HONOURS STUDENTS
SUPERVISOR
C Jekimovs
BAppSc(Hons)
K Khanna
B Botterill
BAppSc
M Jones
J Johnson
BSc(Hons) BBusMgt
G Trench
S Goh
BSc
K Fischer
K Jones
BSc
M Gandhi
L Grant
BAppSc
M Gandhi
B Kendall
MBBS
D Whiteman
Y Grewal
BIT DipIT
G Gorman
S Lane
MBBS(Hons)
A Boyd
E Heng
DipMolBio BSc
M Lavin
E Leddy
BAppSc(Hons)
N Subramaniam
C Ho
BSc
E Whitelaw
Y Leow
BAppSc MSc
M Jones
B Hoad
BBioMedSc
K Khanna
H Leow
BSc(Hons) MSc
J McCarthy
C Huang
BSc
E Whitelaw
Y Lim
BSc(Hons)
M Lavin
C Mirciov
BSportSc
G Anderson
M Lin
BSc MA DipEng
D Harrich
S Mustafah
DipScBio BSc
C Engwerda
A Lord
BSc(Hons)
M Breakspear
N Osman
BBioMedSc
G Hill
Y Lu
BEcon(Hons) MSc
P Visscher
C Perry
BAppSc
D McManus
H Luong
BMed BPed MMedSc
G Montgomery
E Sedlacek
BSc
A Spurdle
K Markey
BEng(Hons)
G Hill
A Tabib
BBioMedSc
G Gorman
Nico Martin
MSc BSc
N Martin
S Toh
BSc
M Jones
J McCarron
BAppSc(Hons)
A Boyd
A Woods
BSc
K Andrews
A Molehin
MRes
D McManus
A Yeo
BSs
M Lavin
B Morrison
MSc BA
A Lopez
P Yeo
DipScBio BSc
C Engwerda
M Mosing
MPsych BPsych DipPsych
N Martin
H Zowawi
BAppSc
K Sriprakash
S Mujaj
BSc(Hons)
M Gandhi
SUPERVISOR
D Muslim
BSc(Hons) BBioSc
N Subramaniam
MBBS BAppSc BEcon
P Parsons
S Nawaratna
MPh MBBS(Hons)
M Jones
S Nayler
BAppSc(Hons)
M Lavin
A Neill
BAppSc GradDipHlthMgt MPH MNurs
P Webb
P Nguyen
MPH BMed
P Ryan
D Pattinson
BSc(Hons)
D Doolan
C Peatey
BSc (Hons)
D Gardiner
K Phillipps
BBiotech(Hons)
M Good
Y Poo
BSc(Hons)
A Suhrbier
A Redmond
MBBS
D Doolan
M Reiter
BSc(Hons)
C Schmidt
MASTERS SCHOLARS R Barr C Biondi
GradCertPubHlth PhD
P Webb
L Desbarrieres
BSc
C Engwerda
V Mathai
MBBS MPH MHM
P Webb
K Oftedal
BSc(Hons)
K Khanna
PHD SCHOLARS
124
SUPERVISOR
N Abdul Murad
MMSc BSc
M Lavin
S Ahmad
BSc(Hons) MSc
G Anderson
B Appleyard
MPH BSc(Hons)
J McCarthy
S Arabshahi
GradDipPubHlth MSPh BSc
A Green
A Bain
BSc(Hons) BSc
M Renteria Rodriguez
BSc
N Martin
F Bieri
MSc
D McManus
N Ross
BSc (Hons)
M Gandhi
G Blokland
MSc
N Martin
M Rubinov
BMedSc MBBS
M Breakspear
C Bond
Bphysio MSc
B Leggett
M Sa'Ariwijaya
MSc BSc(Hons)
M Lavin
R Brennan
BSc(Hons)
S Burrows
S Schussek
MSc
D Doolan
S Charmsaz
MBiotech BBiotech
A Boyd
M Sikulu
BSc MSc
K Sriprakash
T Chuah
MBBS BMedSc
M Lavin
J Simmons
Bbiotech(Hons)
K Khanna
V Dasari
BSc MSc
R Khanna
K Smith
MBChB
D Whiteman
H Driguez
BMarineSc(Hons) BA BAdvSc
D McManus
S Tey
FRCPA FRACP MBBS(Hons)
R Khanna
M D'Souza
Bbiotech MMolBiol
P Parsons
A Thrift
BAppSc(Hons)
D Whiteman
K Dutton-Regester
BAppSc(Hons)
N Hayward
P Tran
MPH BMed
P Ryan
W Fernando
BTech MMolBiol
B Leggett
C Verweij
BPsych MSc
N Martin
I Gillions
BAppSc(Hons)
A Lopez
K Warren
BMedSc(Hons)
D Harrich
C Gordon
BSc(Hons)
D McManus
M Wood
RACP MBBS
G Ramm
D Hall
MBBS BSc(Hons)
P Parsons
R Zhang
BSc(Hons)
E Whitelaw
QIMR Annual Report 2009/10
VISITING SCIENTISTS CANCER & CELL BIOLOGY DIVISION
J Doecke
PhD BSc(Hons)
I Ferriera
R Aizawa
MD
E Fearnley
MAppEpi PhD BEnvHlth
S Gaze
PhD MSc BSc
S Allan
MBBS
C Filippich
BAppSc
C Keane
MBBCh MRCPI FRCPATH
J Aylward
PhD MSc BSc
J Flanagan
PhD BSc(Hons) BAppSc
A Kelso
BSc(Hons) PhD
G Beadle
FRACP MBBS
T Flatscher-Bader PhD BSc(Hons)
N Kienzle
PhD MA BSc
R Buttenshaw
CertChem
S Freeman
RN
H Mcsorley
PhD MSc
D Chin
PhD
N Gillespie
PhD BA(Hons)
I Misko
PhD BSc(Hons)
BSc(Hons) PhD
D Goldgar
PhD MD BA
T Mynott
PhD BAgSc(Hons)
PhD FJFICM FRACP MBBS
J Gratten
PhD BSc(Hons)
D Nguyen-Van
MD MSc PhD
FIAC PhD FRCPA MBBS
E Hacker
PhD
M Pender
MD PhD FRACP MBBS
L Fletcher
PhD BSc(Hons)
A Hadley
BMed(Hons)
MSc BSc
F Gardiner
MD FRACS FRCS MBBS
P Hatemi
PhD MA BSBA
V Pousada Da Hora
A Hallahan
DipPaed MBBS BSc FRACP
A Heath
PhD BA
A Rickinson
BA MA PhD
R Clarke M Coulthard M Cummings
J Hancock
BSc(Hons)
J Jayanthan
BSc(Hons)
T Sculley
M Heritage
PhD BBiomedSc(Hons)
S Jordan
MBBS(Hons) PhD
L Smallwood
BSc(Hons) MBBS PhD
P Inglis
MBBS FRACP
N Kaminen-Ahola PhD MSc
T Woodberry
PhD BAppSc(Hons)
W Ingram
PhD BSc(Hons)
P Keith
K Wynn
PhD BAppSc
H Xu
PhD MMed BMed
T Ishii
M Keller
V Jain
A Knaapila
BSc
S Lakhani
Bsc MBBS MD FRCPath FRCPA
INFECTIOUS DISEASES DIVISION
M Kim
A Lane
DipClinSci
R Anders
P Lewindon
MBBS FRACP FRCP
M Larsson
PhD BSocSc
P Bartley
MBBS(Hons) BMedSc
C Loo
PhD MBBS BMedSc
M Lynskey
PhD MSc BSc(Hons)
G Birrell
MSc PhD
G MacDonald
FRACP MBBS(Hons) PhD
D MacFarlane
MBBS FRACP
L Jaskowski
P Masci
AssDipCLT
MBiochem MSc BSc
C McDermott T Murphy
MSc BSc
S Ogbourne
PhD BSc(Hons)
C Peng
MMed
PhD BAgSc
D Mackey
C Brown
PhD BSc(Hons)
P Madden
PhD MSc BSc
M Chavchich
MSc PhD
N Malik
BSc(Hons)
C Chuah
BBiotech(Hons)
B Mason
A Clements
BVetSci (Hons) MVetMed PhD
S Miller
M Conrad
BBiol MSc
BSc
J Croese
G Miller
D Gray
BSc MSc GradPhil PhD
B Mowry
MBBS BA(Hons) MD FRANZCP
C Gray
BSc(Hons) PhD
A Nelson
BA
A Henningham
E Nelson
MD BA
N Ketheesan
GradCertEd PhD MSc MD
MBBS MD
P Pakkiri
MMedPath MBChB(Hons)
A Loukas
PhD BSc(Hons)
C Smart
PhD BSc(Hons)
H Rangappa
MPH MBBS
H Mcwilliam
BSc
J Smith
PhD BSc MSc
L Reid
MMSc BSc
K Mounsey
BSc (Hons) PhD
C Rosty
MD PhD
J Mulvenna
PhD BSc(Hons) BComm BEng BIntStud
L Powell
FRCP PhD FRACP MD MRACP
S Reece
FRACGP MD FRCS FRACS MBBS
R Shepherd
L Teng
F Milne
A Umapathy
BSc(Hons)
I Rowlands
H Nguyen
S Vuckovic
PhD MSc BSc
S Sadeghi
MD DipPubHlth PhD
M Nguyen
BSc(Hons)
D Walker
MBBS(Hons) BMedSc
K Sanderson
BAppSc
V Pallaval
PhD
D Watters
BSc(Hons) PhD
J Saunus
BSc(Hons) PhD
G Raso
PhD MSc
PhD BSc(Hons)
R Shepherd
BSc(Hons) PhD
T Seidens
BSc
P Simpson
PhD BSc
D Shanks
MPh MD BSc
W Slutske
BA PhD BSc
P Smeesters
PhD BMed
H Smith
BSc
K Spann
PhD BSc(Hons) AssocDipMusic
S Srinivasan
BSc(Hons)
L St Pierre
BSc(Hons) PhD
V Whitehall K Zhao
PhD MSc BSc
GENETICS AND POPULATION HEALTH DIVISION R Arden
BA(Hons)
R Sturm
PhD BSc(Hons)
N Waters
R Ataee
Pharm D
D Tam
MBBS BPhar
G Williams
PhD MSc BSc(Hons)
S Treloar
PhD
C Willis
PhD MSc BSc
A Vargas Calderson
MBBS
Y Yang
MMed BMed
P Yonglitthipagon
BSc
N Waddell
PhD
V Zhang
BSc(Hons)
N Wayte
BSc(Hons)
L Zhang
PhD
B Zietsch
PhD
C Bain
MSc MPh MBBS BSc
T Bates J Batra
PhD
S Broadley
BSc(Hons) ChB MRCP PhD FRACP CCST
K Buchanski
BSc
L ClemensDaxinger
MSc PhD
L Da Silva A De Witt
F Freyer
PhD
N Anstey
PhD FRACP DTM & H MSc MBBS(Hons)
CORPORATE DIVISION
MD
N Davis-Poynter
PhD
M Mcintyre
AssDipAssSc
BNurs
K Ellem
R Sutharsan
PhD BSc
W Coventry A Cronin
MENTAL HEALTH DIVISON
IMMUNOLOGY DIVISION BEng MMan MBBS
125
ACRONYMS AASLD American Association for the Study of Liver Diseases
ARC Australian Research Council
ACITH Australian Centre for International and Tropical Health
ASARCO American Smelting and Refining Company
ACVD Australian Centre for Vaccine Development
ASIP Agouti signalling protein
AHMRC Aboriginal Health and Medical Research Council
ATM Ataxia-telangiectasia mutated
CTL Cytotoxic T lymphocyte CVD Cardiovascular disease DC Dendritic cells DNA Deoxyribonucleic acid EBV Epstein-Barr virus
GMRC Griffith Medical Research College GU Griffith University GVHD Graft-versus-host disease GVL Graft-versus-leukaemia
ENU N-ethyl-N-nitrosourea
GWAS Genome-wide association study
BCC Basal cell carcinoma
EVC Emory Vaccine Centre
HCC Hepatocellular carcinoma
AMATA Australasian Microarray and Associated Technologies Association
BRCA Breast cancer gene
FACS Fluorescence-activated cell sorter
HCMV Human cytomegalovirus
ANU Australian National University
CF Cystic fibrosis
GAS Group A streptococcus
HGSA Human Genetics Society of Australasia
CMR Centre for Magnetic Resonance
GC Germinal cell
HIF Hypoxia inducible factor
G-CSF Granulocyte colony stimulating factor
HIV Human immunodeficiency virus
CRCAH Cooperative Research Centre for Aboriginal Health
GFP Green fluorescent protein
HL Hodgkin’s lymphoma
GGS Group G streptococcus
HLA Human leukocyte antigen
APHA Australian Private Hospitals Association
CSIRO Commonwealth Scientific and Industrial Research Organisation
GITR Glucocorticoid-induced tumor necrosis factor receptor
API Antiretroviral protease inhibitors
CSLD Chronic suppurative lung disease
AIDS Acquired Immune Deficiency Syndrome
AOA1 Ataxia with oculomotor apraxia type 1 AOCS Australian Ovarian Cancer Study APC Antigen presenting cells
126
A-T Ataxia-telangiectasia
CT Computed axial tomography
QIMR Annual Report 2009/10
CDKN2A Cyclin-dependent kinase inhibitor 2A
CNV copy number variant
HDC Higher Degrees Committee
FAS Fetal alcohol syndrome
GMP Good manufacturing practice
HPS Hyperplastic polyposis syndrome IL-2 Interleukin 2
IMB Institute of Molecular Bioscience
MLPA Multiplex ligationdependent probe amplification
JCC Joint Consultative Committee
MLST Multilocus sequence typing
JCU James Cook University
MRC Medical Research Council
LAW cohort Longitudinal Ageing Women’s cohort
mRNA Messenger ribonucleic acid
LDRL Liver Disease Review Letters
MS Multiple sclerosis MYH MutY homologue
MALVAC Malaria Vaccine Advisory Committee
NCI National Cancer Institute
MBL Mannose-binding lectin
NCRIS National Collaborative Research Infrastructure Strategy
MCP-1 Monocyte chemotaxis protein-1 MDR Multi-drug resistant MEGA Epidemiology Molecular, Environmental, Genetic & Analytic Epidemiology
NHMRC National Health and Medical Research Council NIAID National Institute of Allergy and Infectious Disease NIH National Institute of Health
MGE Mobile genetic elements
NKT-cell Natural Killer T-cell
MHC Major histocompatibility complex
NPC Nasopharyngeal carcinoma
MIC-1 Macrophage inhibitory cytokine 1
PDC Protein discovery centre PET Positron emission tomography PFOR Pyruvate ferredoxin oxidoreductase PHERP Public Health Education and Research Program PTEN Phosphatase and tensin homologue PTLD Post-transplant lymphoproliferative disease QTL Quantitative trait locus
SMIPP Scabies mite inactivated protease paralogue SNP Single nucleotide polymorphisms SPH School of Population Health TCR T-cell receptor TLR Toll-like receptor TNF Tumour necrosis factor UK The United Kingdom
QUT Queensland University of Technology
UNESCO United Nations Educational, Scientific and Cultural Organization
RBWH Royal Brisbane and Women’s Hospital
UQ The University of Queensland
RDT Rapid diagnostic test
UV Ultra violet
RISS Research Infrastructure Support Services
VIPBG Virginia Institute for Psychiatric and Behavioural Genetics
RNA Ribonucleic acid RSV Respiratory synctival virus
WEHI Walter and Eliza Hall Institute
PACMISC Pacific Malaria Initiative Support Centre
RT-PCR Reverse transcription polymerase chain reaction
WHO World Health Organization
PCA3 Prostate cancer gene 3
SCC Squamous cell carcinoma
YSA Young Scientist of Australia
127
Administrative Support
ORGANISATIONAL STRUCTURE
General Manager
Corporate Services
Building Services
Safety
Administrative Support
Regulatory Affairs
Purchasing
Business Development
ScientiďŹ c Services
Stores
Graphic Support
HR & Payroll
Flow Cytometry
Fundraising
Records & Information
Glassware Services
Information Technology
Histotechnology
Grants
DNA & Peptide Facility
Culture & Media Services
Animal Facility
Q-Gen
Project Manager Compilation Editing Design Graphic Support Photography
Sarah Tennant Deborah Bishop Sarah-Jane Matthews Rowland Madeleine Kersting Heather Matthews, Tony Phillips
Published September 2010 Copies can be obtained by phoning 1800 993 000 or enquiries@qimr.edu.au Online version available at www.qimr.edu.au 128
QIMR Annual Report 2009/10
Science Communication
Animal Welfare
Finance
300 Herston Road, Herston QLD 4006, Australia T: (+61) 7 3362 0222 E: enquiries@qimr.edu.au www.qimr.edu.au
External Relations
DIRECTOR
DEPUTY DIRECTOR
Assistant Director
Strategic Science Committee (Advisory)
Assistant Director
Clinical & Translational Research Committee (Advisory)
Senior Executive Team (Advisory)
Infectious Diseases Division Head
Immunology Division Head
Cancer & Cell Biology Division Head
Genetics & Population Studies Division Head
Bacterial Vaccines
Cellular Immunology
Iron Metabolism
Cancer Genetics
Systems Neuroscience
Malaria Drug Resistance
Molecular Vaccinology
Leukaemia Foundation
Indigenous Health
Psychiatric Genetics
Malaria Biology
Immunology & Infection
CCQ Transgenics
Cancer & Population Studies
Protein Discovery Centre
Clinical Immunohaematology
Signal Transduction
Oncogenomics
HIV Molecular Virology
Molecular Immunology
Radiation Biology & Oncology
Genetic Epidemiology
Parasite Cell Biology
Bone Marrow Transplantation
RBWH Foundation Conjoint Gastroenterology
Scabies
Tumour Immunology
Drug Discovery Group
Tropical Parasitology
Dendritic Cells & Cancer
Hepatic Fibrosis
Inammatory Bowel Disease Molecular Epidemiology
Neurogenetics
Gynaecological Cancer Group Clinical Tropical Medicine
EBV Biology
Molecular Parasitology
Cancer Immunotherapy
Mosquito Control
Immunovirology
Membrane Transport Molecular Cancer Epidemiology
Familial Cancer
Qld Statistical Genetics Molecular Genetics
Bacterial Pathogenesis
Immunity & Vaccinology
Antigen Presentation & Immunoregulation
Cancer Control Group
Skin Cancer Carcinogenesis
Epigenetics
Mental Health Research Division Head
ANNUAL REPORT
2009-10 300 Herston Road, Herston QLD 4006, Australia P: (+61) 7 3362 0222 F: (+61) 7 3362 0111 www.qimr.edu.au enquiries@qimr.edu.au